MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
A Phase 2/3 Randomized, Double-blind, Palivizumab-controlled
Study to Evaluate the Safety of MEDI8897, a Monoclonal
Antibody With an Extended Half-life Against Respiratory
 Syncytial Virus, in High-risk Children (MEDLEY)
Spons or Protocol N u m b er:
Applica t io n  N u m b er:
Inve s tigatio n al Pro du ct:
Spons or :D5290C00005
IND number 118524
MEDI8897
MedImmune, LLC, a wholly owned s ub s idiary of
AstraZeneca P LC, , Gaither s bu r g,
Maryland, 20878, U S A
Med ical Mo n itor:
, AstraZe n eca
Contract Re s earc h  Orga n izatio n :
Protocol Hi s tory, Date : Original P rotocol, 05Apr2019
Protocol Amendment 1, 31 M ar2021
This document contain s  trade s ecret s  and commercial information that i s  privileged or
confidential and may not be di s clo s ed without prior authorization from M edImmune.
CONFIDENTIAL AND PROPRIETARY 1 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
PROTOCOL  AMENDMENT  SUMMARY  OF  CHANGES  TABLE
Ame ndm e n t 1 (31Mar2021)
Overall Ratio n ale for t h e Ame nd me n t
The principal rea s on for thi s  amendment wa s  to update the s ample s ize for target enrollment,
introduce a primary analy s i s  and S ea s on 2 analy s i s  to allow earlier a ss e ss ment of S ea s on 1
and S ea s on 2 data, re s pectively, and add a de s cription about the proce ss  to s afeguard the
blind.
Secti on
Title  P a g e
Synops i s,
1.7 R e s ea r c h Hypo t h e s e s,
4.8.2 S a mp le  S ize
Synops i s,
3.1.1 Ov e rv ie w,
4.1.1 Numb e r of Sub ject s,
4.8.2 S a mp le  S ize ,
4.8.4 Eff icac y
Synops i s,
4.8 S tati s tical  Ev al u ati on
Synops i s,
4.8.4 Eff icac y
Synops i s,
4.8.6.3 H ealt h ca r e
Resour ce  U tilizati on a nd
Care g i v e r Burd e n
4.5.1.4 R e por ti ng Produ ct
Comp lai n t sDescri pt i on of Chang e
Update d t h e  m e d ical  mon it or
inform ati on
Remov e d hypo t h e s e s s ecti on w it h
clarif icati on
Update d t h e  s a mp le  s ize
Adde d pr i m a ry a n al ys i s a nd S ea son 2
analys i s
Remov e d s i d e -by-s i d e  e ff icac y
summ a r ie s for 2 c ons ec u ti v e  s ea sons
Summ a r ize d HRU ov e r all  a nd for
subject s w it h at  lea s t  1 on e  m e d icall y
attend e d RSV LRTI (pro t o c o l  d e f i n e d) ;
other subgroups w e r e  r e mov e d
Remov e d t h e  f a x numb e r a nd t h e
+1-877-MEDI-411 (+1-877-633-4411)
phon e  numb e rBrief Rat i ona le
Chang e  i n m e d ical  mon it or for t h i s
study
The s t udy i s d e s c r i p ti v e  by d e s i gn
and t h e r e  i s no form al  hypo t h e s i s
testing, t h e r e for e  t h e  hypo t h e s e s
section w a s r e mov e d t o a vo i d
poten tial  c onfus i on. A l so a dd e d a
clarif icati on / r ati on ale  t o d e s c r i b e
why form al  hypo t h e s i s te s ti ng for
efficac y i s no t  f ea s i b le .
Give n t h e  c h alle ng e  of s t udy
enroll m e n t  du e  t o t h e  COVID-19
pand e m ic , t h e  s a mp le  s ize  w a s
reduce d from or i g i n all y p la nn e d i n
the pro t o c o l .
To all ow ea r lie r a ss e ssm e n t  of
Season 1 a nd S ea son 2 d ata
As th e  i n ci d e n ce  of m e d icall y
attend e d RSV LRTI a nd RSV
hospitalizati on ( a nd t h e  r ele v a n t
HRU) a r e  e xp ecte d t o b e  l ow e r i n
Season 2 ( i nf a n t ’s s ec ond RSV
season) t h a n t h at  i n S ea son 1,
comb i n i ng t h e  e v e n t s from S ea son 1
and S ea son 2 m a y no t  c onf e r v al u e  i n
additi on t o t h e  i nd i v i du al  summ a ry
for eac h s ea son
To fo c us HRU a nd ca r e g i v e r burd e n
summ a r ie s on t h e  mos t  i mpor ta n t
efficac y e v e n t s, wh ic h a r e  m e d icall y
attend e d RSV LRTIs (pro t o c o l
defin e d), e sp eciall y g i v e n t h at
COVID-19 p a nd e m ic  h a s a  h i gh
impact  on t h e  numb e r of RSV a nd
non-RSV LRTIs
The numb e rs r e mov e d a r e  no l ong e r
in us e
CONFIDENTIAL AND PROPRIETARY 2 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Secti on
4.8.1 G e n e r al
Cons i d e r ati ons
5.3.1 Hyp e rs e ns iti v it y,
Includ i ng An a phy la x i s,
5.7.3.1 Hyp e rs e ns iti v it y,
Includ i ng An a phy la x i s
Throughou tDescri pt i on of Chang e
Adde d d e s c r i p ti on a bou t  s t r ate gy t o
main tai n t h e  b li nd
Clari f ie d hyp e rs e ns iti v it y by a dd i ng
imme d iate  ( t yp e  I)
Minor e d it or ial  r e v i s i onsBrief Rat i ona le
To ensur e  t r ial  i n te gr it y a nd t h e
blind i ng of t h e  S ea son 2 t r eat m e n t
assignm e n t  for CLD / CHD sub ject s
who w e r e  r a ndom ize d t o t h e
paliv iz um a b a rm i n S ea son 1
For cla r it y
Minor, t h e r e for e , w e r e  no t
summ a r ize d
CHD = c ong e n ital  h ea r t  d i s ea s e;  CLD = c hron ic  l ung d i s ea s e;  COVID-19 = c oron a v i rus d i s ea s e  2019 ;
HRU = h ealt h ca r e  r e sour ce  u tilizati on ;  LRTI = l ow e r r e sp i r at ory t r act  i nf ecti on ;  RSV = r e sp i r at ory syn c y tial
virus.
CONFIDENTIAL AND PROPRIETARY 3 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
PROTOCOL  SYNOPSIS
TITLE
A Ph a s e  2 / 3 R a ndom ize d, Doub le -b li nd, P ali v iz um a b- c on t ro lle d S t udy t o Ev al u ate  t h e  S a f et y of MEDI8897, a
Mono cl on al  An ti body W it h a n Ex te nd e d H al f- li f e  Ag ai ns t  R e sp i r at ory Syn c y tial  V i rus, i n H i gh-r i sk Ch il dr e n
(MEDLEY)
OBJECTIVES and ASSOCIATED ENDPOINTS
Type
Prima r y
Safet y
Seconda r yObjec t i v e
To ev al u ate  t h e  s a f et y a nd t o le r a b ilit y of
MEDI8897 c omp a r e d t o p ali v iz um a b
when a dm i n i s te r e d t o pr ete rm i nf a n t s
enter i ng t h ei r f i rs t  RSV s ea son a nd
childr e n w it h CLD or CHD e n te r i ng t h ei r
first a nd s ec ond RSV s ea sonEndpo i nt
Safet y a nd t o le r a b ilit y of MEDI8897 a s
assess e d by t h e  o cc urr e n ce  of all  TEAEs,
TESAEs, AESIs, a nd NOCDs
PKTo ev al u ate  s e rum c on ce n t r ati ons of
MEDI8897 a nd p ali v iz um a b• MEDI8897 a nd p ali v iz um a b s e rum
conce n t r ati ons
• MEDI8897 a nd p ali v iz um a b PK
param ete rs :  Summ a ry of s e rum
conce n t r ati ons a nd e s ti m ate d PK
param ete rs (C max , AUC, a pp a r e n t
clear a n ce , a nd t 1 / 2 , i f d ata  p e rm it )
ADA
Efficac yTo ev al u ate  ADA r e spons e s t o MEDI8897
and t o p ali v iz um a b i n s e rum
To ass e ss t h e  d e s c r i p ti v e  e ff icac y of
MEDI8897 wh e n a dm i n i s te r e d a s a  s i ng le
IM dos e  of 50 mg t o i nf a n t s < 5 kg or
100 mg t o i nf a n t s ≥ 5 kg i n t h e  f i rs t  RSV
season or a  s i ng le  200-mg IM dos e
admi n i s te r e d i n t h e  s ec ond RSV s ea son, i n
reduci ng m e d icall y atte nd e d LRTI
(inpatie n t  a nd ou t p atie n t ) a nd
hospitalizati on du e  t o RT-PCR- c onf i rm e d
RSV, c omp a r e d t o p ali v iz um a bIncid e n ce  of ADA t o MEDI8897 a nd
paliv iz um a b i n s e rum
• In ci d e n ce  of m e d icall y atte nd e d LRTI
(inpatie n t  a nd ou t p atie n t ) du e  t o RT-PCR-
confi rm e d RSV t hrough 150 d a ys a f te r
Dose  1 for S ea son 1 a nd S ea son 2
• In ci d e n ce  of hosp italizati ons du e  t o
RT-PCR- c onf i rm e d RSV t hrough 150 d a ys
after Dos e  1 for S ea son 1 a nd S ea son 2
CONFIDENTIAL AND PROPRIETARY 4 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Type Obj ec t i v e Endpo i nt
Expl o r ato r y
RSV
neutr alizi ng
antibodyTo dete rm i n e  a n ti -RSV n e u t r alizi ng
antibody le v el s i n s e rum a fford e d by a
single  dos e  of MEDI8897 c omp a r e d t o
5 mon t h l y dos e s of p ali v iz um a b• An ti -RSV n e u t r alizi ng a n ti body le v el s
(IU/mL) i n s e rum for MEDI8897 r eci p ie n t s
comp a r e d t o p ali v iz um a b r eci p ie n t s
• Summ a ry of s e rum RSV n e u t r alizi ng
antibody le v el s (m a y i n cl ud e  GMT, GMFR,
Cmax, a pp a r e n t  clea r a n ce , a nd t 1 / 2 )
RSV
serol ogyTo ev al u ate  e xposur e  t o RSV by
measur i ng s e ror e spons e s t o d i ff e r e n t  RSV
protei ns i n MEDI8897 a nd p ali v iz um a b
recip ie n t s
To ev al u ate  t h e  le v el s of m ate rn al  RSV-
speci f ic  a n ti body i n MEDI8897 a nd
paliv iz um a b r eci p ie n t s• An ti body le v el s t o RSV F, G a , Gb, or N at
diffe r e n t  ti m e  po i n t s
• Ch a ng e s i n RSV a n ti body le v el s
(seror e spons e ) i nd icati ng e xposur e  t o RSV
• RSV a n ti g e n a n ti body le v el s (AbU / mL)
to mu lti p le  RSV a n ti g e ns
• Summ a ry of s e rum RSV a n ti body le v el s
(may i n cl ud e  GMT, GMFR,
seroc onv e rs i on r ate s, a pp a r e n t  clea r a n ce ,
and t 1 / 2 )
HRU a nd
careg i v e r
burde nTo ass e ss HRU a nd ca r e g i v e r burd e n for
MEDI8897 r eci p ie n t s c omp a r e d t o
paliv iz um a b r eci p ie n t s• M a gn it ud e  of HRU ( e g, numb e r of
admi ss i ons t o hosp ital s a nd ICUs a nd
durati on of s ta y ;  numb e r of sub ject s who
requi r e  r e sp i r at ory suppor t  a nd
supple m e n tal  oxyg e n a nd t h e  dur ati on of
use; numb e r a nd t yp e  of ou t p atie n t  v i s it s
[eg, ER, urg e n t  ca r e , ou t p atie n t  cli n ic ] ;  a nd
numb e r of pr e s c r i p ti on a nd OTC
medicati ons a nd dur ati on of us e ) for
MEDI8897 r eci p ie n t s c omp a r e d t o
paliv iz um a b r eci p ie n t s
• Ca r e g i v e r burd e n ( e g, ca r e g i v e r m i ss e d
work d a ys, sub ject  a bs e n ce  from d a y ca r e )
for sub ject s w it h m e d icall y atte nd e d LRTI
cause d by RT-PCR- c onf i rm e d RSV
RSV
resista n ce
monit or i ng
RSV LRTI
after D a y 151To ch a r acte r ize  r e s i s ta n ce  t o MEDI8897
and p ali v iz um a b t hrough g e no t yp ic  a nd
pheno t yp ic  a n al ys e s
To ass e ss t h e  i n ci d e n ce  of m e d icall y
attend e d LRTI du e  t o RT-PCR- c onf i rm e d
RSV, c omp a r e d t o p ali v iz um a b a f te r
Day 151Geno t yp ic  a n al ys i s a nd sus ce p ti b ilit y of RSV
varia n t s t o n e u t r alizati on by MEDI8897 a nd
paliv iz um a b
Incid e n ce  of m e d icall y atte nd e d LRTI
(inpatie n t  a nd ou t p atie n t ) du e  t o RT-PCR-
confi rm e d RSV from D a y 152 t o D a y 361 for
Season 1 a nd S ea son 2
AbU / mL = a n ti body un it  p e r mL ;  ADA = a n ti -drug a n ti body ;  AESI = a dv e rs e  e v e n t  of sp ecial  i n te r e s t;  AUC
= area  und e r t h e  c on ce n t r ati on- ti m e  c urv e  ;  CHD = c ong e n ital  h ea r t  d i s ea s e;  CLD = c hron ic  l ung d i s ea s e;
Cmax  = m a x i mum obs e rv e d c on ce n t r ati on ;  ER = e m e rg e n c y room ;  GMFR = g e om et r ic  m ea n fo l d-r i s e;  GMT
= geom et r ic  m ea n tite r ;  HRU = h ealt h ca r e  r e sour ce  u tilizati on ;  ICU = i n te ns i v e  ca r e  un it;  IM =
intramus c u la r ;  LRTI = l ow e r r e sp i r at ory t r act  i nf ecti on ;  NOCD = n e w ons et  c hron ic  d i s ea s e;  OTC = ov e r-
the-c oun te r ;  PK = ph a rm ac ok i n etic;  RSV = r e sp i r at ory syn c y tial  v i rus ;  RT-PCR = r e v e rs e  t r a ns c r i p ta s e -
polym e r a s e  c h ai n r eacti on ;  t 1 / 2  = te rm i n al  h al f- li f e;  TEAE = t r eat m e n t - e m e rg e n t  a dv e rs e  e v e n t;  TESAE =
treatm e n t - e m e rg e n t  s e r i ous a dv e rs e  e v e n t .
CONFIDENTIAL AND PROPRIETARY 5 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
STUDY DESIGN
Study D5290C00005 (MEDLEY) i s a  p i vo tal  Ph a s e  2 / 3 r a ndom ize d, doub le -b li nd, p ali v iz um a b- c on t ro lle d
study t o e v al u ate  t h e  s a f et y, PK, ADA r e spons e , a nd d e s c r i p ti v e  e ff icac y for MEDI8897 i n h i gh-r i sk i nf a n t s
eligib le  t o r ecei v e  p ali v iz um a b wh e n e n te r i ng t h ei r f i rs t  or s ec ond RSV s ea son (S ea son 1 or S ea son 2,
respecti v el y). Approx i m atel y 900 p ali v iz um a b- eli g i b le  i nf a n t s e n te r i ng t h ei r f i rs t  RSV s ea son w ill  b e  e nro lle d
into on e  of 2 c ohor t s :  (1) pr ete rm c ohor t , i n cl ud i ng a pprox i m atel y 600 pr ete rm i nf a n t s (≤ 35 w ee ks g e s tati on al
age [GA]) w it hou t  CLD / CHD, or (2) CLD / CHD c ohor t , i n cl ud i ng a pprox i m atel y 300 i nf a n t s w it h CLD of
prem at ur it y or h e modyn a m icall y s i gn i f ica n t  CHD. A m i n i mum of 100 i nf a n t s w it h h e modyn a m icall y
signi f ica n t  CHD w ill  b e  e nro lle d. W it h i n eac h c ohor t , r a ndom izati on w ill  b e  s t r ati f ie d by h e m i sph e r e
(nort h e rn, sou t h e rn) a nd sub ject  a g e  at  t h e  ti m e  of S ea son 1 r a ndom izati on (≤ 3 mon t hs, > 3 t o ≤ 6 mon t hs,
> 6 mon t hs).
Season 1, P re t er m and CLD / CHD Coho r ts
All sub ject s w ill  b e  r a ndom ize d 2 : 1 t o eit h e r t h e  MEDI8897 group ( a pprox i m atel y 600 sub ject s, i n cl ud i ng
approx i m atel y 400 sub ject s i n t h e  pr ete rm c ohor t  a nd a pprox i m atel y 200 sub ject s i n t h e  CLD / CHD c ohor t ) or
paliv iz um a b group ( a pprox i m atel y 300 sub ject s, i n cl ud i ng a pprox i m atel y 200 sub ject s i n t h e  pr ete rm c ohor t
and a pprox i m atel y 100 sub ject s i n t h e  CLD / CHD c ohor t ). Sub ject s i n t h e  MEDI8897 group w ill  r ecei v e  a
single  f i x e d IM dos e  of MEDI8897 fo ll ow e d by 4 on ce -mon t h l y IM dos e s of p lace bo. Th e  MEDI8897 dos e
level  w ill  b e  s t r ati f ie d by w ei gh t  b a nd, ie , 50 mg for i nf a n t s w ei gh i ng < 5 kg or 100 mg for i nf a n t s w ei gh i ng ≥
5 kg. Sub ject s i n t h e  p ali v iz um a b group w ill  r ecei v e  5 on ce -mon t h l y IM dos e s of 15 mg / kg p ali v iz um a b.
Season 2, CLD / CHD Coho r t On l y
•  Sub ject s w it h CLD / CHD ≤ 24 mon t hs of a g e  who w e r e  r a ndom ize d t o t h e  MEDI8897 group for
Season 1 w ill  r ecei v e  a  s i ng le  f i x e d IM dos e  of 200 mg MEDI8897 fo ll ow e d by 4 on ce -mon t h l y
IM dos e s of p lace bo ( a pprox i m atel y 200 sub ject s).
• Sub ject s w it h CLD / CHD ≤ 24 mon t hs of a g e  who w e r e  r a ndom ize d t o t h e  p ali v iz um a b group for
Season 1 w ill  b e  r e -r a ndom ize d 1 : 1 t o eit h e r t h e  MEDI8897 group or t h e  p ali v iz um a b group. Sub ject s i n
the MEDI8897 group w ill  r ecei v e  a  s i ng le  f i x e d IM dos e  of 200 mg MEDI8897 fo ll ow e d by
4 once -mon t h l y IM dos e s of p lace bo ( a pprox i m atel y 50 sub ject s). Sub ject s i n t h e  p ali v iz um a b group w ill
recei v e  5 on ce -mon t h l y IM dos e s of 15 mg / kg p ali v iz um a b ( a pprox i m atel y 50 sub ject s).
In Sea son 1 or S ea son 2, sub ject s i n t h e  CLD / CHD c ohor t  who und e rgo ca rd iac  surg e ry w it h ca rd i opu l mon a ry
bypa ss a f te r r ecei p t  of Dos e  1 bu t  pr i or t o r ecei p t  of Dos e  5 w ill  r ecei v e  a  r e p lace m e n t  dos e  of t h e  s t udy drug
they r ecei v e d for Dos e  1 i mm e d iatel y fo ll ow i ng t h e  surg e ry wh e n d ete rm i n e d by t h e  phys icia n t o b e  m e d icall y
stable  for a n IM i n jecti on. Any subs e qu e n t  dos e s of s t udy drug w ill  c on ti nu e  t o b e  g i v e n acc ord i ng t o t h e
proto c o l -sp eci f ie d dos i ng s c h e du le .
Subject s i n t h e  pr ete rm c ohor t  w ill  b e  fo ll ow e d t hrough 1 y ea r a f te r S ea son 1 / Dos e  1, a nd sub ject s i n t h e
CLD / CHD c ohor t  w ill  b e  fo ll ow e d t hrough 1 y ea r a f te r S ea son 2 / Dos e  1. Sub ject s i n t h e  CLD / CHD c ohor t
who r ecei v e  a  r e p lace m e n t  dos e  i n S ea son 2 w ill  b e  fo ll ow e d t hrough 1 y ea r a f te r t h e  la s t  r e p lace m e n t  dos e .
Subject s w ill  b e  mon it or e d t hroughou t  t h e  s t udy for LRTI. A ll  sub ject s s ee k i ng m e d ical  atte n ti on for a
respi r at ory ill n e ss ( i n eit h e r t h e  i np atie n t  or ou t p atie n t  s etti ng) w ill  b e  e v al u ate d for LRTI, i n cl ud i ng pro t o c o l -
defin e d m e d icall y atte nd e d RSV LRTI. A ll  sub ject s e v al u ate d for LRTI w ill  h a v e  r e sp i r at ory s a mp le s
obtai n e d a nd te s te d ce n t r all y for RSV us i ng t h e  Un ite d S tate s Food a nd Drug Adm i n i s t r ati on- clea r e d a nd
Conf orm ité  Europ ée nn e  or Europ ea n Conform it y-m a rk e d i n v it ro d ia gnos tic  r eal - ti m e  RT-PCR a ss a y.
Blood s a mp le s w ill  b e  c o llecte d for PK, ADA, a nd RSV n e u t r alizi ng a n ti body a nd RSV s e ro l ogy.
TARGET SUBJECT POPULATION
Prete rm i nf a n t s e n te r i ng t h ei r f i rs t  RSV s ea son who a r e  eli g i b le  t o r ecei v e  p ali v iz um a b, a nd c h il dr e n w it h
CLD or CHD who a r e  e n te r i ng t h ei r f i rs t  RSV s ea son a nd t h e  s a m e  c h il dr e n ≤ 24 mon t hs of a g e  e n te r i ng t h ei r
second RSV s ea son
CONFIDENTIAL AND PROPRIETARY 6 of 80 T e mp late  18.0
3, 4, 5Dose  1MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
TREATMENT GROUPS AND REGIMENS
Subject s w ill  b e  r a ndom l y a ss i gn e d t o r ecei v e  s t udy drug a s d e s c r i b e d i n t h e  S t udy D e s i gn s ecti on a nd
prese n te d b el ow :
Coho r t
Prete rm
(N = 600)MEDI8897
(N = 400)Season 1
50 mg ( i f < 5 kg) or
100 mg ( i f ≥ 5 kg) IM
Dose s 2, P lace bo IMSeason 2
Not a pp lica b le
CLD / CHD
(N = 300Paliv iz um a b
(N = 200)
MEDI8897
(N = 200)
Paliv iz um a b
(N = 100)Dos e s 1,
2, 3, 4, 5
Dose  1
Dose s 2,
3, 4, 5
Dos e s 1,
2, 3, 4, 515 mg / kg IM
50 mg ( i f < 5 kg) or
100 mg ( i f ≥ 5 kg) IM
Place bo IM
15 mg / kg IMMEDI8897
(N = 200)
MEDI8897
(N = 50)
Paliv iz um a b
(N = 50)Dose  1
Dose s 2,
3, 4, 5
Dose  1
Dose s 2,
3, 4, 5
Dos e s 1,
2, 3, 4, 5200 mg IM
Place bo IM
200 mg IM
Place bo IM
15 mg / kg IM
STATISTICAL METHODS
Samp le  S ize : W it h r e sp ect  t o s a f et y, 600 sub ject s e xpos e d t o MEDI8897 i n S ea son 1 w ill  prov i d e  a
95% prob a b ilit y of obs e rv i ng at  lea s t  1 a dv e rs e  e v e n t  (AE) i f t h e  t ru e  e v e n t  r ate  i s 0.5% ;  i f no AEs a r e
observ e d, t h i s s t udy prov i d e s 95% c onf i d e n ce  t h at  t h e  t ru e  e v e n t  r ate  i s < 0.5%. Th e  s a mp le  s ize  i s for s a f et y
consi d e r ati on.
With r e sp ect  t o e ff icac y, a pprox i m atel y 600 sub ject s w ill  b e  e xpos e d t o MEDI8897 a nd 300 sub ject s w ill  b e
expos e d t o p ali v iz um a b i n S ea son 1 t o obs e rv e  num e r icall y s i m ila r e ff icac y for bo t h mono cl on al  a n ti bod ie s.
Beca us e  of t h e  r e du ce d i n ci d e n ce  of RSV d i s ea s e  i n t h i s popu lati on fo ll ow i ng t h e  i n t rodu cti on of p ali v iz um a b,
a sup e r i or it y or non- i nf e r i or it y d e s i gn i s no t  pr actical . A v ali d non- i nf e r i or it y m a rg i n ca nno t  b e  e s ta b li sh e d
due t o t h e  lac k of h i s t or ical  e ff icac y d ata  for t h e  m e d icall y atte nd e d RSV LRTI e ndpo i n t  for p ali v iz um a b.
There for e , t h e r e  i s no hypo t h e s i s te s ti ng for e ff icac y. Us i ng a n a ssump ti on of a  6% RSV LRTI r ate  i n
paliv iz um a b r eci p ie n t s, a pprox i m atel y 18 e v e n t s w ill  b e  obs e rv e d i n t h at  group. Th e  6% RSV LRTI r ate
(1.9% RSV hosp italizati ons a nd 3.9% ou t p atie n t  RSV ill n e ss) w a s b a s e d on a  pr i or s t udy i n pr ete rm i nf a n t s
with a nd w it hou t  CLD who r ecei v e d p ali v iz um a b. Assum i ng a  6% r ate  of RSV LRTI i n MEDI8897
recip ie n t s, 600 MEDI8897 sub ject s i n S ea son 1 w ill  prov i d e  a pprox i m atel y 36 e v e n t s i n t h at  group. How e v e r,
becaus e  of t h e  la rg el y r e du ce d RSV ci r c u lati on du e  t o COVID-19 p a nd e m ic -r elate d m ea sur e s, t h e  obs e rv e d
even t  r ate s c ou l d b e  mu c h l ow e r. On l y summ a r ie s w ill  b e  prov i d e d for e ff icac y un le ss sp eci f ie d o t h e rw i s e .
Stati st ic a l  Ana l ys e s
Ther e  a r e  3 p la nn e d a n al ys e s for t h i s s t udy :  t h e  pr i m a ry a n al ys i s, S ea son 2 a n al ys i s, a nd t h e  f i n al  a n al ys i s.
The pr i m a ry a n al ys i s w ill  b e  c ondu cte d a f te r all  r a ndom ize d sub ject s h a v e  c omp lete d fo ll ow-up t hrough t h e
first 5-mon t h RSV s ea son ( ie , S ea son 1 D a y 151 v i s it ) a nd i n cl ud e  all  a v aila b le  S ea son 1 s a f et y, e ff icac y, PK,
and ADA d ata  at  t h e  ti m e  of t h e  d ata  c u t off. Th e  S ea son 2 a n al ys i s w ill  b e  c ondu cte d a f te r all  CLD / CHD
subject s h a v e  c omp lete d fo ll ow-up t hrough t h e  s ec ond 5-mon t h RSV s ea son ( ie , S ea son 2 D a y 151 v i s it ) a nd
includ e  all  a v aila b le  S ea son 1 d ata  a nd S ea son 2 s a f et y, e ff icac y, PK, a nd ADA d ata  at  t h e  ti m e  of t h e  d ata
cutoff. Th e  f i n al  a n al ys i s w ill  b e  c ondu cte d wh e n all  sub ject s h a v e  c omp lete d t h e  la s t  v i s it  of t h e  s t udy a nd
includ e  all  d ata  c o llecte d i n t h e  s t udy.
Safety :  S a f et y of MEDI8897 w ill  b e  summ a r ize d by t r eat m e n t  group b a s e d on t h e  As- t r eate d Popu lati on
(defi n e d a s all  sub ject s who r ecei v e  a ny i nv e s ti g ati on al  produ ct  a n al y ze d acc ord i ng t o t r eat m e n t  r ecei v e d) for
each s ea son, a s w ell  a s for t h e  2 c ons ec u ti v e  RSV s ea sons ( ie , S ea son 1 a nd S ea son 2). For t h e  S ea son 1
summ a ry, t h e  a n al ys i s d ata s et  w ill  i n cl ud e  sub ject s from t h e  pr ete rm c ohor t  a nd CLD / CHD c ohor t , pr e s e n te d
CONFIDENTIAL AND PROPRIETARY 7 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
by th e  t r eat m e n t  r ecei v e d i n S ea son 1 ;  for t h e  S ea son 2 summ a ry a nd t h e  2 c ons ec u ti v e -s ea son summ a ry, t h e
analys i s d ata s et  w ill  i n cl ud e  sub ject s from t h e  CLD / CHD c ohor t , pr e s e n te d by t h e  t r eat m e n t  r ecei v e d t hrough
the 2 s ea sons.
AEs w ill  b e  gr a d e d acc ord i ng t o t h e  c urr e n t  v e rs i on of t h e  N ati on al  C a n ce r Ins tit u te  Common T e rm i no l ogy
Crite r ia  for Adv e rs e  Ev e n t s wh e r e  a pp lica b le  for p e d iat r ic  a ss e ssm e n t s. AEs w ill  b e  c od e d by M e d ical
Dicti on a ry for R e gu lat ory A cti v itie s a nd t h e  t yp e , i n ci d e n ce , s e v e r it y, a nd r elati onsh i p t o s t udy drug w ill  b e
summ a r ize d by t r eat m e n t  group. O t h e r s a f et y a ss e ssm e n t s w ill  i n cl ud e  t h e  o cc urr e n ce  of AESIs, d e f i n e d a s
AEs of hyp e rs e ns iti v it y t o s t udy drug ( i n cl ud i ng a n a phy la x i s), t hrombo c y t op e n ia , a nd i mmun e  c omp le x
disea s e  ( e g, v a s c u liti s, e ndo ca rd iti s, n e ur iti s, g l om e ru l on e phr iti s), a nd NOCDs fo ll ow i ng s t udy drug
admi n i s t r ati on.
Effic a c y :  A ll  e ff icac y summ a r ie s w ill  b e  b a s e d on t h e  In te n t - t o- t r eat  (ITT) Popu lati on (d e f i n e d a s all
random ize d sub ject s a n al y ze d acc ord i ng t o r a ndom ize d t r eat m e n t  a ss i gnm e n t ). Th e  i n ci d e n ce  of m e d icall y
attend e d RSV LRTI ( i np atie n t  a nd ou t p atie n t ) t hrough 150 d a ys pos t  Dos e  1 ( ie , dur i ng a  t yp ical  5-mon t h
RSV s ea son) i n S ea son 1, b a s e d on RSV te s t  r e su lt s (p e rform e d ce n t r all y us i ng r eal - ti m e  RT-PCR) a nd
objecti v e  pro t o c o l -d e f i n e d LRTI c r ite r ia , i s t h e  pr i m a ry e ff icac y e ndpo i n t  a nd w ill  b e  summ a r ize d by S ea son 1
treatm e n t  group for all  900 sub ject s. Th e  95% c onf i d e n ce  i n te rv al  (CI) of t h e  p e r ce n ta g e  of sub ject s m eeti ng
the pr i m a ry e ff icac y e ndpo i n t  w ill  b e  pr e s e n te d by t r eat m e n t  group. In a dd iti on, t h e  i n ci d e n ce  of RSV LRTI
through 150 d a ys pos t  Dos e  1 i n S ea son 2 w ill  b e  summ a r ize d for t h e  300 sub ject s i n t h e  CLD / CHD c ohor t
based on t h e  t r eat m e n t  a ss i gnm e n t s t hrough S ea son 1 a nd S ea son 2 :  ie , ( a ) MEDI8897 (S ea son 1) / MEDI8897
(Season 2), (b) p ali v iz um a b (S ea son 1) / MEDI8897 (S ea son 2), a nd ( c ) p ali v iz um a b (S ea son 1) / p ali v iz um a b
(Season 2).
The i n ci d e n ce  of RSV hosp italizati on t hrough 150 d a ys a f te r dos i ng ( ie , dur i ng t h e  5-mon t h RSV s ea son) w ill
be summ a r ize d by t r eat m e n t  group us i ng a  s i m ila r s t r ate gy a s d e s c r i b e d for RSV LRTI.
PK: Ind i v i du al  MEDI8897 a nd p ali v iz um a b s e rum c on ce n t r ati on d ata  w ill  b e  ta bu late d by t r eat m e n t  group
along w it h d e s c r i p ti v e  s tati s tic s. PK p a r a m ete rs w ill  b e  e s ti m ate d us i ng non- c omp a r t m e n tal  a n al ys i s, i f d ata
perm it .
ADA :  Th e  i n ci d e n ce  of ADA t o MEDI8897 a nd t o p ali v iz um a b w ill  b e  a ss e ss e d a nd summ a r ize d by numb e r
and p e r ce n ta g e  of sub ject s who a r e  ADA pos iti v e  by t r eat m e n t  group. Th e  i mp act  of ADA on PK, a nd
associati on w it h TEAEs a nd TESAEs, w ill  b e  a ss e ss e d.
RSV n e ut r a lizi ng ant i body :  Ind i v i du al  MEDI8897 a nd p ali v iz um a b s e rum a n ti -RSV n e u t r alizi ng a n ti body
level s w ill  b e  ta bu late d by t r eat m e n t  group al ong w it h d e s c r i p ti v e  s tati s tic s. An ti -RSV n e u t r alizi ng a n ti body
level s i n s e rum w ill  b e  summ a r ize d by g e om et r ic  m ea n tite r a nd g e om et r ic  m ea n-fo l d r i s e  a nd c orr e spond i ng
95% CI for eac h t r eat m e n t  group at  eac h v i s it . An ti -RSV n e u t r alizi ng a n ti body le v el  t 1 / 2  w ill  b e  e s ti m ate d
using non- c omp a r t m e n tal  a n al ys i s, i f d ata  p e rm it .
RSV s er o l ogy :  An al ys i s of a n ti -RSV a n ti g e ns a n ti body le v el s i n s e rum i n MEDI8897 a nd p ali v iz um a b
recip ie n t s w ill  b e  summ a r ize d by g e om et r ic  m ea n tite r a nd g e om et r ic  m ea n-fo l d r i s e  a nd c orr e spond i ng
95% CI for eac h t r eat m e n t  group at  eac h v i s it . S e ror e spons e s i n MEDI8897 a nd p ali v iz um a b r eci p ie n t s w ill  b e
determ i n e d by e x a m i n i ng t h e  fo l d-r i s e  i n a n ti bod ie s t o G a , Gb, a nd N a n ti g e ns.
HRU and c a re g i v er  bu r d e n :  Th e  HRU a nd ca r e g i v e r burd e n summ a r ie s w ill  b e  p e rform e d on t h e  ITT
Popu lati on. Th e  m a gn it ud e  of HRU ( e g, numb e r of a dm i ss i ons t o hosp ital s a nd ICUs a nd dur ati on of s ta y ;
numb e r of sub ject s who r e qu i r e  r e sp i r at ory suppor t  a nd supp le m e n tal  oxyg e n a nd t h e  dur ati on of us e;  numb e r
and t yp e s of ou t p atie n t  v i s it s, e g, ER, urg e n t  ca r e , ou t p atie n t  cli n ic;  a nd numb e r of pr e s c r i p ti on a nd OTC
medicati ons a nd dur ati on of us e ) w ill  b e  summ a r ize d ov e r all  by t r eat m e n t  group a nd for sub ject s w it h at  lea s t
one m e d icall y atte nd e d LRTI (pro t o c o l  d e f i n e d) ca us e d by RT-PCR- c onf i rm e d RSV.
Car e g i v e r burd e n ( e g, ca r e g i v e r m i ss e d work d a ys, sub ject  a bs e n ce  from d a y ca r e ) for sub ject s w it h m e d icall y
atte nd e d LRTI (pro t o c o l  d e f i n e d) ca us e d by RT-PCR- c onf i rm e d RSV w ill  b e  summ a r ize d by t r eat m e n t  group.
Mon i to ri ng RSV re s i stan ce  to MEDI8897 and pa li v iz umab: G e no t yp ic  a n al ys i s of t h e  fu ll - le ng t h m at ur e
F pro tei n w ill  b e  c ondu cte d on all  RSV-pos iti v e  i so late s c onf i rm e d ce n t r all y us i ng t h e  Lyr a  RSV + hum a n
meta pn e umov i rus r eal - ti m e  RT-PCR a ss a y m a nuf act ur e d by Qu i d el  Corpor ati on. RSV g e no t yp ic  a n al ys i s w ill
repor t  t h e  s e qu e n ce  c h a ng e s i n t h e  m at ur e  F pro tei n from all  RSV pos iti v e  i so late s c omp a r e d t o c on te mpor a ry
RSV A a nd RSV B r e f e r e n ce  s t r ai ns. Sus ce p ti b ilit y of nov el  RSV v a r ia n t s t o MEDI8897 a nd p ali v iz um a b w ill
be te s te d a nd c omp a r e d t o c on t ro l  v i rus e s.
CONFIDENTIAL AND PROPRIETARY 8 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
RSV LRTI o cc u rri ng f r om Day 152 to Day 361 :  Th e  i n ci d e n ce  of m e d icall y atte nd e d RSV LRTI ( i np atie n t
and ou t p atie n t ) from D a y 152 t o D a y 361 for S ea son 1 a nd S ea son 2 w ill  b e  b a s e d on RSV te s t  r e su lt s
(perform e d ce n t r all y v ia  RT-PCR) a nd ob jecti v e  cli n ical  LRTI c r ite r ia  a nd w ill  b e  summ a r ize d by t r eat m e n t
group.
CONFIDENTIAL AND PROPRIETARY 9 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
TABLE  OF  CONTENTS
PROTOCOL A M END M ENT S U MM ARY O F  CHANGE S  TABLE.................................... 2
PROTOCOL S YNO PS I S ...................................................................................................... 4
LIST O F  ABBREVIATION S  ........ . ................................................................................. . .. 14
1
1.1
1.2
1.3
1.4
1.4.1
1.5
1.6
1.6.1
1.6.2
1.6.3
2
2.1
2.1.1
2.1.2
3
3.1
3.1.1
3.1.2
3.1.2.1
3.1.2.2
3.1.2.3
3.2
3.2.1
3.2.2
3.2.3
4
4.1
4.1.1
4.1.2
4.1.3
4.1.4
4.1.5
4.1.6
4.1.7
4.1.8INTRODUCTION ......................................................................................... . .. 16
Disea s e Background ...................................................................................... . .. 16
MEDI8897 Backgroun d .................................................................................... 17
Summary of Nonclinical Experience.............................................................. . .. 18
Summary of Clinical E x perience....................................................................... 18
Study D5290C00003...................................................................................... . .. 18
Rationale for Conducting the S tudy ............................................................... . .. 20
Benefit-Ri s k and Ethical A ss e ss ment ............................................................. . .. 21
Potential Benefit ............................................................................................... 21
Potential Ri s k ................................................................................................... 21
Overall Benefit-Ri s k ......................................................................................... 22
OBJECTIVE S  AND E N D P OINT S ................................................................... 22
Primary Objective and Ass ociated Endpoint ..................................................... 22
Secondary Objective s  and A ss ociated Endpoint s ............................................... 22
Exploratory Objective s  and A ss ociated Endpoint s  ............................................ 23
STUDY DE S IGN ........ . ................................................................................. . .. 24
Description of the S tudy ................................................................................... 24
Overview ..................... . .................................................................................... 24
Dosing Regimen ............................................................................................... 27
Season 1, P reterm Coh o rt and CLD/CHD Cohort.............................................. 27
Season 2, CLD/CHD C o hort............................................................................. 27
Season 1 or S ea s on 2, CLD/CHD Cohort - Replacement Do s e.......................... 28
Rationale for Do s e, P opulation, and Endpoint s  ................................................. 29
Dose Rationale.................................................................................................. 29
Rationale for S tudy P opulation ......................................................................... 30
Rationale for Endpoint s  .................................................................................... 30
MATERIAL S  AND M ETHOD S  ...................................................................... 31
Subject s ............................................................................................................ 31
Number of S ubject s  ....................................................................................... . .. 31
Inclu s ion Criteria ......... . ................................................................................. . .. 32
Exclu s ion Criteria ........ . ................................................................................. . .. 32
Subject Enrollment and Randomization ............................................................ 33
Withdrawal from the S t u dy............................................................................... 34
Discontinuation of Inve s tigational P roduct........................................................ 34
Replacement of S ubject s ................................................................................... 34
Withdrawal of Informed Con s ent for Data and Biological S ample s ................... 34
CONFIDENTIAL AND PROPRIETARY 10 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
4.2
4.2.1
4.2.2
4.3
4.3.1
4.3.1.1
4.3.1.2
4.3.1.3
4.3.2
4.3.3
4.3.4
4.3.5
4.3.5.1
4.3.5.2
4.3.6
4.3.7
4.3.8
4.4
4.5
4.5.1
4.5.1.1
4.5.1.2
4.5.1.3
4.5.1.4
4.5.2
4.5.3
4.5.4
4.5.5
4.5.6
4.6
4.6.1
4.6.2
4.6.3
4.6.3.1
4.7
4.7.1
4.7.2
4.8
4.8.1
4.8.2
4.8.3
4.8.3.1
4.8.4
4.8.5
4.8.5.1Schedule of S tudy P rocedure s ........................................................................... 35
Enrollment/ S creening P eriod ............................................................................ 35
Treatment and F ollow- u p P eriod s  ..................................................................... 36
Description of S tudy P r o cedure s ....................................................................... 43
Efficacy. ........................................................................................................... 43
Lower Re s piratory Tract Infection .................................................................... 43
Respiratory S ecretion s  for R S V Detection ........................................................ 46
Monitoring for R S V Re s i s tance ........................................................................ 46
Medical Hi s tory and P hy s ical Examination, Weight, and Vital S ign s ............. . .. 47
Pharmacokinetic Evaluation and M ethod s ......................................................... 47
Anti-drug Antibody Evaluation and M ethod s .................................................... 48
RSV-neutralizing Antibody and R S V S erology Evaluation s  and M ethod s ......... 48
RSV Neutralizing Antibody........................................................................... . .. 48
RSV S erology................................................................................................... 48
Healthcare Re s ource Utilization and Caregiver Burden..................................... 48
Skin Reaction s .................................................................................................. 48
Estimate of Volume of Blood to be Collected ................................................... 49
Study or S tudy Component S u s pen s ion or Termination..................................... 49
Inves tigational P roducts.................................................................................... 50
Identity of Inve s tigational P roduct s ................................................................... 50
Inves tigational P roduct In s pection .................................................................... 51
Dose P reparation S tep s  and Treatment Admini s tration...................................... 51
Monitoring of Do s e Admini s tration .................................................................. 54
Reporting P roduct Complaint s .......................................................................... 55
Additional S tudy M edication s ........................................................................ . .. 55
Labeling ........................................................................................................... 55
Storage ............................................................................................................. 55
Treatment Compliance...................................................................................... 55
Accountability .................................................................................................. 55
Treatment A ss ignment and Blinding ................................................................. 56
Method s  for A ss igning Treatment Group s ......................................................... 56
Method s  to En s ure Blinding........................................................................... . .. 56
Method s  for Unblindin g .................................................................................... 56
Unblinding in the Event of a M edical Emergency ............................................. 56
Restriction s  During the S tudy and Concomitant Treatment( s ) ........................ . .. 57
Permitted Concomitant M edication s  ................................................................. 57
Prohibited Concomitant M edication s  ................................................................ 57
Statis tical Evaluation ........................................................................................ 57
General Con s ideration s ..................................................................................... 57
Sample S ize ................................................................................................... . .. 58
Safety ............................................................................................................... 59
Analy s i s  of Adver s e Event s  ........................................................................... . .. 59
Efficacy……… ................................................................................................. 59
Analy s i s  of P harmacokinetic s  and Anti-drug Antibody..................................... 60
Pharmacokinetic Analysi s .............................................................................. . .. 60
CONFIDENTIAL AND PROPRIETARY 11 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
4.8.5.2
4.8.6
4.8.6.1
4.8.6.2
4.8.6.3
4.8.6.4
4.8.6.5
4.8.7
5
5.1
5.2
5.3
5.3.1
5.3.2
5.3.3
5.4
5.5
5.5.1
5.5.2
5.5.3
5.5.4
5.5.5
5.6
5.7
5.7.1
5.7.2
5.7.3
5.7.3.1
5.7.3.2
5.7.3.3
5.7.4
6
6.1
6.2
6.2.1
6.2.2
6.2.3
6.3
6.4
6.5
7
7.1Anti-drug Antibody Analy s i s ............................................................................ 60
Exploratory Analy s e s ..................................................................................... . .. 60
RSV Neutralizing Antibody.............................................................................. 60
RSV S erology................................................................................................... 61
Healthcare Re s ource Utilization and Caregiver Burden..................................... 61
RSV Re s i s tance M onit o ring.............................................................................. 61
RSV LRTI Occurring Fr om Day 152 to Day 361 .............................................. 61
Independent Data M onitoring Committee ......................................................... 61
ASSE SSM ENT O F  S AFETY ........................................................................... 61
Definition of Adver s e Event s ............................................................................ 61
Definition of S eriou s  Adver s e Event s  ............................................................ . .. 62
Definition of Adver s e Event s  of S pecial Intere s t ............................................... 62
Hyper s en s itivity, Including Anaphylaxi s ........................................................... 63
Immune Complex Di s ea s e ................................................................................ 63
Thrombocytopenia......................................................................................... . .. 63
Definition of New On s et Chronic Di s ea s e......................................................... 64
Recording of Adver s e Event s ............................................................................ 64
Time P eriod for Collection of Adver s e Event s .................................................. 64
Follow-up of Unre s olved Adver s e Event s ......................................................... 65
Death s  .............................................................................................................. 65
Adver s e Event s  Ba s ed o n S ign s  and S ymptom s  ................................................ 65
Adver s e Event s  Ba s ed o n Examination and Te s t s .............................................. 65
Reporting of S eriou s  Adver s e Event s ................................................................ 66
Other Event s  Requiring Immediate Reporting................................................... 66
Overdo s e ..................... . ................................................................................. . .. 66
Medication Error............................................................................................... 67
Adver s e Event s  of S pecial Intere s t.................................................................... 68
Hyper s en s itivity, Including Anaphylaxi s ........................................................... 68
Immune Complex Di s ea s e ............................................................................. . .. 68
Thrombocytopenia............................................................................................ 68
New On s et Chronic Disea s e........................................................................... . .. 69
STUDY AND DATA M ANAGE M ENT........................................................... 69
Training of S tudy S ite Per s onnel....................................................................... 69
Monitoring of the S tudy.................................................................................... 69
Source Data ................................................................................................... . .. 70
Study Agreement s ........ . .................................................................................... 70
Archiving of S tudy Document s ......................................................................... 70
Study Timetable and End of S tudy.................................................................... 70
Data M anagement........ . .................................................................................... 70
Medical M onitor Coverage ............................................................................... 71
ETHICAL AND REGULATORY REQUIRE M ENT S ...................................... 71
Subject Data P rotection..................................................................................... 71
CONFIDENTIAL AND PROPRIETARY 12 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
7.2 Ethic s  and Regulatory Review .......................................................................... 71
7.3 Informed Con s ent ........ . ................................................................................. . .. 72
7.4 Change s  to the P rotocol and Informed Con s ent F orm..................................... . .. 72
7.5 Audit s  and In s pection s ...................................................................................... 73
8 RE F ERENCE S ................................................................................................. 74
LIST  OF  TABLES
Table 1
Table 2
Table 3
Table 4
Table 5
Table 6
Table 7
Table 8
Table 9
Table 10
Table 11Primary Objective and A ss ociated Endpoint ............................................ 22
Secondary Objective s  and A ss ociated Endpoint s ................................... . .. 22
Exploratory Objective s  and Endpoint s ..................................................... 23
Schedule of S creening P rocedure s  ........................................................... 35
Schedule of Treatment P eriod and F ollow-up P eriod S tudy P rocedure s :
Season 1, P reterm and CLD/CHD Cohort s ............................................... 37
Schedule of Treatment P eriod and F ollow-up P eriod S tudy P rocedure s :
Season 2, CLD/CHD Cohort Only ........................................................... 40
Criteria for M eeting the P rotocol-defined Endpoint of M edically
Attended R S V LRTI - S ubject s  Without Underlying Lung Di s ea s e....... . .. 44
Criteria for M eeting the P rotocol-defined Endpoint of M edically
Attended R S V LRTI – S ubject s  With Underlying Lung Di s ea s e (CLD o r
CHD)....................................................................................................... 45
Volume of Blood to be Collected, S ea s on 1 ............................................. 49
Volume of Blood to be Collected, S ea s on 2 ............................................. 49
Identification of Inve s tigational P roduct s .............................................. . .. 50
LIST  OF  FIGURES
Figure 1
Figure 2
Figure 3
Figure 4Study F low Diagram................................................................................ 26
Dos ing Regimen: S ea s on 1 – P reterm Cohort and CLD/CHD Cohort....... 27
Dosing Regimen: S ea s on 2 – CLD/CHD Cohort, M EDI8897 Group in
Season 1 ............. . ................................................................................. . .. 28
Dosing Regimen: S ea s on 2 – CLD/CHD Cohort, P alivizumab Group i n
Season 1 ............. . .................................................................................... 28
LIST  OF  APPENDICES
Appe nd ix A
Appe nd ix BAdditional S afety Guidance ..................................................................... 77
National In s titute of Allergy and Infectiou s  Di s ea s e s  and F ood Allergy
and Anaphylaxi s  Network Guidance for Anaphylaxi s  Diagno s i s .............. 80
CONFIDENTIAL AND PROPRIETARY 13 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
LIST  OF  ABBREVIATIONS
Abbre v i at i on o r
Speci a lize d T er m
aa a m i no aci dDefin i t i on
AAP Am e r ica n A ca d e my of P e d iat r ic s
ADA a n ti -drug a n ti body
AE a dv e rs e  e v e n t
AESI a dv e rs e  e v e n t  of sp ecial  i n te r e s t
ATP As- t r eate d Popu lati on
AUC a r ea  und e r t h e  c on ce n t r ati on- ti m e  c urv e
CE Con f orm ité  Europ ée nn e
CHD c ong e n ital  h ea r t  d i s ea s e
CI c onf i d e n ce  i n te rv al
CLD c hron ic  l ung d i s ea s e
Cmax m a x i mum obs e rv e d c on ce n t r ati on
eCRF elect ron ic  ca s e  r e por t  form
EDC elect ron ic  d ata  ca p t ur e
ER e m e rg e n c y room
EU Europ ea n Un i on
F fus i on
GA g e s tati on al  a g e
GCP Good C li n ical  Pr actice
HIV hum a n i mmunod e f icie n c y v i rus
hMPV hum a n m eta pn e umov i rus
HRU h ealt h ca r e  r e sour ce  u tilizati on
ICH In te rn ati on al  Coun cil  for H a rmon i s ati on
ICU i n te ns i v e  ca r e  un it
IEC Ind e p e nd e n t  E t h ic s Comm ittee
IgG i mmunog l obu li n G
IgG1κ i mmunog l obu li n G1 k a pp a
IM i n t r a mus c u la r
IRB Ins tit u ti on al  R e v ie w Bo a rd
ITT In te n t - t o- t r eat
IV i n t r a v e nous
IWRS i n te r acti v e  w e b r e spons e  sys te m
CONFIDENTIAL AND PROPRIETARY 14 of 80 T e mp late  18.0
MedImmun e
MEDI8897
Abbre v i at i on o r
Speci a lize d T er m
JCVI
LRTI
mAb
MEDLEY
NCI CTCAE
NOCD
OTC
PK
RRR
RSV
RT-PCR
SAE
SID
t1/2
TEAE
TESAE
UK
US FDA
USA
YTEProt o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Defin i t i on
Joint  Comm ittee  on V acci n ati on a nd Immun i s ati on
lowe r r e sp i r at ory t r act  i nf ecti on
mono cl on al  a n ti body
Study D5290C00005
Nation al  C a n ce r Ins tit u te  Common T e rm i no l ogy Cr ite r ia  for Adv e rs e  Ev e n t s
new ons et  c hron ic  d i s ea s e
over- t h e - c oun te r
pharm ac ok i n etic (s)
relati v e  r i sk r e du cti on
respi r at ory syn c y tial  v i rus
revers e  t r a ns c r i p ta s e -po l ym e r a s e  c h ai n r eacti on
serious a dv e rs e  e v e n t
subject  i d e n ti f icati on
termi n al  h al f- li f e
treatm e n t - e m e rg e n t  a dv e rs e  e v e n t
treatm e n t - e m e rg e n t  s e r i ous a dv e rs e  e v e n t
Unite d K i ngdom
Unite d S tate s Food a nd Drug Adm i n i s t r ati on
Unite d S tate s of Am e r ica
M257Y / S259T / T261E [M252Y / S254T / T256E t r i p le  a m i no aci d subs tit u ti on
CONFIDENTIAL AND PROPRIETARY 15 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
1 INTRODUCTION
Prevention of re s piratory s yncytial viru s  (R S V) illne ss e s  in all infant s  i s  a major public health
priority. H owever, de s pite more than 50 year s  of attempted vaccine development, there are no
licen s ed v accine s  and no approved R S V prophylaxi s  for the broader population of healthy
infant s . There are no s pecific R S V therapeutic option s  s o the current medical management is
limited t o  s upportive care.
The only currently approved prophylaxi s  for R S V, palivizumab ( S ynagi s ® ) wa s  developed by
MedImmune and i s  only indicated for u s e in high-ri s k children: preterm infant s  ≤ 35 weeks
gestational age (GA), children with chronic lung di s ea s e (CLD) of prematurity, and child r en
with hemodynamically s ignificant congenital heart di s ea s e (CHD). In addition, further
restriction s  have been implemented by local or national recommending bodie s  on the u s e o f
palivizumab. F or example, in the United S tate s  of America (U S A) per the American Academy
of Pediatric s  (AA P ) guideline s , palivizumab i s  not recommended for healthy preterm infants
≥ 29 week s  GA ( American Academy of P ediatric s , 2014 ). In the United Kingdom (UK),
palivizumab i s  recommended by the J oint Committee on Vaccination and Immuni s ation
(JCVI) for preterm infant s  with CL D  or hemodynamically s ignificant, acyanotic CHD
based on the GA at birth and chronological age at the s tart of the R S V s ea s on ( J CVI, 20 1 0a,
2010b ).
1.1 Disease  Background
RSV i s  the mo s t common cau s e of lower re s piratory tract infection (LRTI) among infant s
and young children, re s ulting in annual epidemic s  worldwide ( Hall et al, 2009 ; Hall, 2012 ;
Madhi et al, 2006 ; S hay et al, 1999 ; S hi et al, 2017 ; S tockman et al, 2012 ). All children,
including healthy term infant s , are at ri s k for s evere LRTI with primary R S V infection du r ing
infancy. Ninety percent of children are infected with R S V in the fir s t 2 year s  of life, and up to
40% of them will have LRTI with t h e initial epi s ode ( American Academy of P ediatric s , 2014 ;
Greenou g h et al, 2001 ; M ei ss ner, 2003 ; P arrott et al, 1973 ). R S V LRTI, characterized
predominantly a s  bronchioliti s  or pneumonia, repre s ent s  a s eriou s  illne ss  with
acute and perhap s  long-term con s e q uence s  to the developing lung s  in the s e young children
(Blanke n  et al, 2013 ). It i s  e s timate d  that R S V cau s e s  up to 90% of childhood bronchiolitis
and up to 40% of pediatric pneumonia s  (Hall, 2001 ). R S V bronchioliti s  wa s  the leading cause
of ho s pital admi ss ion s  for infant s  < 1 year of age for any rea s on between 1997 and 1999
(Leader and Kohlha s e, 2002 ). In 20 1 5, an e s timated 33.1 million (uncertainty range, 21.6 to
50.3 million) new epi s ode s  of R S V-a ss ociated LRTI occurred worldwide in children you n ge r
than 5 year s  (28% of LRTI epi s ode s ), with approximately 3.2 million (range, 2.7 to
3.8 million) epi s ode s  nece ss itating h o s pitalization, leading to 59,600 (range, 48,000 to 74,500 )
in-ho s pital death s . Children younger than 1 year of age had an e s timated 2.3 million ho s pital
admi ss ion s . The overall mortality due to R S V LRTI wa s  e s timated to be a s  high a s  118,200
(uncertainty range, 94,600 to 149,400)( S hi et al, 2017 ).
CONFIDENTIAL AND PROPRIETARY 16 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Although ho s pitalization i s  well recognized a s  an important con s equence of R S V illne ss ,
a large percentage of the healthcare burden from R S V occur s  out s ide of the ho s pital ( Car r oll
et al, 2008 ; Hall et al, 2009 ; P aramore et al, 2010 ) s uch that office vi s it s  and emergency
department vi s it s  are more frequent than s ub s equent ho s pitalization, e s pecially in healthy
infant s . The general s everity of R S V infection ob s erved among infant s  in outpatient s ettings is
almo s t a s  s evere a s  tho s e ob s erved in ho s pitalized infant s , including labored breathing
requirin g  s upplemental oxygen, wheezing, and fever ( Hall, 2012 ). While 95% of children
hospitalized with R S V had labored r e s piration s , s imilar percentage s  of outpatient s  were also
observe d  to have labored re s piration s  (85% of children cared for in emergency departme n ts
and 73% of children treated in private practice s etting s  (Hall et al, 2009 ). The outpatient
burden a n d s everity of di s ea s e account s  for a s ignificant portion of the morbidity a ss ociated
with R SV  in all infant s .
Palivizumab i s  the only approved a g ent for R S V prophylaxi s , and it s  u s e i s  limited to
high-ri s k children. Becau s e of it s  terminal half-life (t½) of approximately 1 month, infants and
young children need to receive monthly intramu s cular (I M ) do s e s  of palivizumab throughout
the typical 5-month R S V s ea s on to maintain protection. Thi s  con s titute s  a s ignificant burden
on healt h care provider s  a s  well a s  the infant s /children and their familie s . Additionally, many
infant s  who receive palivizumab are unable to comply with the monthly do s ing
schedule and non-compliance ha s  been s hown to re s ult in increa s ed ri s k of ho s pitalization
(Frogel et al, 2010 ; S tewart et al, 2013 ). F urthermore, the co s t of palivizumab prophylaxis has
led to additional re s triction s  being implemented by many countrie s , including the U S A
(American Academy of P ediatric s , 2014 ) and the UK ( J CVI, 2010a , 2010b ).
1.2 MEDI8897  Background
MEDI88 9 7 i s  briefly de s cribed below. Refer to the current Inve s tigator’ s  Brochure for details.
MEDI8897 i s  a recombinant human immunoglobulin G1 kappa (IgG1 κ) monoclonal antibody
(mAb) directed again s t the prefu s ion conformation of the R S V fu s ion ( F ) protein. The
antibody ha s  been engineered with a triple amino acid s ub s titution (YTE;
M257Y/ S 259T/T261E [ M 252Y/ S 254T/T256E, according to the European Union (EU)
numberi n g s y s tem]) in the fragment cry s tallizable ( F c) region to prolong the t 1 / 2 , which is
expected to provide protection from s eriou s  R S V di s ea s e for the duration of the R S V s ea s on.
MEDI88 9 7 neutralize s  R S V by bin d ing the prefu s ion conformation of the R S V F  protein at a
site di s tinct from that bound by palivizumab. In preclinical s tudie s , M EDI8897 wa s
> 150-fold more potent than palivizumab in vitro and approximately 9-fold more potent than
palivizumab in vivo in the cotton rat model ( Zhu et al, 2017 ). M EDI8897 i s  currently un d e r
development by M edImmune for the pa ss ive immunization of all infant s  entering their fi r st
RSV s ea s on and children with CL D  or CHD entering their fir s t and s econd R S V s ea s on f o r
the prevention of LRTI cau s ed by R S V. M EDI8897 may provide a co s t-effective opportunity
CONFIDENTIAL AND PROPRIETARY 17 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
to protect all infant s  from R S V di s ea s e ba s ed on an improvement in potency and the extended
t1/2 that is expected to s upport once-per-R S V- s ea s on do s ing.
1.3 Summary  of  Nonclinical  Experience
Toxicity, toxicokinetic s , and immunogenicity of M EDI8897 were evaluated in a Good
Laborat o ry P ractice-compliant repeat-do s e intravenou s  (IV) and I M  toxicology s tudy
conducted in cynomolgu s  monkey s.  Toxicology s tudie s  in cynomolgu s  monkey s  indicate that
there i s  no evidence of M EDI8897 toxicity in the s e animal model s .
Overall, data from
nonclinical s tudie s  do not reveal any M EDI8897-related s afety concern s .
Detail s  of the s e s tudie s  are included in the current Inve s tigator’ s  Brochure.
1.4 Summary  of  Clinical  Experience
MEDI8897 ha s  been inve s tigated in 3 completed clinical s tudie s , including a fir s t-time-in -
human P ha s e 1a s tudy in healthy adult s  ( S tudy D5290C00001), a fir s t-time-in-pediatric
Phase 1b/2a s tudy in healthy preterm infant s  ( S tudy D5290C00002), and a P ha s e 2b s afety
and efficacy s tudy in healthy preterm infant s  ( S tudy D5290C00003). M EDI8897 had a
favorable s afety profile, with generally s imilar proportion s  of treatment-emergent adver s e
event s  (TEAE s ) reported in the M EDI8897 and placebo-control group s  acro ss  the 3 s tudies.
A summary of S tudy D5290C0000 3  i s  pre s ented below. Refer to the current Inve s tigator’s
Brochure for detail s  on all M EDI8 8 97 clinical s tudie s .
1.4.1 Study  D5290C00003
The P ha s e 2b S tudy D5290C00003 wa s  a randomized, double-blind, placebo-controlled
single-do s e s tudy that evaluated the s afety, efficacy, P K, and ADA re s pon s e of M EDI8897 in
healthy p reterm infant s . S ubject s  were 29 to < 35 week s  GA entering their fir s t R S V s eason
who would not receive R S V proph y laxi s  ba s ed on the J CVI, AA P , or other local or national
guideline s . Overall, 1,453 s ubject s  were randomized 2:1 to receive a s ingle do s e of 50 m g  I M
MEDI8897 (n = 969) or placebo (n = 484). A total of 1,447 s ubject s  were do s ed, including
966 s ubject s  in the M EDI8897 group and 481 s ubject s  in the placebo group. S ubject s  were
CONFIDENTIAL AND PROPRIETARY 18 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
followed for approximately 360 day s  after do s ing. The s tudy wa s  completed on 06Dec2 0 18
(last s ubject la s t vi s it).
Result s  f r om the planned primary a n aly s i s  conducted after all randomized s ubject s  who
remained in the s tudy completed the Day 151 vi s it demon s trated a s tati s tically s ignificant
relative ri s k reduction (RRR) in the incidence of the primary endpoint of R S V-confirme d
LRTI (inpatient and outpatient) and the s econdary endpoint of R S V ho s pitalization.
Based on the primary analy s i s , the safety profile for the M EDI8897 group wa s  comparable to
the place b o group, with no identified ri s k s . Overall, of s ubject s  in the M EDI8897
group and of s ubject s  in the p lacebo group had at lea s t 1 TEAE. The majority of the
TEAE s  were mild or moderate in s everity. TEAE s  ≤ 1 day po s t do s e occurred in 2.5% of
subject s  in both group s . In compari s on to the placebo group, the M EDI8897 group had a
lower incidence of TEAE s  occurring ≤ 7 day s  po s t do s e (15.2% v s  12.5%, re s pectively),
TEAE s  ≥ Grade 3 in s everity (12.3 %  v s  7.4%, re s pectively), and treatment-emergent s erious
adver s e event s  (TE S AE s ; 16.7% v s  10.4%, re s pectively). The mo s t common TE S AE s , based
on the M EDI8897 group, were bronchioliti s  (2.1% M EDI8897, 4.2% placebo), LRTI
(1.4% M EDI8897, 2.7% placebo), pneumonia (1.4% M EDI8897, 2.1% placebo), and
bronchiti s  (1.2% M EDI8897, 2.3% placebo). None of the TE S AE s  were con s idered related to
study treatment by the inve s tigator. F ive death s  were reported during the s tudy through
Day 361, including 2 s ubject s  (0.2 % ) in the M EDI8897 group and 3 s ubject s  (0.6%) in the
placebo group. None of the death s  w ere related to s tudy drug according to the inve s tigato r .
Overall, the incidence of inve s tigational product-related TEAE s  ( M EDI8897 2.3%, placebo
2.1%); adver s e event s  of s pecial intere s t (AE S I s ), including hyper s en s itivity, immune
complex di s ea s e, and thrombocytopenia ( M EDI8897 0.5%, placebo 0.6%); and new on s et
chronic di s ea s e s wa s  low and generally
compara b le between the placebo and M EDI8897 group s . AE S I s  were reported in 5 s ubjects
(4 subject s  with ra s h or ra s h macular and 1 s ubject with petechiae) in the M EDI8897 group
and 3 s ubject s  (ra s h or ra s h papular) in the placebo group. All event s  were Grade 1 in s eve r ity.
The TEAE of petechiae that wa s  reported a s  an AE S I wa s  1-day duration and wa s  reported by
the s ite inve s tigator ba s ed on de s cri p tion by the parent. There were no laboratory a ss e ss ments
for the petechiae.
CONFIDENTIAL AND PROPRIETARY 19 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
TEAE s  that involved the s kin and s ubcutaneou s  ti ss ue s  (including diaper ra s h) were collected
as skin reaction s , with a few exception s  for s kin reaction s  that could be definitively diagnosed
such a s  impetigo, varicella, and s cabie s .
Following a s ingle fixed 50-mg I M  do s e of M EDI8897, over 95% of mea s urable Day 151
concentration s  were greater than the nonclinical EC 90  target of 6.8 μg/mL. The median area
under the concentration-time curve from time 0 to infinity (AUC 0- ∞ ) and e s timated apparent
t½ were 5.3 day.mg/mL (range, 3.2 to 10.2 day.mg/mL) and 56.5 day s  (range, 46.8 to
81.1 days), re s pectively.
Overall, the rate and titer s  of ADA were low, and in ADA-po s itive s ubject s  there wa s  no
effect on P K or s afety. Of the s ubject s  who had s erum s ample s  available for te s ting, AD A  was
detected po s t ba s eline in 4.3% (40/921) of s ubject s  in the M EDI8897 group and
2.8% (1 3 /466) of s ubject s  in the placebo group; with le ss  than 5% of s ubject s  in either group
being ADA po s itive at any vi s it. ADA titer s  ranged from 1:50 to 1:3,200 in the M EDI88 9 7
group and 1:50 to 1:200 in the placebo group. Of the M EDI8897 s ubject s  who were
post-ba s eline ADA po s itive, ADA targeting the YTE domain wa s  ob s erved in 4/17 s ubjects
on Day 151 and 10/15 on Day 361. Two M EDI8897 s ubject s  had ADA on Day 361.
1.5 Rationale  for  Conducting  the  Study
Prevention of R S V illne ss e s  in all infant s  i s  a major public health priority; however, de s pite
more than 50 year s  of attempted vaccine development, there are no licen s ed vaccine s . While
RSV prevention exi s t s  in the form o f a s pecific R S V IgG ( S ynagi s ® , palivizumab) requiring
5 once-monthly injection s , it i s  lice ns ed only for infant s  who experience the greate s t
morbidit y  and mortality from R S V: preterm infant s  born ≤ 35 week s  GA, children with CLD
of prematurity, and children with hemodynamically s ignificant CHD. In addition, due to the
cost of prophylaxi s , further re s triction s  have been implemented by local or national
recommending bodie s . F or example, the U S A national guideline s  provided by the American
Academy of P ediatric s  (American Academy of P ediatric s , 2014 ) limit the recommendation f o r
palivizumab to (a) preterm infant s  born before 29 week s  GA who are younger than 12 months
of age at the s tart of the R S V s ea s on, (b) preterm infant s  with a GA of < 32 week s  and CLD
for the fir s t year of life with con s ideration of prophylaxi s  during the s econd year if continued
medical s upport i s  required, and (c) infant s  with hemodynamically s ignificant CHD who a r e
12 month s  of age or younger. In the UK, palivizumab i s  recommended by the J oint Committee
on Vaccination and Immuni s ation ( J CVI) for preterm infant s  with CLD or hemodynamically
significant, acyanotic CHD ba s ed on the GA at birth and chronological age at the s tart of the
RSV s ea s on ( J CVI, 2010a , 2010b ). M EDI8897 i s  being developed a s  a co s t-effective
opportu n ity to protect all infant s , including tho s e who currently receive palivizumab, from
RSV di s ea s e ba s ed on improved potency and an extended t 1 / 2 , which i s  expected to s uppo r t
once-per-R S V- s ea s on do s ing.
CONFIDENTIAL AND PROPRIETARY 20 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
The M EDI8897 clinical development program include s  two pivotal s tudie s  for infant s  ente r ing
their fir s t R S V s ea s on: the completed P ha s e 2b s tudy (D5290C00003) and a planned P hase 3
study (D5290C00004 [ M ELODY]). Becau s e of the s ignificant advantage of one do s e per R S V
season that M EDI8897 would provide, M edImmune recognize s  the potentially important
benefit s  for the current pediatric po p ulation receiving palivizumab who mu s t receive monthly
injections during the typical 5-month R S V s ea s on for protection. Therefore, thi s  P ha s e 2/3
study i s  planned to s upport an indication in the high-ri s k palivizumab-eligible population
entering their fir s t and s econd R S V s ea s on s  to compare the s afety, P K, ADA, and efficacy
trend of MEDI8897 once-per-R S V- s ea s on do s ing with palivizumab once-per-month do s ing
during the R S V s ea s on.
1.6 Benefit-Risk  and  Ethical  Assessment
The s tudy will be performed in accordance with ethical principle s  that have their origin in the
Declaration of Hel s inki and are con s i s tent with International Council for Harmoni s ation
(ICH)/Good Clinical P ractice (GCP), and applicable regulatory requirement s .
See S ection 1.4 for a s ummary of M EDI8897 clinical s afety and efficacy. M ore detailed
information about the known and e x pected benefit s  and ri s k s  of M EDI8897 can be found in
the Investigator ’ s  Brochure.
1.6.1 Potent i a l Benef i t
Palivizumab, the only currently approved R S V prophylaxi s , require s  5 once-monthly
injection s  for protection and due to co s t i s  re s tricted for u s e only in infant s  at the greate s t r isk
for morbidity and mortality from R S V. A s  there i s  no approved treatment for active R SV
infection ,  the current s tandard of ca r e for patient s  with s eriou s  R S V illne ss  i s  s upportive ca r e.
Thus , there i s  a s ignificant unmet medical need for R S V prophylaxi s  in high-ri s k infant s  and
children. F avorable efficacy and s afety data from the P ha s e 2b S tudy D5290C00003 in
preterm infant s  who received a s ingle do s e of M EDI8897, s ugge s t that M EDI8897 may
provide an important alternative an d  co s t-effective option.
1.6.2 Potent i a l R i sk
MEDI8897 ha s  no endogenou s  target s , and no s afety concern s  were identified in nonclinical
studie s . The potential ri s k s  are ba s ed primarily on common s afety ri s k s  ob s erved with an y
immunoglobulin, including mAb s  s uch a s  palivizumab. The s e potential ri s k s  include, but a r e
not limited to, hyper s en s itivity (including anaphylaxi s ), immune complex di s ea s e,
thrombocytopenia, and injection s ite reaction s . To date, there have been no ob s erved events o f
anaphylaxi s , s ignificant hyper s en s itivity reaction s , immune complex di s ea s e, or
thrombocytopenia attributable to M EDI8897 in the clinical s tudie s . Nonethele ss , s ubjects in
MEDI8897 clinical s tudie s  will be monitored for important potential ri s k s , and routine
pharmacovigilance and ri s k minimization activitie s  will be performed accordingly.
CONFIDENTIAL AND PROPRIETARY 21 of 80 T e mp late  18.0
Safet yMEDI8897 c omp a r e d t o p ali v iz um a b wh e n
assess e d by t h e  o cc urr e n ce  of all
TEAEs, TESAEs, AESIs, a nd NOCDsMedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
1.6.3 Overa ll Benef i t-R i sk
The current s tudy will compare the safety, P K, ADA, and de s criptive s tati s tic s  of M EDI8897
with pali v izumab in high-ri s k prete r m infant s  and children. The s ingle-do s e regimen for
MEDI8897 v s  the 5 once-monthly do s ing regimen for palivizumab pre s ent s  a potentially
important and co s t-effective treatment option for R S V prophylaxi s  in thi s  high-ri s k pediat r ic
population of preterm infant s  and children up to 2 year s  of age with CLD or CHD.
The de s i g n of the current s tudy aim s  to minimize the ri s k s  to s ubject s  and include s  the
protocol inclu s ion and exclu s ion criteria, re s triction s  on concomitant medication during the
study, s afety monitoring (including review of all s afety data by the independent data
monitoring committee), and s tudy s topping criteria.
Overall, the benefit-ri s k a ss e ss ment for thi s  P ha s e 2/3 s tudy i s  acceptable.
2 OBJECTIVES  AND  ENDPOINTS
2.1 Primary  Objective  and  Associated  Endpoint
Table 1                Primary O b jec t ive a nd  A ss ociate d  E ndp oi n t
Type Obj ec t i v e Endpo i nt
To ev al u ate  t h e  s a f et y a nd t o le r a b ilit y of
admi n i s te r e d t o pr ete rm i nf a n t s e n te r i ng t h ei r S a f et y a nd t o le r a b ilit y of MEDI8897 a s
first RSV s ea son a nd c h il dr e n w it h CLD or
CHD e n te r i ng t h ei r f i rs t  a nd s ec ond RSV
season
AESI = a dv e rs e  e v e n t  of sp ecial  i n te r e s t;  CHD = c ong e n ital  h ea r t  d i s ea s e;  CLD = c hron ic  l ung d i s ea s e;
NOCD = n e w ons et  c hron ic  d i s ea s e;  RSV = r e sp i r at ory syn c y tial  v i rus ;  TEAE = t r eat m e n t - e m e rg e n t  a dv e rs e
even t;  TESAE = t r eat m e n t - e m e rg e n t  s e r i ous a dv e rs e  e v e n t .
2.1.1 Secondary  Object i ves  and  Assoc i ated  Endpo i nts
Table 2                S eco nd ary O b jective s  a nd  A ss ociate d  E ndp oi n t s
Type
PKObjec t i v e
To ev al u ate  s e rum c on ce n t r ati ons of
MEDI8897 a nd p ali v iz um a bEndpo i nt
• MEDI8897 a nd p ali v iz um a b s e rum
conce n t r ati ons
• MEDI8897 a nd p ali v iz um a b PK
param ete rs :  Summ a ry of s e rum
conce n t r ati ons a nd e s ti m ate d PK
param ete rs (C max , AUC, a pp a r e n t
clear a n ce , a nd t 1 / 2 , i f d ata  p e rm it )
ADATo ev al u ate  ADA r e spons e s t o MEDI8897
and t o p ali v iz um a b i n s e rumIncid e n ce  of ADA t o MEDI8897 a nd
paliv iz um a b i n s e rum
To ass e ss t h e  d e s c r i p ti v e  e ff icac y of
MEDI8897 wh e n a dm i n i s te r e d a s a  s i ng le
Efficac y IM dos e  of 50 mg t o i nf a n t s < 5 kg or
100 mg t o i nf a n t s ≥ 5 kg i n t h e  f i rs t  RSV
season or a  s i ng le  200-mg IM dos e• In ci d e n ce  of m e d icall y atte nd e d LRTI
(inpatie n t  a nd ou t p atie n t ) du e  t o
RT-PCR- c onf i rm e d RSV t hrough
150 d a ys a f te r Dos e  1 for S ea son 1 a nd
Season 2
CONFIDENTIAL AND PROPRIETARY 22 of 80 T e mp late  18.0
MedImmun e
MEDI8897
Table 2Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Seco nd ary O b jective s  a nd  A ss ociate d  E ndp oi n t s
Type Obj ec t i v e Endpo i nt
admi n i s te r e d i n t h e  s ec ond RSV s ea son, i n• In ci d e n ce  of hosp italizati ons du e  t o
reduci ng m e d icall y atte nd e d LRTI ( i np atie n t            RT-PCR- c onf i rm e d RSV t hrough
and ou t p atie n t ) a nd hosp italizati on du e  t o 150 d a ys a f te r Dos e  1 for S ea son 1 a nd
RT-PCR- c onf i rm e d RSV, c omp a r e d t o S ea son 2
paliv iz um a b
ADA = a n ti -drug a n ti body ;  AUC = a r ea  und e r t h e  c on ce n t r ati on- ti m e  c urv e;  C max  = m a x i mum obs e rv e d
conce n t r ati on ;  IM = i n t r a mus c u la r ;  LRTI = l ow e r r e sp i r at ory t r act  i nf ecti on ;  PK = ph a rm ac ok i n etic;  RSV =
respi r at ory syn c y tial  v i rus ;  RT-PCR = r e v e rs e  t r a ns c r i p ta s e -po l ym e r a s e  c h ai n r eacti on ;  t 1 / 2  = te rm i n al  h al f- li f e .
2.1.2 Exp l oratory  Object i ves  and  Assoc i ated  Endpo i nts
Table 3                Ex p loratory O bj ective s  a nd  E ndp oi n t s
Type
RSV n e u t r alizi ng
antibody
RSV s e ro l ogy
HRU a nd
careg i v e r burd e nObjec t i v e
To dete rm i n e  a n ti -RSV n e u t r alizi ng
antibody le v el s i n s e rum a fford e d by a
single  dos e  of MEDI8897 c omp a r e d t o
5 mon t h l y dos e s of p ali v iz um a b
To ev al u ate  e xposur e  t o RSV by
measur i ng s e ror e spons e s t o d i ff e r e n t  RSV
protei ns i n MEDI8897 a nd p ali v iz um a b
recip ie n t s
To ev al u ate  t h e  le v el s of m ate rn al  RSV-
speci f ic  a n ti body i n MEDI8897 a nd
paliv iz um a b r eci p ie n t s
To ass e ss HRU a nd ca r e g i v e r burd e n for
MEDI8897 r eci p ie n t s c omp a r e d t o
paliv iz um a b r eci p ie n t sEndpo i nt
• An ti -RSV n e u t r alizi ng a n ti body le v el s
(IU/mL) i n s e rum for MEDI8897
recip ie n t s c omp a r e d t o p ali v iz um a b
recip ie n t s
• Summ a ry of s e rum RSV n e u t r alizi ng
antibody le v el s (m a y i n cl ud e  GMT,
GMFR, C max , a pp a r e n t  clea r a n ce , a nd t 1 / 2 )
• An ti body le v el s t o RSV F, G a , Gb, or N
at diff e r e n t  ti m e  po i n t s
• Ch a ng e s i n RSV a n ti body le v el s
(seror e spons e ) i nd icati ng e xposur e  t o
RSV
• RSV a n ti g e n a n ti body le v el s (AbU / mL)
to mu lti p le  RSV a n ti g e ns
• Summ a ry of s e rum RSV a n ti body le v el s
(may i n cl ud e  GMT, GMFR,
seroc onv e rs i on r ate s, a pp a r e n t  clea r a n ce ,
and t 1 / 2 )
• M a gn it ud e  of HRU ( e g, numb e r of
admi ss i ons t o hosp ital s a nd ICUs a nd
durati on of s ta y ;  numb e r of sub ject s who
requi r e  r e sp i r at ory suppor t  a nd
supple m e n tal  oxyg e n a nd t h e  dur ati on of
use; numb e r a nd t yp e  of ou t p atie n t  v i s it s
[eg, ER, urg e n t  ca r e , ou t p atie n t  cli n ic ] ;
and numb e r of pr e s c r i p ti on a nd OTC
medicati ons a nd dur ati on of us e ) for
MEDI8897 r eci p ie n t s c omp a r e d t o
paliv iz um a b r eci p ie n t s
• Ca r e g i v e r burd e n ( e g, ca r e g i v e r m i ss e d
work d a ys, sub ject  a bs e n ce  from d a y
care) for sub ject s w it h m e d icall y atte nd e d
LRTI ca us e d by RT-PCR- c onf i rm e d RSV
CONFIDENTIAL AND PROPRIETARY 23 of 80 T e mp late  18.0
RSV r e s i s ta n ce
monit or i ngMedImmun e
MEDI8897
Table 3Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Exploratory O bj ective s  a nd  E ndp oi n t s
Type Obj ec t i v e Endpo i nt
To ch a r acte r ize  r e s i s ta n ce  t o MEDI8897 G e no t yp ic  a n al ys i s a nd sus ce p ti b ilit y of
and p ali v iz um a b t hrough g e no t yp ic  a nd RSV v a r ia n t s t o n e u t r alizati on by
pheno t yp ic  a n al ys e s MEDI8897 a nd p ali v iz um a b
To ass e ss t h e  i n ci d e n ce  of m e d icall y In ci d e n ce  of m e d icall y atte nd e d LRTI
RSV LRTI a f te r atte nd e d LRTI du e  t o RT-PCR- c onf i rm e d ( i np atie n t  a nd ou t p atie n t ) du e  t o RT-PCR-
Day 151 RSV, c omp a r e d t o p ali v iz um a b a f te r c onf i rm e d RSV from D a y 152 t o D a y 361
Day 151 for S ea son 1 a nd S ea son 2
AbU / mL = a n ti body un it  p e r mL ;  C max  = m a x i mum obs e rv e d c on ce n t r ati on ;  ER = e m e rg e n c y room ;  GMFR =
geom et r ic  m ea n fo l d-r i s e;  GMT = g e om et r ic  m ea n tite r ;  HRU = h ealt h ca r e  r e sour ce  u tilizati on ;  ICU = i n te ns i v e
care un it;  LRTI = l ow e r r e sp i r at ory t r act  i nf ecti on ;  OTC = ov e r- t h e - c oun te r ;  RSV = r e sp i r at ory syn c y tial  v i rus ;
RT-PCR = r e v e rs e  t r a ns c r i p ta s e -po l ym e r a s e  c h ai n r eacti on ;  t 1 / 2  = te rm i n al  h al f- li f e .
3 STUDY  DESIGN
3.1 Description  of  the  Study
3.1.1 Overv i ew
Study D5290C00005 ( M EDLEY) i s  a pivotal P ha s e 2/3 randomized, double-blind,
palivizumab-controlled s tudy to evaluate the s afety, P K, ADA re s pon s e, and de s criptive
efficacy for M EDI8897 in high-ri sk  infant s  eligible to receive palivizumab when enterin g
their fir s t or s econd R S V s ea s on ( S ea s on 1 or S ea s on 2, re s pectively). Approximately
900 palivizumab-eligible infant s  entering their fir s t R S V s ea s on will be enrolled into one o f
2 cohorts ( F igure 1 ): (1) preterm cohort, including approximately 600 preterm infant s
(≤ 35 week s  GA) without CLD/CH D , or (2) CLD/CHD cohort, including approximately
300 infant s  with CLD of prematurity or hemodynamically s ignificant CHD. A s  minimum o f
100 infant s  with hemodynamically s ignificant CHD will be enrolled. Within each cohort,
randomization will be s tratified by hemi s phere (northern, s outhern) and s ubject age at the time
of Sea s on 1 randomization ( ≤ 3 mo n th s , > 3 to ≤ 6 month s , > 6 month s ).
Seas o n  1 , Preterm a nd  CLD/CHD Co h ort s
All s ubject s  will be randomized 2:1 to either the M EDI8897 group (approximately
600 s ubject s , including approximately 400 s ubject s  in the preterm cohort and approximately
200 s ubject s  in the CLD/CHD cohort) or palivizumab group (approximately 300 s ubject s ,
including approximately 200 s ubject s  in the preterm cohort and approximately 100 s ubjects in
the CLD/CHD cohort). S ubject s  in the M EDI8897 group will receive a s ingle fixed I M  dose
of M EDI8897 followed by 4 once-monthly I M  do s e s  of placebo. The M EDI8897 do s e level
will be s tratified by weight band, ie ,  50 mg for infant s  weighing < 5 kg or 100 mg for infants
weighing ≥ 5 kg. S ubject s  in the palivizumab group will receive 5 once-monthly I M  do s es o f
15 mg/kg palivizumab.
CONFIDENTIAL AND PROPRIETARY 24 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Seas o n  2 , CLD/CHD Co h ort O n ly
 S ubject s  with CLD/CHD ≤ 24 month s  of age who were randomized to the M EDI8897
group for S ea s on 1 will receive a s ingle fixed I M  do s e of 200 mg M EDI8897 followed by
4 once-monthly I M  do s e s  of placebo (approximately 200 s ubject s ).
 S ubject s  with CLD/CHD ≤ 24 month s  of age who were randomized to the palivizumab
group for S ea s on 1 will be re-randomized 1:1 to either the M EDI8897 group or the
paliv izumab group. S ubject s  in the M EDI8897 group will receive a s ingle fixed I M  dose
of 200 mg M EDI8897 followed by 4 once-monthly I M  do s e s  of placebo (approximately
50 su bject s ). S ubject s  in the palivizumab group will receive 5 once-monthly I M  do s es o f
15 mg/kg palivizumab (approximately 50 s ubject s ).
In Sea s o n  1 or S ea s on 2, s ubject s  in the CLD/CHD cohort who undergo cardiac s urgery with
cardiopulmonary bypa ss  after receipt of Do s e 1 but prior to receipt of Do s e 5 will receive a
replacement do s e of the s tudy drug they received for Do s e 1 immediately following the
surgery when determined by the phy s ician to be medically s table for an I M  injection. Any
subsequent do s e s  of s tudy drug will continue to be given according to the protocol- s pecified
dosing s chedule. S ee S ection 3.1.2. 3  for detail s  on replacement do s ing.
Subject s  in the preterm cohort will b e followed through 1 year after S ea s on 1/Do s e 1, and
subject s  in the CLD/CHD cohort will be followed through 1 year after S ea s on 2/Do s e 1.
Subject s  in the CLD/CHD cohort w ho receive a replacement do s e in S ea s on 2 will be
followed through 1 year after the la s t replacement do s e.
Subject s  in the CLD/CHD cohort with a weight < 7 kg at the time of do s ing for S ea s on 2 will
have increa s ed monitoring of adver s e event s  (AE s ). Any S AE s  or Grade 3 or Grade 4 AEs
that occur in the fir s t month after do s ing will be s ent to the independent data monitoring
committee for immediate review.
Subject s  will be monitored throughout the s tudy for LRTI ( s ee S ection 4.3.1 ). All s ubjects
seeking medical attention for a re s piratory illne ss  (in either the inpatient or outpatient s etting )
will be evaluated for LRTI, including protocol-defined medically attended R S V LRTI
(Table 7 and Table 8 ). All s ubject s  evaluated for LRTI will have re s piratory s ample s  obtained
and te s te d  centrally for R S V u s ing the United S tate s  F ood and Drug Admini s tration
(US F D A )-cleared and Confo r mité Eu r opéenne (CE) or European Conformity-marked in vit r o
diagno s tic real-time rever s e tran s cripta s e-polymera s e chain reaction (RT- P CR) a ss ay ( s ee
Section 4.3.1.2 ).
Blood s ample s  will be collected for P K, ADA, and R S V neutralizing antibody and R S V
serology a s  defined in S ection s  4.3.3 , 4.3.4 , and 4.3.5 , re s pectively.
The end p oint s  to be mea s ured in thi s  s tudy are de s cribed in S ection 2.
CONFIDENTIAL AND PROPRIETARY 25 of 80 T e mp late  18.0
MedI mm un e
MEDI8897
Figure 1 Study Flow DiagramProt o c o l  D5290 C 00005 (M E D LE Y) A me nd me n t  1
 31M a r2021 ;  F i n al
ADA  =  anti-drug  antibody;  CHD  =  congenital  heart  disease;  CLD  =  chronic  lung  disease;  IM  =  intramuscular;  PK  =  pharmacokinetic.
SEASON  1:  Randomization  for  Season  1  Day  1,  2:1  MEDI8897  or  palivizumab  group
SEASON  2  (CLD/CHD  cohort  only):  Randomization  for  Season  2  Day  1:  Subjects  who  were  randomized  in  Season  1  to  receive  MEDI8897  will  receive  MEDI8897  in  Season  2.
Subjects  who  were  randomized  to  receive  palivizumab  in  Season  1  will  receive  MEDI8897  or  palivizumab  in  Season  2
Blood  samples  for  PK  and  ADA:  Season  1  for  both  cohorts  –  Screening  or  Day  1  predose  and  on  Days  31  (predose),  151,  and  361  (for  CLD/CHD  cohort,  prior  to  Season  2
dosing);  Season  2  for  CLD/CHD  cohort  only  -  Days  31  (predose),  151,  and  361.  Additionally,  samples  will  be  collected  during  both  seasons  from  all  subjects  hospitalized  for  a
respiratory  infection,  and  before  and  after  cardiac  surgery  with  cardiopulmonary  bypass  for  subjects  with  CHD  requiring  a  replacement  dose  of  study  drug.
Safety  assessments  will  be  performed  through  Day  361  for  each  respective  season.
a In  the  MEDI8897  group  Season  1,  dose  level  will  be  stratified  by  body  weight  at  time  of  dosing;  subjects  will  receive  50  mg  MEDI8897  if  <  5  kg  or  100  mg  MEDI8897  if
≥ 5 kg.
CONFID E N T IA L  AND P R OP R I ET A R Y 26 of 80 Tem p late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
3.1.2 Dos i ng  Reg i men
Subject s  will be randomly a ss igned to receive s tudy drug a s  outlined in F igure 1 .
3.1.2.1 S ea s o n  1, Preterm Cohort a nd  CLD/CHD Co h ort
In Sea s on 1, s ubject s  in the preterm cohort and CLD/CHD cohort will receive either
MEDI88 9 7 or palivizumab a s  pre s ented in F igure 2 . S ection 3.1.2.3 provide s  detail s  on
replacement do s ing for s ubject s  in the CLD/CHD cohort who undergo cardiac s urgery with
cardiopulmonary bypa ss  s urgery.
Figu re 2 Do s i n g Regime n : S ea s o n  1 – Preterm Co h ort a nd  CLD/CHD Co h or t
CHD = c ong e n ital  h ea r t  d i s ea s e;  CLD = c hron ic  l ung d i s ea s e;  IM = i n t r a mus c u la r.
a V i s it  1 / S c r ee n i ng a nd V i s it  2 / D a y 1 a nd ca n o cc ur on t h e  s a m e  d a y.
b B a s e d on body w ei gh t  at  ti m e  of dos i ng.
3.1.2.2 S ea s o n  2, CLD/CHD Co h ort
In Sea s o n  2, s ubject s  in the CLD/C H D cohort only will receive either M EDI8897 or
palivizumab ba s ed on their randomized do s ing group in S ea s on 1. F igure 3 pre s ent s  the dosing
regimen for s ubject s  who were randomized to receive M EDI8897 in S ea s on 1. F igure 4
present s  the do s ing regimen for s ubject s  who were randomized to receive palivizumab in
Season 1. S ection 3.1.2.3 provide s  detail s  on replacement do s ing for s ubject s  in the
CLD/CHD cohort who undergo cardiac s urgery with cardiopulmonary bypa ss  s urgery.
CONFIDENTIAL AND PROPRIETARY 27 of 80 T e mp late  18.0
MedImmun e
MEDI8897
Figu re 3Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Dosi n g Regime n:  S ea s o n  2 – CLD/CHD Co h ort, MED I 8897 Gro up  i n
Seas o n  1
CHD = c ong e n ital  h ea r t  d i s ea s e;  CLD = c hron ic  l ung d i s ea s e;  IM = i n t r a mus c u la r.
Figu re 4 Do s i n g Regime n:  S ea s o n  2 – CLD/CHD Co h ort, Paliviz u ma b  Grou p  i n
Seas o n  1
CHD = c ong e n ital  h ea r t  d i s ea s e;  CLD = c hron ic  l ung d i s ea s e;  IM = i n t r a mus c u la r.
a B a s e d on body w ei gh t  at  ti m e  of dos i ng.
3.1.2.3 S ea s o n  1 or S ea s o n  2, CLD/CHD Co h ort - Re p laceme n t Do s e
Subject s  in the CLD/CHD cohort w ho undergo cardiac s urgery with cardiopulmonary by p ass
after receipt of Do s e 1 but prior to receipt of Do s e 5 will receive a replacement do s e of the
study dr u g that they received for Do s e 1 immediately following the s urgery when determined
by the phy s ician to be medically s table for an I M  injection. Any s ub s equent do s e s  of s tu d y
drug will continue to be given according to the protocol- s pecified do s ing s chedule. In s ubjects
requiring multiple s urgerie s  during the s ame s ea s on, the do s ing and timing s cheme de s cribed
below s hould be followed relative to the mo s t recent replacement do s e.
CONFIDENTIAL AND PROPRIETARY 28 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Detail s  for the replacement do s e by randomized group are pre s ented below.
MED I 8897 Gro up
S eason 1
 Subject s  undergoing s urge r y < 90 day s  po s t fir s t do s e who originally received 5 0  mg
MEDI8897 will receive a single 50-mg M EDI8897 I M  replacement do s e if < 5 kg
body weight at time of replacement do s ing or a s ingle 100-mg M EDI8897 I M
replacement do s e if ≥ 5 kg body weight at time of replacement do s ing.
Subject s  undergoing s urgery < 90 day s  po s t fir s t do s e who originally received
100 mg M EDI8897 will receive a s ingle 100-mg M EDI8897 I M  replacement dose.
 Subject s  undergoing s urge r y ≥ 90 day s  po s t fir s t do s e who originally received eithe r
50 mg or 100 mg M EDI8897 will receive a s ingle 50-mg M EDI8897 I M  replacement
dose.
S eason 2
Subject s  undergoing s urgery < 90 day s  po s t fir s t do s e will receive a s ingle 200-mg
MEDI8897 I M  replacement do s e.
Subject s  undergoing s urge r y ≥ 90 day s  po s t fir s t do s e will receive a s ingle 100-mg
MEDI8897 I M  replacement do s e.
Paliviz um a b  Gro up
Subject s  will receive a 15 mg/kg palivizumab I M  replacement do s e. Thereafter, do s e s  s hould
be given according to the protocol-specified do s ing s chedule.
3.2 Rationale  for  Dose,  Population,  and  Endpoints
3.2.1 Dose  Rat i ona l e
A single fixed 50-mg I M  do s e wa s  s hown to be efficaciou s  in the P ha s e 2b S tudy
D5290C00003 in preterm infant s  (29 to < 35 week s  GA) in their fir s t R S V s ea s on.
Model-ba s ed analy s e s  of the P ha s e 2b clinical P K and efficacy data identified a projected
serum AUC 0 - ∞  of a s  the protective expo s ure thre s hold. The ri s k of medically
attended R S V-confirmed LRTI over the cour s e of the R S V s ea s on wa s  s ignificantly lowe r  in
infant s  w ith higher projected AUC 0 - ∞ . Infant s  with AUC 0- ∞  above had a
statis tically s ignificantly higher pro b ability of protection ba s ed on expo s ure-re s pon s e analysis
using Cox proportional hazard regre ss ion.
Henceforth, ba s ed on
these analy s e s , a s tratified fixed do s ing s trategy by weight band s  will be implemented to
ensure an adequate do s e to maintain M EDI8897 s erum concentration s  above the target A UC
CONFIDENTIAL AND PROPRIETARY 29 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
throughout the R S V s ea s on. Ba s ed on do s e optimization analy s i s  de s igned to maximize the
proporti o n of infant s  with clinicall y  efficaciou s  M EDI8897 s erum expo s ure, a s ingle fixed
50-mg I M  do s e will be admini s tered for infant s  < 5 kg in their fir s t R S V s ea s on while a single
fixed 100-mg do s e will be admini s tered for tho s e weighing ≥ 5 kg entering their fir s t R SV
season. Additionally, the body weight range for the P ha s e 2/3 population in the s econd yea r  o f
life at time of do s ing i s  expected to be approximately 8.5 to 15 kg. Therefore, with the s ame
rationale ,  a s ingle fixed 200-mg do s e of M EDI8897 i s  propo s ed for infant s  in the s econd yea r
of life to achieve and maintain efficaciou s  expo s ure during the entire s econd R S V s ea s on.
The appr o ved palivizumab do s ing regimen of 15 mg/kg admini s tered I M  once monthly du r ing
the R S V s ea s on (ie, once monthly for 5 month s ) will be u s ed for thi s  s tudy.
3.2.2 Rat i ona l e  for  Study  Popu l at i on
MEDI8897 ha s  the potential to add r e ss  a s eriou s  unmet medical need by protecting all in f ants
from R S V di s ea s e ba s ed on it s  demon s trated increa s ed potency and expected extended
half-life that may s upport once per sea s on do s ing. Becau s e of the s e s ignificant advantages
over palivizumab, including the potential for a s ingle do s e ver s u s  up to 5 monthly do s e s  o f
palivizumab, M EDI8897 may al s o p rovide a s ignificant improvement for prevention of R S V
disea s e in the pediatric population indicated for palivizumab, ie, high-ri s k preterm infant s  and
children up to 2 year s  of age with CLD or CHD. Therefore, thi s  P ha s e 2/3 s tudy i s  planned to
evaluate M EDI8897 in high-ri s k palivizumab-eligible infant s  and young children entering
their fir s t and s econd R S V s ea s on s .
3.2.3 Rat i ona l e  for  Endpo i nts
MEDI8897 i s  being developed to p r ovide R S V immunoprophylaxi s  for all infant s  enteri n g
their fir s t R S V s ea s on and children with CLD of prematurity or hemodynamically s ignificant
CHD entering their fir s t and s econd s ea s on s . The primary endpoint for thi s  s tudy i s  s afety and
tolerability, with the aim of comparing the profile s  for M EDI8897 and palivizumab in this
population. The s tandard mea s ure s  of TEAE s /TE S AE s , AE S I s , and NOCD s  will be u s ed f o r
this a ss e ss ment. All s ubject s  will be followed for approximately 1 year after the la s t do s e o f
MEDI88 9 7. S ubject s  with CLD/CHD who receive M EDI8897 for S ea s on 1 and S ea s on 2 and
subject s  who receive a replacement do s e of M EDI8897 after cardiopulmonary bypa ss  will
provide d ata for the s afety a ss e ss ment of infant s  who receive more than a s ingle do s e of
MEDI8897.
Serum concentration of M EDI8897 at s elected time point s  will be evaluated a s  a s econda r y
endpoint to confirm that s erum concentration s  are maintained at an efficaciou s  level for at
least 5 month s  after do s ing. P alivizumab s erum concentration s  will al s o be evaluated.
MEDI8897 and palivizumab P K data will be s ummarized by non-compartmental analy s is.
Additionally, s erum concentration data will be u s ed to characterize the P K of M EDI8897 in
infant s  u s ing a population P K approach s eparately. F or infant s  who require ho s pitalization f o r
CONFIDENTIAL AND PROPRIETARY 30 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
LRTI or any re s piratory infection, an additional s erum s ample for mea s urement of
MEDI8897/palivizumab concentration and ADA will be obtained contemporaneou s  with time
of ho s pitalization. Expo s ure-re s ponse analy s i s  will be performed to relate M EDI8897 s e r um
concentration s  and efficacy endpoint s  (LRTI including R S V-a ss ociated ho s pitalization).
To determine M EDI8897 and palivizumab s erum level s  po s t do s ing and to correlate wit h  the
potential development of ADA, s erum concentration s  will be mea s ured up to 360 day s  post
Dose 1 (when M EDI8897 would be given) for both S ea s on 1 and, a s  applicable, S ea s on 2.
ADA to M EDI8897 and to palivizumab will be mea s ured at s elected time point s  through o ut
the stud y  and up to 360 day s  po s t D o s e 1 for each s ea s on a s  well.
This s tu d y will al s o s ummarize efficacy of M EDI8897 and palivizumab in term s  of incidence
of RS V LRTI. Re s piratory s yncytial viru s  re s ult s  in a s ignificant burden of di s ea s e con s isting
of ho s pitalization, vi s it s  to the eme r gency room (ER), and vi s it s  to outpatient clinic s . This
endpoint i s  de s igned to allow the capture of thi s  total burden of di s ea s e. A s eparate endpoint
of RS V ho s pitalization will al s o be evaluated. Becau s e of the reduced incidence of R S V
disea s e in thi s  population following the introduction of palivizumab, a s uperiority or
non-inferiority de s ign (with RRR of M EDI8897 over palivizumab a s  the endpoint) i s  not
practical. Thi s  P ha s e 2/3 s tudy i s  de s igned to confirm the s afety and P K while incidence o f
RSV LRTI (and R S V ho s pitalization) will be s ummarized and no formal s tati s tical te s t w ill be
conducted. It i s  anticipated that efficacy from the P ha s e 2b and P ha s e 3 s tudie s  in preterm and
term infant s  will be predictive of efficacy in the palivizumab population.
Exploratory endpoint s  will examine magnitude of healthcare re s ource utilization (HRU) and
caregive r  burden due to R S V illne s s in the current population. Thi s  will allow the
determination of s ocial and economic re s ource s  that are required for infant s  who have LRT I .
Serum anti-R S V neutralizing antibody level s  will be evaluated for correlation with s erum
MEDI8897 and palivizumab concentration s . R S V s erology will be evaluated to identify
potential expo s ure to R S V. To monitor for R S V re s i s tance, the F  protein from collected R S V
isolate s  w ill be genetically characterized and novel variant s  will be phenotypically
characte r ized for M EDI8897 and palivizumab s u s ceptibility. The incidence of medically
attended LRTI (inpatient and outpatient) due to RT- P CR-confirmed R S V from Day 152 to
Day 361 in S ea s on 1 and S ea s on 2 will be a ss e ss ed to determine if there i s  a po ss ible effect o f
MEDI8897 pa s t Day 151.
4 MATERIALS  AND  METHODS
4.1 Subjects
4.1.1 Number  of  Subjects
A total of approximately 900 s ubject s  will be enrolled and randomized to either the
MEDI8897 group (approximately 6 0 0 s ubject s , including approximately 400 s ubject s  in the
CONFIDENTIAL AND PROPRIETARY 31 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
preterm cohort and approximately 200 s ubject s  in the CLD/CHD cohort) or palivizumab
group (approximately 300 s ubject s , including approximately 200 s ubject s  in the preterm
cohort and approximately 100 s ubject s  in the CLD/CHD cohort).
4.1.2 Inc l us i on  Cr i ter i a
Subject s  mu s t meet all of the follo w ing criteria:
1F or the preterm cohort (excluding s ubject s  with CLD or hemodynamically s ignifica n t
CHD ): preterm infant s  in their f ir s t year of life and born ≤ 35 week s  0 day s  GA eligible to
receive palivizumab in accordance with national or local guideline s , including tho s e with:
(a) U ncomplicated s mall atrial or ventricular s eptal defect s  or patent ductu s  arterio s us, or
(b) A ortic s teno s i s , pulmonic s teno s i s , or coarctation of the aorta alone
2F or the CLD/CHD cohort:
(a) Subject s  with CLD - infant s  in their fir s t year of life and a diagno s i s  of CLD of
prematurity requiring medical intervention/management (ie, s upplemental oxygen,
bronchodilator s , or diuretic s ) within the 6 month s  prior to randomization
(b) Subject s  with CHD - infant s  in their fir s t year of life and documented,
hemodynamically s ignificant CHD (mu s t be unoperated or partially corrected C H D )
Note : Infant s  with hemod y namically s ignificant acyanotic cardiac le s ion s  mu s t have
pulmonary hyperten s ion (≥ 40 mmHg mea s ured pre ss ure in the pulmonary artery )  o r
the need for daily medicati o n to manage CHD
3Infant s  who are entering their fir s t R S V s ea s on at the time of s creening
4Written informed con s ent and any locally required authorization (eg, Health In s urance
Portability and Accountability A ct in the U S A, EU Data P rivacy Directive in the E U)
obtained from the s ubject' s  parent( s )/legal repre s entative( s ) prior to performing any
protocol-related procedure s , including s creening evaluation s
5S ubject' s  parent( s )/legal repre s entative( s ) able to under s tand and comply with the
requirement s  of the protocol including follow-up and illne ss  vi s it s  a s  judged by the
investigator
6 S ubject i s  available to complete the follow-up period, which will be 1 year after S ea s on 1/
Dose 1 for s ubject s  without CLD/CHD, or 1 year after S ea s on 2/Do s e 1 (or la s t
replacement do s e a s  applicable for CHD) for s ubject s  with CLD/CHD
4.1.3 Exc l us i on  Cr i ter i a
Any of the following would exclude the s ubject from participation in the s tudy:
1Any fever ( ≥ 100.4° F  [≥ 38.0°C], regardle ss  of route) or acute illne ss  within 7 day s  p r io r
to randomization
2Any hi s tory of LRTI or active LRTI prior to, or at the time of, randomization
3Kno w n hi s tory of R S V infecti o n or active R S V infection prior to, or at the time of,
randomization
CONFIDENTIAL AND PROPRIETARY 32 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
4Ho sp italization at the time of randomization, unle ss  di s charge i s  expected within the
7 days  after randomization
5Req u irement for mechanical ventilation, extracorporeal membrane oxygenation, C PAP ,
or other mechanical re s pirator y  or cardiac s upport at the time of randomization
6Anticipated cardiac s urgery within 2 week s  after randomization
7Anticipated s urvival of < 6 month s  after randomization
8Receipt of any inve s tigational drug
9Kno w n renal impairment
10 Known hepatic dy s function including known or s u s pected active or chronic hepatiti s
infection
11 Clinically s ignificant congenital anomaly of the re s piratory tract
12 Chr o nic s eizure, or evolving or un s table neurologic di s order
13 P rio r  hi s tory of a s u s pected or actual acute life-threatening event
14 Known immunodeficiency, including human immunodeficiency viru s  (HIV)
15 M other with HIV infection (unle ss  the child ha s  been proven to be not infected)
16 Any known allergy, including to immunoglobulin product s , or hi s tory of allergic reaction
17 Receipt of palivizumab or othe r  R S V mAb or any R S V vaccine, including maternal R S V
vaccination
18 Receipt of any monoclonal or p olyclonal antibody (for example, hepatiti s  B immune
globu lin, intravenou s  immunoglobulin) or anticipated u s e during the s tudy
19 Any condition that, in the opinion of the inve s tigator, would interfere with evaluation o f
the study drug or interpretation of s ubject s afety or s tudy re s ult s
20 Concurrent enrollment in another interventional s tudy
21 Children of employee s  of the s pon s or, clinical s tudy s ite, or any other individual s
involved with the conduct of t h e s tudy, or immediate family member s  of s uch indivi d uals
4.1.4 Subject  Enro ll ment  and  Random i zat i on
Study participation begin s  (ie, a s u b ject i s  “enrolled”) once written informed con s ent i s
obtained. Once informed con s ent i s  obtained, a s ubject identification ( S ID) number will be
assigned by a central s y s tem (eg, an interactive web re s pon s e s y s tem [IWR S ]), and the
screening evaluation s  may begin to a ss e ss  s tudy eligibility (inclu s ion/exclu s ion) criteria. The
SID number will be u s ed to identify the s ubject during the s creening proce ss  and throug h out
study participation, if applicable.
A ma s te r  log of all con s ented s ubject s  will be maintained at the s ite and will document all
screenin g  failure s  (ie, s ubject s  who are con s ented but do not meet s tudy eligibility criteria
and/or are not randomized), including the rea s on( s ) for s creening failure.
CONFIDENTIAL AND PROPRIETARY 33 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Subject s  who fail to meet the inclu s ion/exclu s ion criteria (ie, s creening failure s ) s hould not be
randomized or admini s tered s tudy drug. The inve s tigator mu s t con s ult with the s pon s or be f o r e
a subject who ha s  failed s creening may be con s idered for re s creening.
4.1.5 W i thdrawa l from  the  Study
Subject s  may at any time be withdrawn from the s tudy without prejudice to further treatment
(withdrawal of con s ent). The caregiver s  of s uch s ubject s  will alway s  be a s ked about the
reason( s ) for withdrawal and the pre s ence of any AE s . If po ss ible, the s ubject will be s ee n  and
assess ed by the inve s tigator. AE s  w ill be followed up. If a s ubject withdraw s  from furthe r
participation in the s tudy, then no further s tudy vi s it s  or data collection s hould take place.
4.1.6 D i scont i nuat i on  of  Invest i gat i ona l Product
An individual s ubject will not receive additional do s e s  of s tudy drug, including continued
dosing in S ea s on 2 for s ubject s  with CLD/CHD, if any of the following occur in the s ubject in
question:
1Withdrawal of con s ent
2Hyper s en s itivity reaction a ss e s sed a s  related to s tudy drug
Subject s  who have received any s tudy drug will be followed for protocol- s pecified
assess ment s  including follow-up of any AE s  unle ss  con s ent i s  withdrawn s pecifically from
further s tudy participation ( S ection 4.1.5 ) or the s ubject i s  lo s t to follow-up. S ubject s  wh o
have not received s tudy drug, regardle ss  of rea s on, will not be followed.
4.1.7 Rep l acement  of  Subjects
Subject s  will not be replaced.
4.1.8 W i thdrawa l of  Informed  Consent  for  Data  and  B i o l og i ca l Samp l es
MedImmune en s ure s  that biological s ample s  are de s troyed at the end of a s pecified period as
described in the informed con s ent.
If a s ubject withdraw s  con s ent to the u s e of donated biological s ample s , the s ample s  will be
dispo s ed of/de s troyed, and the acti o n documented. If s ample s  are already analyzed,
MedImmune i s  not obliged to de s troy the re s ult s  of thi s  re s earch.
The P rincipal Inve s tigator:
 En s ure s  s ubject s ’ withdrawal of informed con s ent to the u s e of donated s ample s  i s
notified immediately to M edImmune.
 En s ure s  that biological s ample s  from that s ubject, if s tored at the s tudy s ite, are
immediately identified, di s po s ed of/de s troyed, and the action documented.
CONFIDENTIAL AND PROPRIETARY 34 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
En su re s  the organization( s ) holding the s ample s  i s /are informed about the withdrawn
consent immediately and that s ample s  are di s po s ed of/de s troyed, the action documented,
and the s igned document returned to the s tudy s ite.
En s ure s  that the s ubject and M edImmune are informed about the s ample di s po s al.
MedImmune en s ure s  the organization s  holding the s ample s  i s /are informed about the
withdrawn con s ent immediately and that s ample s  are di s po s ed of/de s troyed and the action
docume n ted and returned to the s tudy s ite.
4.2 Schedule  of  Study  Procedures
Whenever vital s ign s  and blood dra ws  are s cheduled for the s ame nominal time, vital s igns
should occur prior to blood draw s .
4.2.1 Enro ll ment / Screen i ng  Per i od
Table 4 show s  all procedure s  to be conducted at the s creening vi s it.
Table 4 S c h e du le of S cree n i n g Proce du re s
Study P eri od
Visit Numb er
Proce du re  /  Study Day
Writte n i nform e d c ons e n t/  a ss i gnm e n t  of SID numb e r
Medical  h i s t ory
Phys ical  e x a m i n ati on
Weigh t
Vital  s i gns
Blood s a mp le  for PK, ADA, RSV n e u t  Ab, a nd RSV s e ro l ogy a
Asse ssm e n t  of AEs / SAEs
Conc om ita n t  m e d icati ons
Verify eli g i b ilit y c r ite r iaScree n i ng
V1
Day -30 to Day 1
 X
 X
 X
 X
 X
X
X
X
X
ADA = a n ti -drug a n ti body ;  AEs = a dv e rs e  e v e n t s ;  n e u t  Ab = n e u t r alizi ng a n ti body ;  PK = ph a rm ac ok i n etic;
RSV = r e sp i r at ory syn c y tial  v i rus ;  SAEs = s e r i ous a dv e rs e  e v e n t s ;  SID = sub ject  i d e n ti f icati on ;  V = v i s it .
Visit  1 / S c r ee n i ng a nd V i s it  2 / D a y 1 v i s it s m a y o cc ur on t h e  s a m e  d a y.
a If V i s it  1 / S c r ee n i ng a nd V i s it  2 / D a y 1 do no t  o cc ur on t h e  s a m e  d a y, b l ood s a mp le  for PK, ADA, RSV
neut Ab, a nd RSV s e ro l ogy ca n b e  c o llecte d at  eit h e r V i s it  1 / S c r ee n i ng or V i s it  2 / D a y 1 pr e dos e .
CONFIDENTIAL AND PROPRIETARY 35 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
4.2.2 Treatment  and  Fo ll ow-up  Per i ods
All procedure s  to be conducted during the treatment and follow-up period s  are pre s ented in
Table 5 f or S ea s on 1, preterm and CLD/CHD cohort s  and Table 6 for S ea s on 2, CLD/C H D
cohort only.
CONFIDENTIAL AND PROPRIETARY 36 of 80 T e mp late  18.0
MedImmun e
MEDI8897
Table 5Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Sche du le of Treatme n t Perio d  a nd  Follow- up  Perio d  S t ud y Proce du res :  S easo n  1, Pre t er m  a nd  CLD/CHD
Cohort s
Study  Period Treatment  Period Follow-up  Period
Visit  Number V2  a TC V3 V4 V5 V6 V7 V8 V9  b TC LRTISkin
Reaction
Procedure  /
Study  Day
Medical  history
update
Physical
examination
Weight
Vital  signs
Blood  sample  for
PK, ADA,  RSV
neut Ab,  and  RSV
serology  d
Assessment  of
AEs/SAEs,  AESIs,
NOCDs
Concomitant
medications
Verify  eligibility
criteria
Randomization  g
Study  drug
administration  h
Assessment  of  LRTI
or any  respiratory
infection  that
requires
hospitalization
Nasal  swab
collection
Assessment  of  skin
reactionD8 D15 D31
D1 (±  2 (±  2 (±  2
days) days) days)
X X X
X X X
X X X
X c X               X  c
X
X e (pre-
dose)
X X X X
X X X X
X
X
X XD61            D91           D121           D151
(± 2            (±  2            (±  2             (±  7
days)          days)          days)          days)
X X X X
X X X X
X               X                X                 X
Xc                 X  c                 X  c                   X
X
X X X X
X X X X
X X XD361 D1-151
(± 7              Q2W
days) (±  5  days)
X
X
X
X
X
X X
X XD152-361
monthly
(± 5 days)
X
XD1-361
as needed
X f
X
X
X f
X fD1-361
as needed
X
X
X i
CONFIDENTIAL AND PROPRIETARY 37 of 80 T e mp late  18.0
XMedImmun e
MEDI8897
Table 5Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Sche du le of Treatme n t Perio d  a nd  Follow- up  Perio d  S t ud y Proce du res :  S easo n  1, Pre t er m  a nd  CLD/CHD
Cohort s
Study  Period Treatment  Period Follow-up  Period
Visit  Number V2  a TC V3 V4 V5 V6 V7 V8 V9  b TC LRTISkin
Reaction
Procedure  /
Study  Day
Telephone
contact  jD8 D15 D31
D1 (±  2 (±  2 (±  2
days) days) days)
XD61            D91           D121           D151
(± 2            (±  2            (±  2             (±  7
days)          days)          days)          days)D361 D1-151
(± 7              Q2W
days) (±  5  days)
XD152-361
monthly
(± 5 days)
XD1-361
as neededD1-361
as needed
HRU  and  caregiver
burden  k
ADA  =  anti-drug  antibody;  AEs  =  adverse  events;  AESIs  =  adverse  events  of  special  interest;  CHD  =  congenital  heart  disease;  CLD  =  chronic  lung  disease;  D  =  study  day;  ER
= emergency  room;  HRU  =  healthcare  resource  utilization;  ICU  =  intensive  care  unit;  IM=intramuscular;  LRTI  =  lower  respiratory  tract  infection;  neut  Ab  =  neutralizing
antibody;  NOCDs  =  new  onset  chronic  diseases;  OTC  =  over-the-counter;  PK  =  pharmacokinetic;  Q2W  =  once  every  2  weeks;  RSV  =  respiratory  syncytial  virus;  SAEs  =
serious  adverse  events;  SID  =  subject  identification;  TC  =  telephone  call;  V  =  visit.
a Visit  2/Day  1  and  Visit  1/Screening  can  occur  on  the  same  day.
b For  subjects  in  the  CLD/CHD  cohort,  the  Season  1  Visit  9/Day  361  may  be  the  same  as  the  Season  2  Visit  10/Day  1  (Dose  1).
c  All  vital  signs  (temperature,  blood  pressure,  heart  rate,  and  respiratory  rate)  should  be  obtained  within  60  minutes  prior  to  dosing,  and  at  30  minutes  (±  5  minutes)  and
60 minutes  (±  5  minutes)  post  dose.
d Subjects  requiring  a  replacement  dose  of  study  drug  due  to  cardiac  surgery  with  cardiopulmonary  bypass  will  have  a  blood  sample  collected  before  and  after  surgery
(prior  to  administering  replacement  dose)  for  PK  evaluation.
e If  Visit  1/Screening  and  Visit  2/Day  1  do  not  occur  on  the  same  day,  blood  sample  for  PK,  ADA,  RSV  neut  Ab,  and  RSV  serology  can  be  collected  at  either
Visit  1/Screening  or  Visit  2/Day  1  predose.
f Nasal  samples  will  be  collected  from  all  subjects  with  LRTIs  (inpatient  or  outpatient)  and  from  all  hospitalized  subjects  with  any  new  respiratory  infection  (upper  or
lower)  within  approximately  2  days  after  the  initial  healthcare  provider  assessment  and  diagnosis.
Blood  samples  will  be  collected  from  all  subjects  hospitalized  with  LRTI  or  any  respiratory  infection  within  approximately  2  days  following  hospital  admission.
g Subjects  in  each  cohort  (preterm  and  CLD/CHD  cohorts)  will  be  randomized  2:1  to  receive  either  MEDI8897  administered  as  a  stratified  dose  by  weight  band,  which
includes  a  single  fixed  50-mg  IM  dose  for  infants  weighing  <  5  kg  or  100-mg  IM  dose  for  infants  weighing  ≥  5  kg,  followed  by  4  once-monthly  IM  doses  of  placebo;  or
5 once-monthly  IM  doses  of  15  mg/kg  palivizumab.
h Subjects  who  undergo  cardiac  surgery  with  cardiopulmonary  bypass  after  receipt  of  Dose  1  but  prior  to  receipt  of  Dose  5  will  receive  a  replacement  dose  of  the  study  drug
that they  received  for  Dose  1  immediately  following  the  surgery  when  determined  by  the  physician  to  be  medically  stable  for  an  IM  injection.  Any  subsequent  doses  of
study  drug  will  continue  to  be  given  according  to  the  protocol-specified  dosing  schedule.  See  Section  3.1.2.3  for  details.
i Skin  reaction  assessment  will  be  done  for  any  post-dosing  skin  or  skin-related  reaction  regardless  of  severity,  duration,  time  of  onset  post  dosing,  or  relationship  to  study
drug.
CONFIDENTIAL AND PROPRIETARY 38 of 80 T e mp late  18.0
MedImmun e
MEDI8897
Table 5Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Sche du le of Treatme n t Perio d  a nd  Follow- up  Perio d  S t ud y Proce du res :  S easo n  1, Pre t er m  a nd  CLD/CHD
Cohort s
Study  Period Treatment  Period Follow-up  Period
Visit  Number V2  a TC V3 V4 V5 V6 V7 V8 V9  b TC LRTISkin
Reaction
Procedure  /
Study  DayD8 D15 D31
D1 (±  2 (±  2 (±  2
days) days) days)D61            D91           D121           D151
(± 2            (±  2            (±  2             (±  7
days)          days)          days)          days)D361 D1-151
(± 7              Q2W
days) (±  5  days)D152-361
monthly
(± 5 days)D1-361
as neededD1-361
as needed
j Telephone  contact  must  be  verbal  communication.  Written  communication  via  text,  email,  or  other  written  form  is  not  acceptable.
k  HRU  includes  admission  and  duration  of  hospital  and  ICU  stay,  number  of  subjects  who  require  respiratory  support  and  supplemental  oxygen  use,  duration  of  respiratory
support  and  supplemental  oxygen  use,  number  and  type  of  outpatient  visits  (eg,  ER,  urgent  care,  outpatient  clinic),  and  number  and  days  of  prescription  and  OTC
medication.  Caregiver  burden  includes  days  of  worked  missed  by  the  parent(s)/legal  representative  or  other  household  member  as  a  result  of  the  subject’s  illness,  and  days
of daycare/babysitting  missed  by  the  subject  as  a  result  of  illness.
CONFIDENTIAL AND PROPRIETARY 39 of 80 T e mp late  18.0
MedImmun e
MEDI8897
Table 6Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Sche du le of Treatme n t Perio d  a nd  Follow- up  Perio d  S t ud y Proce du res :  S easo n  2, CLD/CHD Co h or t  O n ly
Study  Period Treatment  Period Follow-up  Period
Visit  Number V10  a TC V11 V12 V13 V14 V15 V16 V17 TC LRTISkin
ReactionReplacement
 Dose
Follow-up  b
Procedure  /
Study  Day
Medical  history
update
Physical
examination
Weight
Vital  signs
Blood  sample  for
PK, ADA,  RSV
neut Ab,  and  RSV
serology  d
Assessment  of
AEs/SAEs,  AESIs,
NOCDs
Concomitant
medications
Randomization  f
Study  drug
administration  gD8 D15 D31
D1 (±  2 (±  2 (±  2
days) days) days)
X X X
X X X
X X X
X c X              X c
X
(pre-
dose)
X X X X
X X X X
X
X XD61           D91
(± 2            (±  2
days)         days)
X X
X X
X X
Xc                X c
X X
X X
X XD121        D151
(± 2           (±  7
days)        days)
X X
X X
X             X
Xc                 X
X
X X
X X
XD361 D1-151
(± 7           Q2W
days) (±  5  days)
X
X
X
X
X
X X
X XD152–361      D1-361 D1-361
monthly as                 as
(± 5 days) needed needed
X e
X X X
X X X360  days
post  last
replacement
dose
(± 7 days)
X
X
X
X
X
X
X
CONFIDENTIAL AND PROPRIETARY 40 of 80 T e mp late  18.0
MedImmun e
MEDI8897
Table 6Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Sche du le of Treatme n t Perio d  a nd  Follow- up  Perio d  S t ud y Proce du res :  S easo n  2, CLD/CHD Co h or t  O n ly
Study  Period Treatment  Period Follow-up  Period
Visit  Number V10  a TC V11 V12 V13 V14 V15 V16 V17 TC LRTISkin
ReactionReplacement
 Dose
Follow-up  b
Procedure  /
Study  Day
Assessment  of  LRTI
or any  respiratory
infection  that
requires
hospitalization
Nasal  swab
collection
Assessment  of  skin
reaction
Telephone
contact  i
HRU  and  caregiver
burden  jD8 D15 D31
D1 (±  2 (±  2 (±  2
days) days) days)
XD61           D91
(± 2            (±  2
days)         days)D121        D151
(± 2           (±  7
days)        days)D361 D1-151
(± 7           Q2W
days) (±  5  days)
XD152–361      D1-361 D1-361
monthly as                 as
(± 5 days) needed needed
X e
X e
X h
X
X360  days
post  last
replacement
dose
(± 7 days)
ADA  =  anti-drug  antibody;  AEs  =  adverse  events;  AESIs  =  adverse  events  of  special  interest;  CHD  =  congenital  heart  disease;  CLD  =  chronic  lung  disease;  D  =  study  day;
ER =  emergency  room;  HRU  =  healthcare  resource  utilization;  ICU  =  intensive  care  unit;  IM=intramuscular;  LRTI  =  lower  respiratory  tract  infection;  neut  Ab  =  neutralizing
antibody;  NOCDs  =  new  onset  chronic  diseases;  OTC  =  over-the-counter;  PK  =  pharmacokinetic;  Q2W  =  once  every  2  weeks;  RSV  =  respiratory  syncytial  virus;  SAEs  =
serious  adverse  events;  SID  =  subject  identification;  TC  =  telephone  call;  V  =  visit.
a The  Season  2  Visit  10/Day  1  (Dose  1)  may  be  the  same  as  the  Season  1  Visit  9/Day  361.
b Subjects  who  receive  a  replacement  dose  of  study  drug  due  to  cardiac  surgery  with  cardiopulmonary  bypass  will  be  followed  for  360  days  after  the  last  replacement  dose
with the  same  schedule  for  telephone  calls  and  a  final  visit  360  days  post  the  last  replacement  dose.
c  All  vital  signs  (temperature,  blood  pressure,  heart  rate,  and  respiratory  rate)  should  be  obtained  within  60  minutes  prior  to  dosing,  and  at  30  minutes  (±  5  minutes)  and
60 minutes  (±  5  minutes)  post  dose.
CONFIDENTIAL AND PROPRIETARY 41 of 80 T e mp late  18.0
MedImmun e
MEDI8897
Table 6Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Sche du le of Treatme n t Perio d  a nd  Follow- up  Perio d  S t ud y Proce du res :  S easo n  2, CLD/CHD Co h or t  O n ly
Study  Period Treatment  Period Follow-up  Period
Visit  Number V10  a TC V11 V12 V13 V14 V15 V16 V17 TC LRTISkin
ReactionReplacement
 Dose
Follow-up  b
Procedure  /
Study  DayD8 D15 D31
D1 (±  2 (±  2 (±  2
days) days) days)D61           D91
(± 2            (±  2
days)         days)D121        D151
(± 2           (±  7
days)        days)D361 D1-151
(± 7           Q2W
days) (±  5  days)D152–361      D1-361 D1-361
monthly as                 as
(± 5 days) needed needed360  days
post  last
replacement
dose
(± 7 days)
d  Subjects  requiring  a  replacement  dose  of  study  drug  due  to  cardiac  surgery  with  cardiopulmonary  bypass  will  have  a  blood  sample  collected  before  and  after  surgery  (prior
to administering  replacement  dose)  for  PK  evaluation.
e  Nasal  samples  will  be  collected  from  all  subjects  with  LRTIs  (inpatient  or  outpatient)  and  from  all  hospitalized  subjects  with  any  new  respiratory  infection  (upper  or  lower)
within  approximately  2  days  after  the  initial  healthcare  provider  assessment  and  diagnosis.
Blood  samples  will  be  collected  from  all  subjects  hospitalized  with  LRTI  or  any  respiratory  infection  within  approximately  2  days  following  hospital  admission.
f Subjects  who  were  randomized  to  receive  MEDI8897  for  Season  1  will  receive  a  single  200-mg  IM  dose  of  MEDI8897  followed  by  4  once-monthly  IM  doses  of  placebo
for Season  2.  Subjects  who  were  randomized  to  receive  palivizumab  for  Season  1  will  be  re-randomized  1:1  to  receive  a  single  200-mg  IM  dose  of  MEDI8897  followed  by
4 once-monthly  IM  doses  of  placebo,  or  5  once-monthly  IM  doses  of  15  mg/kg  palivizumab  for  Season  2.
g  Subjects  who  undergo  cardiac  surgery  with  cardiopulmonary  bypass  after  receipt  of  Dose  1  but  prior  to  receipt  of  Dose  5  will  receive  a  replacement  dose  of  the  study  drug
that they  received  for  Dose  1  immediately  following  the  surgery  when  determined  by  the  physician  to  be  medically  stable  for  an  IM  injection.  Any  subsequent  doses  of
study  drug  will  continue  to  be  given  according  to  the  protocol-specified  dosing  schedule.  See  Section  3.1.2.3  for  details.
h Skin  reaction  assessment  will  be  done  for  any  post-dosing  skin  or  skin-related  reaction  regardless  of  severity,  duration,  time  of  onset  post  dosing,  or  relationship  to  study
drug.
i Telephone  contact  must  be  verbal  communication.  Written  communication  via  text,  email,  or  other  written  form  is  not  acceptable.
j  HRU  includes  admission  and  duration  of  hospital  and  ICU  stay,  number  of  subjects  who  require  respiratory  support  and  supplemental  oxygen  use,  duration  of  respiratory
support  and  supplemental  oxygen  use,  number  and  type  of  outpatient  visits  (eg,  ER,  urgent  care,  outpatient  clinic),  and  number  and  days  of  prescription  and  OTC
medication.  Caregiver  burden  includes  days  of  worked  missed  by  the  parent(s)/legal  representative  or  other  household  member  as  a  result  of  the  subject’s  illness,  and  days
of daycare/babysitting  missed  by  the  subject  as  a  result  of  illness.
CONFIDENTIAL AND PROPRIETARY 42 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
4.3
4.3.1
4.3.1.1Description  of  Study  Procedures
Efficacy
Lower Re sp iratory Tract In fectio n
Subject s  will be monitored throughout the s tudy for LRTI ( s ee Table 5 and Table 6 ). All
subject s  seeking medical attention f or a re s piratory illne ss  (in either the inpatient or outpatient
setting) w ill be evaluated for LRTI. All s ubject s  found to have an LRTI and all s ubject s  who
require ho s pitalization for a re s piratory infection, even if there i s  not a diagno s i s  of LRTI,
should have re s piratory s ample s  obtained and re s piratory a ss e ss ment form s  completed.
Sample s  s hould be collected for all of the s e re s piratory event s  even tho s e not meeting the
protocol definition of LRTI. S ubject s  who have a primary ho s pitalization for a re s piratory
infection (ie, upper or lower tract) or a re s piratory deterioration during a ho s pitalization, or
who s eek outpatient medical attenti o n (including ER vi s it s ) for a lower re s piratory illne ss , will
be ass e ss ed clinically for the pre s ence of LRTI and for R S V by central laboratory diagn o stic
testing of re s piratory s ecretion s . Te s ting for R S V will be performed u s ing the U S  F DA-cleared
and CE-marked in vitro diagno s tic real-time RT- P CR a ss ay (Lyra R S V + human
metapneumoviru s  [h MP V] a ss ay; Q uidel Corporation, S an Diego, CA, www.quidel.com; see
Section 4.3.1.2 ). A diagno s i s  of R SV  LRTI require s  having a re s piratory s ample po s itive f o r
RSV by the central laboratory RT- P CR a ss ay.
In addition to the clinical a ss e ss ment of LRTI, there i s  a protocol definition u s ing objective
criteria for the determination of a medically attended protocol-defined LRTI.
For sub ject s  wit h  n o und erlyi n g l un g d i s ea s e:
To meet the protocol-defined endpoint of medically attended R S V LRTI, s ubject s  with s igns
of LRTI mu s t have documented at lea s t one phy s ical examination finding of rhonchi, rales,
crackle s , or wheeze AND at lea s t one of the following clinical s ign s  ( s ee Table 7 ):
Increa s ed re s piratory rate at rest (age: < 2 month s , ≥ 60 breath s /min; 2 to 6 month s ,
≥ 50 breath s /min; > 6 month s , ≥ 40 breath s /min), OR
Hypoxemia (in room air: oxygen s aturation < 95% at altitude s  ≤ 1,800 meter s  or < 9 2%  at
altitude s  > 1,800 meter s ), OR
 Clinical s ign s  of s evere re s piratory di s ea s e (eg, acute hypoxic or ventilatory failure, new
onset apnea, na s al flaring, interco s tal, s ubco s tal or s upraclavicular retraction s , grunting )
or dehydration s econdary to inadequate oral intake due to re s piratory di s tre ss  (need fo r
intravenou s  fluid).
CONFIDENTIAL AND PROPRIETARY 43 of 80 T e mp late  18.0
MedImmun e
MEDI8897
Table 7Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Criteria for Meeti n g t h e Protocol- d efi n e d  E ndp oi n t of Me d ically
Attend e d  R S V LRT I  - Sub ject s  Wit h o u t U nd erlyi n g L un g Di s ea s e
RSV
RSV Conf ir m e d :Lower  R e sp ir ato r y T r a c t
Docum e nt e d phys ic a lMed ic a l  S i gn i f ic an ce
Objec t i v e  m e asu re s of cli n ic a l  s e v eri ty :
•Pos iti v e  by ce n t r al
labor at ory r eal - ti m e
RT-PCR a ss a yexam i nat i on f i nd i ngs l o c a lizi ng
to low er  re sp ir ato r y t r a c t :
•Rhon c h i
•R ale s
•Cr ac k le s
•Wh eeze•In c r ea s e d r e sp i r at ory r ate
•Hypox e m ia
•A c u te  hypox ic  or v e n tilat ory f ail ur e
•N e w ons et  a pn ea
•N a s al  f la r i ng
•R et r acti ons
•Grun ti ng
• D e hydr ati on du e  t o r e sp i r at ory
distre ss
LRTI = l ow e r r e sp i r at ory t r act  i nf ecti on ;  RSV = r e sp i r at ory syn c y tial  v i rus ;  RT-PCR = r e v e rs e  t r a ns c r i p ta s e -
polym e r a s e  c h ai n r eacti on.
Note:  On e  ite m from eac h c o l umn i s r e qu i r e d t o m eet  t h e  pro t o c o l -d e f i n e d e ndpo i n t  of m e d icall y atte nd e d
RSV LRTI.
For subj ect s  wit h  und erlyi n g l un g d i s ea s e (CLD or CHD):
To meet the protocol-defined endpoint of medically attended R S V LRTI, s ubject s  with s igns
of LRTI mu s t have documented at lea s t one new or wor s ened phy s ical examination finding o f
rhonchi, rale s , crackle s , or wheeze A ND at lea s t one of the following clinical s ign s  ( s ee
Table 8 ):
 Increa s e in ba s eline re s piratory rate by ≥ 20% at re s t and that rate i s  greater than the
age-ba s ed criteria e s tabli s hed f o r children with no underlying lung di s ea s e
(age: < 2 month s , ≥ 60 breath s /min; 2 to 6 month s , ≥ 50 breath s /min; > 6 month s ,
≥ 40 breath s /min), OR
Hypoxemia (O 2  s aturation < 95% in room air or O 2  s aturation drop of 5 percentage p oints
from ba s eline in children with ba s eline O 2  s aturation < 95% in room air, or acute
docu mented need for s upplemental O 2  or increa s ed O 2  requirement compared with
baseline), OR
Clinical s ign s  of s evere re s piratory di s ea s e (eg, acute hypoxic or ventilatory failure, new
onset apnea, na s al flaring, interco s tal, s ubco s tal or s upraclavicular retraction s , grunting )
or dehydration s econdary to inadequate oral intake due to re s piratory di s tre ss  (need fo r
intravenou s  fluid), OR
 P re s cription of new or increa s ed (from ba s eline) do s e of medication s  including
bronchodilator s , s teroid s , diuretic s , cardiac medication s
CONFIDENTIAL AND PROPRIETARY 44 of 80 T e mp late  18.0
MedImmun e
MEDI8897
Table 8Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Criteria for Meeti n g t h e Protocol- d efi n e d  E ndp oi n t of Me d ically
Attend e d  R S V LRT I  – Sub ject s  Wit h  U nd erlyi n g L un g Di s ea s e (CLD
or CHD)
RSV
RSV Conf ir m e d :Lower  R e sp ir ato r y T r a c t
Docum e nt e d n e w o r  wo r s e n e dMed ic a l  S i gn i f ic an ce
Objec t i v e  m e asu re s of cli n ic a l  s e v eri ty :
•Pos iti v e  by ce n t r al
labor at ory r eal - ti m e
RT-PCR a ss a yphys ic a l  e xam i nat i on f i nd i ngs
localizi ng to l ow er  re sp ir ato r y
tract :•In c r ea s e d r e sp i r at ory r ate  (from
baseli n e )
•Hypox e m ia
•Rhon c h i
•R ale s
•Cr ac k le s
•Wh eeze•A c u te  hypox ic  or v e n tilat ory f ail ur e
•N e w ons et  a pn ea
•N a s al  f la r i ng
•R et r acti ons
•Grun ti ng
• D e hydr ati on du e  t o r e sp i r at ory
distre ss
•Pr e s c r i p ti on of n e w or i n c r ea s e d
(from b a s eli n e ) dos e  of m e d icati ons
includ i ng bron c hod ilat ors, s te ro i ds,
diuretic s, ca rd iac  m e d icati on
CHD = c ong e n ital  h ea r t  d i s ea s e;  CLD = c hron ic  l ung d i s ea s e;  LRTI = l ow e r r e sp i r at ory t r act  i nf ecti on ;  PE =
physical  e x a m i n ati on ;  RSV = r e sp i r at ory syn c y tial  v i rus ;  RT-PCR = r e v e rs e  t r a ns c r i p ta s e -po l ym e r a s e  c h ai n
reacti on.
Note:  On e  ite m from eac h c o l umn i s r e qu i r e d t o m eet  t h e  pro t o c o l -d e f i n e d e ndpo i n t  of m e d icall y atte nd e d
RSV LRTI.
RSV Ho s pit a liz a tion
An R S V ho s pitalization i s  defined a s  either (1) a re s piratory ho s pitalization with a po s iti v e
RSV te s t within approximately 2 day s  of ho s pital admi ss ion (primary) or (2) a new on s et o f
respirato r y s ymptom s  in an already ho s pitalized s ubject, with an objective mea s ure of
wors ening re s piratory s tatu s  and positive R S V te s t (no s ocomial). P rimary and no s ocomial
RSV hospitalization are further defined below.
Primary R S V Ho sp italizatio n
RSV diagno s tic te s ting will be perf o rmed on re s piratory s ecretion s  obtained within
approximately 2 day s  before or afte r  admi ss ion for s ubject s  ho s pitalized for any re s pirato r y
infection (upper or lower re s piratory tract). If the R S V diagno s tic te s t (performed centrally via
RT-P CR) i s  po s itive, the ho s pitalization will be cla ss ified a s  a primary R S V ho s pitalization.
Death s  that can be demon s trated a s  cau s ed by R S V (by autop s y or clinical hi s tory and
virologic evidence) will al s o be con s idered a s  primary R S V ho s pitalization endpoint s .
CONFIDENTIAL AND PROPRIETARY 45 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Nosocomial R S V Ho sp italizatio n
Subject s  ho s pitalized for a re s piratory illne ss  or non-re s piratory illne ss  who s e R S V diagnostic
test i s  negative may develop no s ocomial R S V illne ss  during the s tudy.
If sign s  ( s uch a s  retraction s , rhonchi, wheezing, crackle s  or rale s ) of a new lower re s pirato r y
illness  occur during a ho s pitalizatio n , whatever the rea s on for ho s pitalization, and there i s  an
objective mea s ure of wor s ening re s piratory s tatu s  (that i s , new requirement for s upplemental
oxygen, increa s e in s upplemental oxygen requirement from prior to the on s et of s ymptoms, o r
need for new or additional mechanical ventilation), a s pecimen will be collected within
approximately 2 day s  from wor s ening of re s piratory s tatu s  for R S V diagno s tic te s ting by the
central laboratory. F or any s ubject who i s  ho s pitalized for a re s piratory infection (upper o r
lower re s piratory tract), the s ubject mu s t return to hi s /her ba s eline re s piratory s tatu s  or be
clearly re s olving the preceding re s piratory illne ss  before a s ub s equent re s piratory deterio r ation
for a no s ocomial R S V ho s pitalizati o n event can be determined.
If the R S V diagno s tic te s t (performed centrally via RT- P CR) i s  po s itive, the s ub s equent
hospital day s  will count a s  a no s ocomial R S V ho s pitalization. The day s  of R S V
hospitalization will be counted beginning with the s tart of the re s piratory deterioration that
resulted in the R S V diagno s tic te s t.
RSV LRTI Outp a ti e nt E ve nt s
Subject s  who s eek outpatient medical attention, including ER and urgent care vi s it s , for an
LRTI s hould have re s piratory s ecretion s  obtained within approximately 2 day s  after the initial
healthcare provider a ss e ss ment.
4.3.1.2 Re sp iratory S ecretio n s for R S V Detectio n
Respiratory s ecretion s  for R S V te s ting mu s t be collected from all s ubject s  with LRTI s
(inpatient or outpatient) and from all ho s pitalized s ubject s  with any new re s piratory infection
(upper or lower) within approximately 2 day s  after the initial healthcare provider a ss e ss ment
and diagno s i s . Na s al s ecretion s  will be obtained unle ss  the s ubject i s  intubated, and then
tracheal secretion s  may be obtaine d .
Respiratory s ecretion s  will be te s ted in a central laboratory for R S V u s ing the U S  F DA-
cleared and CE-marked in vitro dia g no s tic real-time RT- P CR a ss ay (Lyra R S V + h MP V
assay; Quidel Corporation, S an Diego, CA, www.quidel.com). Te s ting may include othe r
respirato r y pathogen s .
4.3.1.3 Mo n itori n g for R S V R e s i s ta n ce
As an exploratory endpoint, novel R S V F  variant s  identified in R S V-po s itive na s al s pecimens
(based o n  the R S V diagno s tic te s t re s ult s ; S ection 4.3.1.2 ) from all s ubject s  will be evaluated
CONFIDENTIAL AND PROPRIETARY 46 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
by genotypic and phenotypic method s  to monitor potential s u s ceptibility change s  to
MEDI8897 and palivizumab neutralization. The s ubtype and genotypic determination of R S V
will be performed directly on the na s al s pecimen s  that are collected from all s ubject s  who a r e
confirmed R S V-po s itive u s ing the Lyra R S V + h MP V real-time RT- P CR a ss ay manufactu r ed
by Quidel Corporation (Lyra R S V + h MP V a ss ay; Quidel Corporation, S an Diego CA,
www.quidel.com). The full-length F gene will be amplified u s ing a s tandard, s ingle-tube
population-ba s ed RT- P CR method and s equenced by S anger s equencing methodology. A mino
acid s ubstitution( s ) within the M EDI8897 binding s ite (amino acid [aa] 62-69 and aa 196 - 212 )
and out s ide the binding s ite in the extracellular region s  of mature F  protein (aa 24-109 and
aa 137-524) will be reported and compared to F  protein s equence s  of contemporary reference
RSV s train s . In vitro phenotypic analy s i s  ( s u s ceptibility to M EDI8897 and palivizumab
neutralization) will be attempted u s ing an R S V neutralization a ss ay with either R S V vir u ses
constructed through s ite-directed m u tagene s i s  of the F  gene and rever s e genetic s  or by cl o ning
the F  ge n e from the i s olate into a laboratory-adapted R S V s train s uch a s  A2 or B9320.
4.3.2 Med i ca l H i story  and  Phys i ca l Exam i nat i on,  We i ght,  and  V i ta l S i gns
A complete medical hi s tory will be obtained at s creening and a medical hi s tory update will be
obtained during the treatment and follow-up period a s  defined in S ection 4.2. A ss e ss ment will
include hi s tory and current medical condition s , pa s t or pre s ent cardiova s cular di s order s ,
respirato r y, ga s trointe s tinal, renal, h epatic, neurological, endocrine, lymphatic, hematologic,
immunologic, dermatological, genitourinary, drug and s urgical hi s tory, or any other di s eases
or dis order s .
A phy s ical examination, including w eight, will be performed at s creening and during the
treatment and follow-up period a s  defined in S ection 4.2.
Vital s ign s  (temperature, blood pre ss ure, heart rate, and re s piratory rate) will be collected at
screening and during the treatment and follow-up period a s  defined in S ection 4.2. On days
when s tudy drug i s  admini s tered, vital s ign s  will be obtained within 60 minute s  prior to
dosing, and at 30 minute s  (± 5 minute s ) and 60 minute s  (± 5 minute s ) po s t do s e.
Baseline information will be collected on brea s tfeeding, s moking in the hou s ehold, and i f  the
infant attend s  day care.
4.3.3 Pharmacok i net i c  Eva l uat i on  and  Methods
A Laboratory M anual will be provi d ed to the s ite s  that s pecifie s  the procedure s  for collection,
proce ss i n g, s torage, and s hipment o f s ample s , a s  well a s  laboratory contact information,
specific to thi s  clinical re s earch s tudy.
Blood s ample s  will be collected to evaluate P K of M EDI8897 and palivizumab in s erum ( see
Section 4 .2.2 for collection time point s ). S ubject s  in the CLD/CHD cohort requiring a
CONFIDENTIAL AND PROPRIETARY 47 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
replacement do s e of s tudy drug due to cardiac s urgery with cardiopulmonary bypa ss  will have
a blood sample collected before and after s urgery (prior to admini s tering replacement dose )  to
evaluate s erum concentration of M EDI8897 or palivizumab. The P K of M EDI8897 and
palivizumab will be mea s ured utilizing validated a ss ay s .
4.3.4 Ant i -drug  Ant i body  Eva l uat i on  and  Methods
Blood s ample s  will be collected to evaluate ADA re s pon s e s  to M EDI8897 and palivizumab in
serum ( s ee S ection 4.2.2 for collection time point s ). Evaluation will be performed u s ing
validated immunoa ss ay s . Tiered analy s e s  will be performed to include s creening,
confirmatory, and titer a ss ay comp o nent s , and the po s itive-negative cut point s  will be
statis tically determined from drug-naive validation s ample s . S ample s  will be utilized for
further characterization of the ADA re s pon s e, including ADA to the YTE domain on
MEDI8897 and the a ss e ss ment of neutralizing antibody to M EDI8897 or palivizumab.
4.3.5
4.3.5.1RSV-neutra li z i ng  Ant i body  and  RSV  Sero l ogy  Eva l uat i ons  and
Methods
RSV Ne u tralizi n g A n ti b o d y
Blood s ample s  will be collected to evaluate anti-R S V neutralizing antibody level s  in
serum ( s ee S ection 4.2.2 for collection time point s ). Analy s e s  will be performed
using an R S V neutralizing antibod y  a ss ay previou s ly de s cribed by S hambaugh et al
(Shambaugh et al, 2017 ).
4.3.5.2 R S V S erology
Blood s ample s  will be collected to mea s ure R S V antigen- s pecific antibody level s  in s erum
(see S ection 4.2.2 for collection time point s ). Evaluation s  will be performed u s ing a validated
immunoa ss ay s imilar to the a ss ay de s cribed by M aifeld et al ( M aifeld et al, 2016 ).
4.3.6 Hea l thcare  Resource  Ut ili zat i on  and  Careg i ver  Burden
Information on HRU and caregiver burden will be collected for all event s  of medically
attended LRTI ( s ee Table 5 and Table 6 ). Thi s  will include admi ss ion to and duration of
hospital and inten s ive care unit (IC U ) s tay, number of s ubject s  who require re s piratory
support and s upplemental oxygen use, duration of re s piratory s upport and s upplemental
oxygen u s e, number and type of outpatient vi s it s  (eg, ER, urgent care, outpatient clinic), and
the number of pre s cription and ove r -the-counter (OTC) medication s  and their duration of use.
Caregiver burden will be a ss e ss ed through, for example, caregiver mi ss ed work day s  and the
subject’ s  ab s ence from day care.
4.3.7 Sk i n  React i ons
Skin reaction a ss e ss ment will be done for any po s t-do s ing s kin or s kin-related reaction to
assis t in determination of the etiology of the reaction ( s ee Table 5 and Table 6 ). Information
CONFIDENTIAL AND PROPRIETARY 48 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
will be collected regardle ss  of event s everity, duration, time of on s et po s t do s ing, or
relation s hip to inve s tigational prod u ct. P arent s /legal repre s entative s  of s tudy s ubject s  will be
given a hyper s en s itivity card and in s tructed to call the s tudy s ite immediately for s ign s  of
hyper s en s itivity or allergic reaction. S ite s  mu s t notify M edImmune within 24 hour s  of
knowledge of s uch event s . F or any skin or s kin-related reaction s , including all ra s he s  that
occur within 7 day s  after do s ing, the child will be brought to the s tudy s ite a s  s oon a s  po s sible
for evaluation.
4.3.8 Est i mate  of  Vo l ume  of  B l ood  to  be  Co ll ected
Blood volume e s timate s  are provided by vi s it/ s tudy day for S ea s on 1 ( Table 9 ) and S ea s on 2
(Table 10 ).
Table 9 Vol u me of Bloo d  to b e Collecte d , S ea s o n  1
Visit / Study Day
Visit  1 / S c r ee n i ng or V i s it  2 / D a y 1
Visit  4 / D a y 31
Visit  8 / D a y 151
Visit  9 / D a y 361
TotalEstimat e d B l ood Vo l um e  (mL)
1.5 mL
1.5 mL
1.5 mL
1.5 mL
6.0 mL
Table 10 Vol u me of Bloo d  to b e Collecte d , S ea s o n  2
Visit / Study Day
Visit  12 / D a y 31
Visit  16 / D a y 151
Visit  17 / D a y 361
TotalEstimat e d B l ood Vo l um e  (mL)
 1.5 mL
 1.5 mL
1.5 mL
4.5 mL
4.4 Study  or  Study  Component  Suspension  or  Termination
MedImmune re s erve s  the right to temporarily s u s pend or permanently terminate thi s  s tudy o r
component of the s tudy at any time. The rea s on s  for temporarily s u s pending or permanently
terminating the s tudy may include but are not limited to the following:
1Death in any s ubject in which the cau s e of death i s  a ss e ss ed a s  related to inve s tigational
product (in thi s  ca s e the s tudy will be pau s ed for the s pon s or s afety review committee to
evaluate the event s )
2Anaphylactic reaction that i s  related to inve s tigational product ( s ee Appendix B for a
definition of anaphylaxi s ; in thi s  ca s e the s tudy will be pau s ed for the s pon s or s afety
review committee to evaluate the event s )
CONFIDENTIAL AND PROPRIETARY 49 of 80 T e mp late  18.0
MedImmun e
MEDI8897
Table 11Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Iden tificatio n  o f  In ve s tigatio n al Pro du ct s
Inve st i gat i ona l  P r odu c t
Paliv iz um a bManufa c tu rer
Astra Z e n ecaConce nt r at i on and Fo r mu l at i on as Supp lie d
Supp lie d a s 50 mg (nom i n al ) p e r v ial  so l u ti on. Th e
soluti on c on tai ns 100 mg / mL p ali v iz um a b, 25 mM
Histi d i n e , 1.6 mM g l y ci n e , 12.5 mM c h l or i d e , pH 6.0.
The nom i n al  f ill  vo l um e  i s 0.5 mL.
HCl = hydro c h l or i d e;  w / v = w ei gh t/ vo l um e .
MEDI8897 and palivizumab will be s upplied to the s ite in open-labeled kit s . Each kit ha s  a
unique number printed on all label s  within the kit (ie, the outer carton label and the label o f
each vial ) .
4.5.1.1 In ve s tigatio n al Pro du ct Insp ectio n
Each vial s elected for do s e admini s tration s hould be in s pected. Refer to Table 11 for
identification of inve s tigational product.
If there are any defect s  noted with the inve s tigational product, the inve s tigator and s ite
monitor s hould be notified immediately. Refer to the P roduct Complaint s ection
(Section 4 .5.1.4 ) for further in s truction s .
4.5.1.2 Do s e Pre p aratio n  S te ps  a nd  Treatme n t A d mi n i s tratio n
The fir s t day of do s ing i s  con s idere d  Day 1.
Study drug ( M EDI8897, placebo, and palivizumab) will be s upplied by an unblinded
inves tigational product manager. Blinding will be performed at the s ite level to en s ure that
MEDI8897, placebo, and palivizumab are indi s tingui s hable in appearance and are not la b eled
to reveal treatment identity.
No incompatibilitie s  between M EDI8897 or palivizumab and polycarbonate or polypropylene
syringe s  have been ob s erved.
MEDI88 9 7 and palivizumab do not contain pre s ervative s  and any unu s ed portion mu s t be
discarded. Total in-u s e s torage time from needle puncture of the s tudy drug vial to
admini s t r ation s hould not exceed 4 hour s  at room temperature. If s torage time exceed s  these
limit s , a n ew vial s hould be u s ed.
CONFIDENTIAL AND PROPRIETARY 51 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
MED I 8897 gro up : S ea s o n  1 a nd  S ea s o n  2, i n cl ud i n g re p laceme n t d o s e( s ) after
card io p ulmo n ary b y p a ss
Subject s  will receive M EDI8897 for Do s e 1 and placebo for Do s e s  2 through 5:
1S ea s o n  1
(a) I nfant s  < 5 kg body weight at time of do s ing:
o Do s e 1: A do s e of 50 mg (ie, 0.5 mL) M EDI8897 will be obtained by
withdrawing the entire content s  of 1 inve s tigational vial with an appropriately
sized s yringe, and admini s tered a s  one s ingle (ie, 0.5 mL) injection
o Do s e s  2 through 5: A corre s ponding volume (0.5 mL) of s aline will be obtained,
and admini s tered a s  one s ingle (ie, 0.5 mL) injection
(b) I nfant s  ≥ 5 kg body weight at time of do s ing :
o Do s e 1: A do s e of 100 mg (ie, 1.0 mL) M EDI8897 will be obtained by
withdrawing the entire content s  of 2 inve s tigational vial s
o Do s e s  2 through 5: A corre s ponding volume (1.0 mL) of s aline will be
admini s tered
o To maintain the blind:
 If the weight i s  ≥ 5 kg to < 6.7 kg then the do s e s hould be admini s tered as
one s ingle (ie, 1.0 mL) injection
 If the weight i s  ≥ 6.7 kg, then the volume of M EDI8897 or s aline s hould be
divided equally int o  2 s yringe s
2S ea s o n  2
o D o s e 1: A do s e of 200 mg (ie, 2.0 mL) M EDI8897 will be obtained by withdrawing
the entire content s  of 4 inve s tigational vial s
o Do s e s  2 through 5: A corre s ponding volume (2.0 mL) of s aline will be admini s te r ed
o To maintain the blind:
 If the weight i s  < 13.4 kg, then the do s e s hould be admini s tered a s  two 1.0 mL
injection s  (ie, 1.0 mL per injection)
 If the weight i s  ≥ 13.4 kg, then the volume of M EDI8897 or s aline s hould be
divided equally into 3 sy ringe s
3Re p laceme n t d o s e( s ) after car d io pu lmo n ary b y p a ss
Seas o n  1
(a) Cardiopulmonary bypa ss  < 90 day s  po s t fir s t do s e of M EDI8897 (or mo s t recent
replacement do s e if previou s  cardiopulmonary bypa ss ) for infant s  < 5 kg:
o Replacement do s e: A do s e of 50 mg (ie, 0.5 mL) M EDI8897 will be obtained by
withdrawing the entire content s  of 1 inve s tigational vial with an appropriately
sized s yringe, and admini s tered a s  one s ingle (ie, 0.5 mL) injection
CONFIDENTIAL AND PROPRIETARY 52 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
(b) Cardiopulmonary bypa ss  < 90 day s  po s t fir s t do s e of M EDI8897 (or mo s t recent
replacement do s e if previou s  cardiopulmonary bypa ss ) for infant s  ≥ 5 kg:
o Replacement do s e: A do s e of 100 mg (ie, 1.0 mL) M EDI8897 will be obtained
by withdrawing the entire content s  of 2 inve s tigational vial s
o To maintain the blind:
 If the weight i s  ≥ 5 k g to < 6.7 kg then the do s e s hould be admini s tered as one
single (ie, 1.0 mL) injection
 If the weight i s  ≥ 6.7 kg, then the volume of M EDI8897 s hould be divided
equally into 2 s yringe s
(c) Cardiopulmonary bypa ss  ≥ 90 day s  po s t fir s t do s e (or mo s t recent replacement dose
if previou s  cardiopulmona r y bypa ss ) for all weight s :
o Replacement do s e: A do s e of 50 mg (ie, 0.5 mL) M EDI8897 will be obtained by
withdrawing the entire content s  of 1 inve s tigational vial with an appropriately
sized s yringe, and admini s tered a s  one s ingle (ie, 0.5 mL) injection
Seaso n  2
(a) Cardiopulmonary bypa ss  < 90 day s  po s t fir s t do s e:
o Replacement do s e: A do s e of 200 mg (ie, 2.0 mL) M EDI8897 will be obtained
by withdrawing the entire content s  of 4 inve s tigational vial s
o To maintain the blind:
 If the weight i s  < 13.4 kg, then the do s e s hould be admini s tered a s  two 1 . 0 mL
injection s  (ie, 1.0 mL per injection)
 If the weight i s  ≥ 13.4 kg, then the volume of M EDI8897 s hould be divided
equally into 3 s yringe s
(b) Cardiopulmonary bypa ss  ≥ 90 day s  po s t fir s t do s e (or mo s t recent replacement dose
if previou s  cardiopulmona r y bypa ss ):
o Replacement do s e: A do s e of 100 mg (ie, 1.0 mL) M EDI8897 will be obtained
by withdrawing the e n tire content s  of 2 inve s tigational vial s
o To maintain the blind:
 If the weight i s  ≥ 5 kg to < 6.7 kg then the do s e s hould be admini s tered as one
single (ie, 1.0 mL) injection
 If the weight i s  ≥ 6.7 kg, then the volume of M EDI8897 s hould be divided
equally into 2 s yringe s
4S witch the needle prior to admini s tration
5 M EDI8897 or placebo ( s aline) s hould be admini s tered in the anterolateral a s pect of the
thigh according to s tandard practice procedure s  for I M  injection s . The injection s hould be
given u s ing s tandard a s eptic technique. When po ss ible, injection s ite s  for s ub s equent
injection s  s hould u s e alternating s ite s  (eg, right then left thigh). The maximum volume to
be admini s tered with each injection i s  1.0 mL
6M EDI8897 or placebo ( s aline) s hould be admini s tered u s ing the appropriate s ize needle
ranging from 22 to 25 gauge and 5/8 to 1.0 inche s  ba s ed on mu s cle s ize and weight o f  the
subject
CONFIDENTIAL AND PROPRIETARY 53 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Paliviz um a b  gro up : S ea s o n  1 a nd  S ea s o n  2, i n cl ud i n g re p laceme n t d o s e( s ) after
card io p ulmo n ary b y p a ss
1 A do s e of 15 mg/kg palivizumab will be obtained by withdrawing the calculated volume
of drug to the neare s t 0.01 mL a s  de s cribed below:
The do s e of palivizumab will be calculated ba s ed on the s ubject’ s  weight (to the nearest
0.01 kg) u s ing the following formula:
Dose (mL) = [ s ubject weight (kg) × do s e level (15 mg/kg)] ÷
palivizumab concentration (100 mg/mL)
The corre s ponding volume of palivizumab s hould be rounded to the neare s t 0.01 mL.
Example s :
A patient who weigh s  4.90 kg at the time of injection r eceive s  0.74 m L  of s tudy d rug
(4.90 kg x 15 mg/kg) ÷ 100 mg/m L  = 0.735 m L  ( r ounded to 0.74 m L )
A patient who weigh s  3.70 kg at the time of injection r eceive s  0.56 m L  of s tudy d rug
(3.70 kg x 15 mg/kg) ÷ 100 mg/m L  = 0.555 m L  ( r ounded to 0.56 m L )
2S witch the needle prior to admini s tration
3P alivizumab s hould be administered in the anterolateral a s pect of the thigh according to
stand ard practice procedure s  f o r I M  injection s . The injection s hould be given u s ing
standard a s eptic technique. When po ss ible, injection s ite s  for s ub s equent injection s
should u s e alternating s ite s  (eg, right then left thigh). The maximum volume to be
admini s tered with each injection i s  1 mL
4P ali v izumab s hould be administered u s ing the appropriate s ize needle ranging from 22 to
25 gauge and 5/8 to 1.0 inche s  b a s ed on mu s cle s ize and weight of the s ubject
4.5.1.3 Mo n itori n g of Do s e A d mi n i s tratio n
Subject s  will be monitored before and after inve s tigational product admini s tration through
assess ment of vital s ign s  (temperature, blood pre ss ure, heart rate, and re s piratory rate). All
vital s ign s  s hould be obtained within 60 minute s  prior to do s ing, and at 30 minute s
(± 5 minute s ) and 60 minute s  (± 5 minute s ) po s t do s e.
As with any biologic product, allergic reaction s  to do s e admini s tration are po ss ible. There f o r e,
appropriate drug s  and medical equipment to treat acute anaphylactic reaction s  mu s t be
immediately available, and s tudy per s onnel mu s t be trained to recognize and treat
anaphylaxi s .
CONFIDENTIAL AND PROPRIETARY 54 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
4.5.1.4 Re p orti n g Pro du ct Com p lai n t s
Any defect s  with the inve s tigational product mu s t be reported immediately to the M edImmune
Product Complaint Department by the s ite with further notification to the s ite monitor. All
defect s  w ill be communicated to M edImmune and inve s tigated further with the P roduct
Complaint Department. During the inve s tigation of the product complaint, all inve s tigati o nal
product mu s t be s tored at labeled condition s  unle ss  otherwi s e in s tructed.
MedImmune contact information f o r reporting product complaint s :
Email:
Phone:
Mail: M edImmune
Attn: P roduct Complaint Department
Gaither s bur g , M D U S A 20878
4.5.2 Add i t i ona l Study  Med i cat i ons
No other s tudy medication s  are s pecified for u s e in thi s  clinical protocol.
4.5.3 Labe li ng
Label s  for the inve s tigational product will be prepared in accordance with Good
Manufacturing P ractice and local regulatory guideline s . Label text will be tran s lated into local
language s , a s  required.
4.5.4 Storage
Store M EDI8897 and palivizumab at 2°C to 8°C. P lacebo ( s aline) s hould be s tored accor d ing
to the manufacturer in s truction s .
4.5.5 Treatment  Comp li ance
Inves tigational product i s  admini s tered by s tudy s ite per s onnel, who will monitor compliance.
4.5.6 Accountab ili ty
The investigator ’ s  or s ite’ s  de s ignated inve s tigational product manager i s  required to maintain
accurate inve s tigational product accountability record s . Upon completion of the s tudy, copies
of inve s tigational product accountability record s  will be returned to M edImmune. All unused
MEDI8897 and palivizumab will be returned to a M edImmune-authorized depot or di s posed
of upon authorization by M edImm u ne.
CONFIDENTIAL AND PROPRIETARY 55 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
4.6 Treatment  Assignment  and  Blinding
4.6.1 Methods  for  Ass i gn i ng  Treatment  Groups
An IWR S  will be u s ed for randomization to a treatment group and a ss ignment of blinded
inves tigational product kit number s.  A s ubject i s  con s idered randomized into the s tudy w hen
the inve s tigator notifie s  the IWR S  that the s ubject meet s  eligibility criteria and the IWRS
provide s  the a ss ignment of blinded inve s tigational product kit number s  to the s ubject.
In Sea s on 1, s ubject s  in the preterm and CLD/CHD cohort s  will be randomized u s ing a
2:1 ratio to either the M EDI8897 group or palivizumab group. Within each cohort, the
randomization will be s tratified by hemi s phere (northern, s outhern) and s ubject age at the time
of Sea s on 1 randomization ( ≤ 3 mo n th s , > 3 to ≤ 6 month s , > 6 month s ).
In Sea s o n  2, s ubject s  in the CLD/C H D cohort only will be randomized. S ubject s  who we r e
randomized to the M EDI8897 group in S ea s on 1 will remain in the M EDI8897 group.
Subject s  who were randomized to the CLD/CHD group in S ea s on 1 will be re-randomized
using a 1:1 ratio to either the M ED I 8897 or palivizumab group.
Study dr u g ( M EDI8897, placebo, o r  palivizumab) mu s t be admini s tered the s ame day the
study drug i s  a ss igned. If there i s  a delay in the admini s tration of s tudy drug s uch that it will
not be admini s tered within the s pecified timeframe, the unblinded inve s tigational product
monitor mu s t be notified immediately.
4.6.2 Methods  to  Ensure  B li nd i ng
This i s  a double-blind s tudy in which M edImmune will provide s ite s  with M EDI8897 and
palivizumab. S ite s  will u s e commercially available s aline a s  the placebo. S yringe barrel s  will
be covered by the unblinded inve s tigational product manager. Neither the s ubject/legal
repre s entative nor the inve s tigator o r any of the s ite s taff who are involved in the treatment o r
clinical evaluation of the s ubject s  will be aware of the treatment received (ICH E9). In the
event that treatment allocation for a s ubject become s  known to the inve s tigator or other
blinded s tudy s taff involved in the management of s tudy s ubject s , the s pon s or mu s t be noti f ied
immediately . If the treatment allocation for a s ubject need s  to be known to treat an individual
subject for an AE, the inve s tigator mu s t notify the s pon s or immediately . The s ite will maintain
a written plan detailing which s taff member s  are blinded/unblinded and the proce ss  of
inves tigational product admini s tration u s ed to maintain the blind.
4.6.3
4.6.3.1Methods  for  Unb li nd i ng
Unbli nd i n g i n  t h e Event of a Me d ical Emerge n cy
In the event of a medical emergenc y , the inve s tigator may unblind an individual s ubject’s
inves tigational product allocation. In s truction s  for unblinding an individual s ubject’ s  s tudy
drug allocation are contained in the IWR S  manual. In general, unblinding s hould only occu r  i f
CONFIDENTIAL AND PROPRIETARY 56 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
management of the medical emergency would be different ba s ed on the s ubject having
received s tudy drug. In the majorit y  of ca s e s , the management of a medical emergency w ould
be the s ame whether or not s tudy drug wa s  received by the s ubject. If thi s  wa s  the ca s e, the
study drug allocation s hould not be unblinded. In the event there i s  unblinding, the
inves tigator s hould promptly document and explain to M edImmune the rea s on for any
premature unblinding.
MedImmune retain s  the right to unblind the treatment allocation for S AE s  that are unexpected
and are sus pected to be cau s ally related to a s tudy drug and that potentially require expe d ited
reporting to regulatory authoritie s .
If a s ubject’ s  s tudy drug allocation i s  unblinded to the blinded s taff or blinded
MedImmune/contract re s earch organization s tudy team, the s ubject s hould be di s continued
from s tudy drug.
4.7 Restrictions  During  the  Study  and  Concomitant  Treatment(s)
The investigator mu s t be informed a s  s oon a s  po ss ible about any medication taken from the
time of s creening until the final s tudy vi s it. Any concomitant medication( s ), including he r bal
preparation s , taken during the s tud y  will be recorded in the electronic ca s e report form
(eCR F ).
4.7.1 Perm i tted  Concom i tant  Med i cat i ons
Inves tigator s  may pre s cribe concomitant medication s  or treatment s  deemed nece ss ary to
provide adequate s upportive care i n cluding routine vitamin s  and iron. S pecifically, s ubjects
should receive full s upportive care during the s tudy, including tran s fu s ion s  of blood and blood
product s , and treatment with antibi o tic s , anti-emetic s , anti-diarrheal s , and analge s ic s , an d
other care a s  deemed appropriate, and in accordance with their in s titutional guideline s .
4.7.2 Proh i b i ted  Concom i tant  Med i cat i ons
Use of concomitant medication s  including over-the-counter medication s  (except for routine
vitamin s  and iron), herbal s upplement s , etc from Day 1 through Day 15 po s t do s e i s
discouraged. S ubject’ s  legal repre s entative mu s t be in s tructed not to admini s ter any
medicati o n s , including over-the-counter product s , without fir s t con s ulting with the
inves tigator.
4.8 Statistical  Evaluation
4.8.1 Genera l Cons i derat i ons
Tabular summarie s  will be pre s ented by treatment group. Categorical data will be s umma r ized
by the number and percentage of s ubject s  in each category. Continuou s  variable s  will be
CONFIDENTIAL AND PROPRIETARY 57 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
summarized by de s criptive s tati s tics. Additional detail s  of s tati s tical analy s e s  will be
described in the s tati s tical analy s i s  plan.
The Intent-to-treat (ITT) P opulation i s  defined a s  all randomized s ubject s , analyzed acco r ding
to randomized treatment a ss ignment. All efficacy analy s e s  will be performed on the ITT
Population.
The A s -treated P opulation (AT P ) i s  defined a s  all s ubject s  who receive any inve s tigational
product, analyzed according to treatment received. All analy s e s , with the exception of
efficacy, will be performed on the AT P  unle ss  otherwi s e s pecified.
A prima r y analy s i s , S ea s on 2 analysi s , and final analy s i s  are planned for the s tudy. The
primary analy s i s  will be conducted after all randomized s ubject s  have completed follow-up
through the fir s t 5-month R S V s ea s on (ie, S ea s on 1 Day 151 vi s it) and include all available
Season 1 s afety, efficacy, P K, and ADA data at the time of the data cutoff. S ea s on 2 anal y sis
will be conducted after all the CLD/CHD s ubject s  have completed follow-up through the
second 5-month R S V s ea s on (ie, S ea s on 2 Day 151 vi s it) and include all available S ea s on 1
data and S ea s on 2 s afety, efficacy, P K, and ADA data at the time of the data cutoff. The final
analy s i s  will be conducted when all s ubject s  have completed the la s t vi s it of the s tudy and
include all data collected in the s tudy.
At the time of the primary analy s i s , the S ea s on 1 data will be unblinded to the
Spon s or/de s ignated clinical re s earc h  organization a ss ociated with the analy s i s , write-up, and
regulato r y s ubmi ss ion.
To en s ure the blinding of S ea s on 2 treatment a ss ignment for CLD/CHD s ubject s  who we r e
randomized to the palivizumab arm in S ea s on 1, any data with potential unblinding ri s k w ill
be split by S ea s on 1 and S ea s on 2 by the corre s ponding third party data vendor s  and when the
primary databa s e lock occur s , only u nblinding data from S ea s on 1 will be tran s ferred to the
Spon s or for analy s i s .
The s ite p er s onnel, participant s , and the s tudy team member s  who participate in the advice o r
decis ion s  involving s tudy s ubject s  and/or day-to-day interaction s  with the s ite, will remain
blinded until the end of the s tudy to en s ure the trial integrity i s  maintained. F urther details will
be specified in the unblinding plan p rior to databa s e lock for the primary analy s i s .
4.8.2 Samp l e  S i ze
With re sp ect to s afety, 600 s ubject s  expo s ed to M EDI8897 in S ea s on 1 will provide a
95% probability of ob s erving at lea s t one AE if the true event rate i s  0.5%; if no AE s  are
observed, thi s  s tudy provide s  95% confidence that the true event rate i s  < 0.5%. The s ample
size i s  fo r  s afety con s ideration.
CONFIDENTIAL AND PROPRIETARY 58 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
With re s pect to efficacy, approximately 600 s ubject s  will be expo s ed to M EDI8897 and 300
subject s  w ill be expo s ed to palivizumab in S ea s on 1 to ob s erve numerically s imilar efficacy
for both mAb s . Becau s e of the reduced incidence of R S V di s ea s e in thi s  population follo w ing
the introduction of palivizumab, a su periority or non-inferiority de s ign i s  not practical. A  valid
non-inferiority margin cannot be e s tabli s hed due to the lack of hi s torical efficacy data for the
medically attended R S V LRTI endpoint for palivizumab. Therefore, there i s  no hypothe s is
testing for efficacy. U s ing an a ss umption of a 6% R S V LRTI rate in palivizumab recipients,
approximately 18 event s  will be ob s erved in that group. The 6% R S V LRTI rate (1.9% R S V
hospitalization s  and 3.9% outpatie n t R S V illne ss ) wa s  ba s ed on a prior s tudy in preterm
infant s  w ith and without CLD who received palivizumab ( Carbonell-E s trany et al, 2010 ).
Assuming a 6% rate of R S V LRTI in M EDI8897 recipient s , 600 M EDI8897 s ubject s  in
Season 1 will provide approximately 36 event s  in that group. However, becau s e of the la r gely
reduced R S V circulation due to COVID-19 pandemic-related mea s ure s , the ob s erved event
rates  could be much lower. Only s ummarie s  will be provided for efficacy unle ss  s pecified
otherwi s e.
4.8.3
4.8.3.1Safety
Analy s i s  of A d ver s e E v e n t s
AEs will be graded according to the current ver s ion of the NCI CTCAE where applicable f o r
pediatric a ss e ss ment s . AE s  will be coded by the M edical Dictionary for Regulatory Activities
and the type, incidence, s everity, a n d relation s hip to s tudy drug will be s ummarized by
treatment group. Other s afety a ss e s sment s  will include the occurrence of AE S I s  defined as
AEs of h y per s en s itivity to s tudy drug (including anaphylaxi s ), thrombocytopenia, and
immune complex di s ea s e (eg, va s culiti s , endocarditi s , neuriti s , glomerulonephriti s ) follo w ing
study drug admini s tration, and the occurrence of NOCD s  following s tudy drug admini s tration.
Safety of M EDI8897 will be s ummarized by treatment group ba s ed on the AT P . The s afety
summary will be provided for each s ea s on, a s  well a s  for the 2 con s ecutive R S V s ea s on s
(ie, S ea s on 1 and S ea s on 2). F or the S ea s on 1 s ummary, the analy s i s  data s et will include
subject s  from the preterm cohort and CLD/CHD cohort, pre s ented by the treatment received
in Sea s on 1; for the S ea s on 2 s ummary and the 2 con s ecutive- s ea s on s ummary, the analy s is
datas et w ill include s ubject s  from the CLD/CHD cohort, pre s ented by the treatment received
through the 2 s ea s on s .
4.8.4 Eff i cacy
The primary efficacy endpoint i s  the incidence of medically attended R S V LRTI (inpatient
and outpatient) through 150 day s  po s t Do s e 1 (ie, during a typical 5-month R S V s ea s on) in
Season 1. The determination of the primary efficacy endpoint will be ba s ed on R S V te s t
result s  (performed centrally u s ing real-time RT- P CR; s ee S ection 4.3.1.2 ) and objective
protocol-defined LRTI criteria ( s ee Table 7 and Table 8 ), and will be s ummarized by S eason 1
CONFIDENTIAL AND PROPRIETARY 59 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
treatment group for all 900 s ubject s . The 95% CI of the percentage of s ubject s  meeting the
primary efficacy endpoint will be p r e s ented by treatment group. F or s ubject s  with multiple
medically attended R S V LRTI eve n t s , only the fir s t occurrence will be u s ed in the primary
efficacy s ummary.
In additi o n, the s ummary of incide n ce of R S V LRTI through 150 day s  po s t Do s e 1 in
Season 2 will be provided for the 3 0 0 s ubject s  in the CLD/CHD cohort ba s ed on the treatment
assignment s  through S ea s on 1 and Sea s on 2: ie, (a) 50 mg M EDI8897 for infant s  with body
weight < 5 kg and 100 mg M EDI8897 for infant s  with body weight ≥ 5 kg ( S ea s on 1)/200 mg
MEDI8897 ( S ea s on 2), (b) palivizumab ( S ea s on 1)/200 mg M EDI8897 ( S ea s on 2), and
(c) palivizumab ( S ea s on 1)/palivizumab ( S ea s on 2).
The inci d ence of R S V ho s pitalization through 150 day s  after do s ing (ie, during the 5-mo n th
RSV s ea s on) will be s ummarized by treatment group u s ing a s imilar s trategy a s  de s cribe d
above for R S V LRTI.
Additional analy s e s  will include s ummarizing R S V-po s itive LRTI endpoint s  u s ing re s ult s
from either the central laboratory or local laboratory.
All efficacy s ummarie s  will be ba s ed on the ITT P opulation.
4.8.5
4.8.5.1Anal ys i s  of  Pharmacok i net i cs  and  Ant i -drug  Ant i body
Pharmaco k i n etic A n aly s i s
Individual M EDI8897 and palivizumab s erum concentration data will be tabulated by
treatment group along with de s criptive s tati s tic s . P K parameter s , eg, maximum ob s erved
concentration (C max ), AUC, apparent clearance, and t 1 / 2  will be e s timated u s ing
non-compartmental analy s i s , if data permit.
4.8.5.2 A n ti- d r u g A n ti b o d y A n aly s i s
The incidence of ADA to M EDI8897 and to palivizumab will be a ss e ss ed and s ummarized by
number and percentage of s ubject s  w ho are ADA po s itive by treatment group. The impact o f
ADA on P K, and a ss ociation with TEAE s  and TE S AE s , will be a ss e ss ed.
4.8.6
4.8.6.1Expl oratory  Ana l yses
RSV Ne u tralizi n g A n ti b o d y
Individual M EDI8897 and palivizumab s erum anti-R S V neutralizing antibody level s  will be
tabulated by treatment group along w ith de s criptive s tati s tic s . Anti-R S V neutralizing antibody
level s  in s erum will be s ummarized by geometric mean titer and geometric mean-fold ri s e and
corre s ponding 95% CI for each treatment group at each vi s it. Anti-R S V neutralizing antibody
level t 1 / 2  will be e s timated u s ing non-compartmental analy s i s , if data permit.
CONFIDENTIAL AND PROPRIETARY 60 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
4.8.6.2 R S V S erology
Analy s i s  of anti-R S V antigen s  antibody level s  in s erum in M EDI8897 and palivizumab
recipients will be s ummarized by geometric mean titer and geometric mean-fold ri s e and
corre s ponding 95% CI for each treatment group at each vi s it. S erore s pon s e s  in M EDI88 9 7
and palivizumab recipient s  will be determined by examining the fold-ri s e in antibodie s  t o  Ga,
Gb, and N antigen s .
4.8.6.3 Healt h care Re s o u rce U tilizatio n  a nd  Caregiver B u r d e n
The mag n itude of HRU (eg, number of admi ss ion s  to ho s pital s  and ICU s  and duration of stay;
number of s ubject s  who require re s piratory s upport and s upplemental oxygen and the duration
of us e; number and type s  of outpatient vi s it s , eg, ER, urgent care, outpatient clinic; and
number o f pre s cription and OTC medication s  and duration of u s e) will be s ummarized o v e r all
by treatment group and for s ubject s  with at lea s t one medically attended LRTI (protocol
defined) cau s ed by RT- P CR-confirmed R S V.
Caregiver burden (eg, caregiver mis s ed work day s , s ubject ab s ence from day care) for s ubjects
with medically attended LRTI (protocol defined) cau s ed by RT- P CR-confirmed R S V will be
summarized by treatment group.
The HR U  and caregiver burden s ummarie s  will be performed on the ITT P opulation.
4.8.6.4 R S V Re s i s ta n ce Mo n i t ori n g
RSV ge n otypic analy s i s  will report the s equence change s  in the mature F  protein from all
RSV po s itive i s olate s  compared to contemporary R S V A and R S V B reference s train s .
Susceptibility of novel R S V variant s  to M EDI8897 and palivizumab will be te s ted and
compared to control viru s e s .
4.8.6.5 R S V LRT I  Occ u rri n g From Day 152 to Day 361
The incidence of medically attended R S V LRTI (inpatient and outpatient) from Day 152 to
Day 361 for S ea s on 1 and S ea s on 2 will be ba s ed on R S V te s t re s ult s  (performed centrally via
RT-P CR )  and objective clinical LRTI criteria and will be s ummarized by treatment group.
4.8.7 Independent  Data  Mon i tor i ng  Comm i ttee
An independent data monitoring committee will review s afety data regularly and make
recommendation s  regarding further s tudy conduct.
5 ASSESSMENT  OF  SAFETY
5.1 Definition  of  Adverse  Events
An adver s e event i s  the development of any untoward medical occurrence in a s ubject or
clinical s tudy s ubject admini s tered a medicinal product and which doe s  not nece ss arily have a
CONFIDENTIAL AND PROPRIETARY 61 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
causal relation s hip with thi s  treatment. An AE can therefore be any unfavorable and
unintended s ign (eg, an abnormal laboratory finding), s ymptom (eg, nau s ea, che s t pain), o r
disea s e temporally a ss ociated with the u s e of a medicinal product, whether or not con s ide r ed
related to the medicinal product.
The term AE i s  u s ed to include bot h  s eriou s  and non- s eriou s  AE s  and can include a
deterioration of a pre-exi s ting medical occurrence. An AE may occur at any time even if no
study treatment ha s  been admini s te r ed.
Elective treatment or s urgery or preplanned treatment or s urgery (that wa s  s cheduled prio r  to
the subject being enrolled into the s tudy) for a documented pre-exi s ting condition that did not
wors en from ba s eline i s  not con s idered an AE ( s eriou s  or non s eriou s ). An untoward medical
event occurring during the pre s cheduled elective procedure or routinely s cheduled treatment
should be recorded a s  an AE or S AE.
5.2 Definition  of  Serious  Adverse  Events
An S AE i s  any AE that:
Re s ult s  in death
I s  immediately life-threatening
Require s  inpatient ho s pitalization or prolongation of exi s ting ho s pitalization
Re s ult s  in per s i s tent or s ignificant di s ability/incapacity
I s  a congenital anomaly/birth defect in off s pring of the s ubject
I s  an important medical event that may jeopardize the s ubject or may require medical
intervention to prevent one of the outcome s  li s ted above
Medical o r s cientific judgment s hould be exerci s ed in deciding whether expedited reporting is
appropriate in thi s  s ituation. Exam p le s  of medically important event s  are inten s ive treatment
in an ER or at home for allergic broncho s pa s m, blood dy s cra s ia s , or convul s ion s  that do not
result in ho s pitalization s .
5.3 Definition  of  Adverse  Events  of  Special  Interest
An AE S I i s  one of s cientific and medical intere s t s pecific to under s tanding of the
inves tigational product and may require clo s e monitoring and rapid communication by the
inves tigator to M edImmune. An AE S I may be s eriou s  or non s eriou s . The rapid reporting o f
AES I s  allow s  ongoing s urveillance of the s e event s  in order to characterize and under s ta n d
them in a ss ociation with the u s e of thi s  inve s tigational product.
CONFIDENTIAL AND PROPRIETARY 62 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
5.3.1 Hypersens i t i v i ty,  Inc l ud i ng  Anaphy l ax i s
Admini s tration of polyclonal immunoglobulin preparation s  and mAb s  ha s  been a ss ociated
with immediate (type I) hyper s en s itivity (including anaphylaxi s ) that occur s  during or afte r
dosing. An immediate hyper s en s itivity reaction i s  defined a s  an acute on s et of an illne ss  w ith
involvement of the s kin, muco s al ti ss ue, or both during admini s tration of inve s tigational
product (but doe s  not meet the definition of anaphylaxi s ). Anaphylaxi s  i s  a rare event, u s ually
occurrin g  after s ub s equent expo s ure to antigen, and it i s  mo s t commonly accompanied by
severe s y s temic s kin and or muco s al reaction s . It i s  potentially a fatal, s y s temic allergic
reaction that i s  di s tinct from s imple allergic reaction s  (eg, ra s h, pruritu s ) becau s e of the
simultaneou s  involvement of s everal organ s y s tem s  ( S amp s on et al, 2006 ). A full definition o f
anaphylaxi s  i s  provided in Appendix B . S ee S ection 5.5 for recording AE s .
5.3.2 Immune  Comp l ex  D i sease
Immune complex di s ea s e can mani f e s t in the form of a number of condition s  s uch a s
vasculitis, endocarditi s , neuriti s , gl o merulonephriti s , s erum s ickne ss , and arthralgia s .
Drug-induced immune complex (type III) hyper s en s itivity reaction s  can occur when ho s t
immune s y s tem generate s  antibodie s  to drug re s ulting in s oluble circulating antigen-anti b ody
complexe s  formation and their dep os ition in blood ve ss el s . S ub s equently thi s  initiate s  ti s sue
damaging inflammatory reaction s  mediated by complement and/or leukocyte s  and ma s t cells.
The pathology and clinical manife s tation s  are dependent on the ti ss ue s /organ s  involved, with
vascular, s kin and renal ti ss ue s  being common s ite s  of injury. Common example s  of immune
complex hyper s en s itivity reaction s  are s erum s ickne ss  ( s y s temic) and Arthu s  reaction s  (local ) .
The clinical manife s tation s  of s erum s ickne ss  include s kin ra s h, fever, malai s e, and
polyarthralgia s  or polyarthriti s . S ymptom s  typically develop 1 to 2 week s  after fir s t exposu r e
to antigen and u s ually re s olve in s everal week s  after withdrawal of the cau s ative agent. Se r um
sickne ss  n eed s  to be differentiated f rom other ‘ s erum- s ickne ss -like’ reaction s  that have a
similar clinical pre s entation (eg, viral infection s , anti- s eizure drug s ), but are believed to have
different pathogenic mechani s m s . Both s erum s ickne ss  and s erum s ickne ss -like reaction s  have
been reported with mAb s  (eg, rituximab, infliximab). Clinical pre s entation and time to onset
should be taken into account for the diagno s i s  and differentiation of the s e reaction s . Diagnosis
of the s e su s pected reaction s  i s  be s t confirmed via biop s y of the affected ti ss ue s . S ee
Section 5.5 for recording AE s .
5.3.3 Thrombocytopen i a
Thrombocytopenia i s  a di s order in w hich there i s  an abnormally low platelet count; a normal
platelet count range s  from 150,000 to 450,000 platelet s  per μL. The 3 major cau s e s  of low
platelet count s  include: (1) in s ufficient platelet s ynthe s i s  in the bone marrow; (2) increa s ed
breakdo w n of platelet s  in the blood s tream; and (3) increa s ed breakdown of platelet s  in the
spleen or liver. General s ymptom s  of thrombocytopenia include bleeding in the mouth a n d
gums , brui s ing, no s ebleed s , and petechiae (pinpoint red s pot s /ra s h). S evere bleeding i s  the
CONFIDENTIAL AND PROPRIETARY 63 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
major complication, which may occur in the brain or ga s trointe s tinal tract. Drug-induced
thrombocytopenia i s  a rever s ible form of thrombocytopenia that s hould be s u s pected in a
subject w ho pre s ent s  with new on s et thrombocytopenia or recurrent epi s ode s  of acute
thrombocytopenia, without an obviou s  alternative etiology. It i s  commonly induced by d r ug
depende n t antibodie s  that cau s e platelet de s truction or clearance by the reticuloendothelial
system (drug-induced immune thrombocytopenia), and le ss  commonly by drug-induced bone
marrow suppre ss ion or autoimmune thrombocytopenia that i s  initiated by expo s ure to the
offending drug but per s i s t s  in it s  ab s ence. The initial approach to the s ubject with s u s pected
drug-ind u ced thrombocytopenia involve s  confirming thrombocytopenia, e s tabli s hing a
temporal relation s hip to a drug, and eliminating other cau s e s  of thrombocytopenia. The
diagno s i s  i s  made clinically by documenting prompt re s olution of thrombocytopenia afte r
discontinuation of the s u s pected drug (typically within 1 week). M o s t s ubject s  with
drug-induced thrombocytopenia require no s pecific treatment, a s  their platelet count s  will
recover promptly following withdrawal of the cau s ative agent. S ee S ection 5.5 for recording
AEs.
5.4 Definition  of  New  Onset  Chronic  Disease
An NOCD i s  a newly diagno s ed medical condition that i s  of a chronic, ongoing nature. It is
observed after receiving the inve s tigational product and i s  a ss e ss ed by the inve s tigator a s
medicall y  s ignificant. Example s  of NOCD s  include, but are not limited to diabete s ,
autoimmune di s ea s e (eg, lupu s , rheumatoid arthriti s ), and neurological di s ea s e (eg, epilepsy ) .
Event s  t h at would not be con s idered a s  NOCD s  are mild eczema, diagno s i s  of a congenital
anomaly pre s ent at s tudy entry, or acute illne ss  (eg, upper re s piratory infection, otiti s  media,
bronchiti s ). S ee S ection 5.5 for rec o rding AE s .
5.5 Recording  of  Adverse  Events
AEs, including S AE s , AE S I s , and NOCD s , will be recorded on the eCR F  u s ing a recognized
medical term or diagno s i s  that accurately reflect s  the event. The s e event s  will be a ss e ss ed by
the inve s tigator for s everity, relation s hip to the inve s tigational product, po ss ible etiologies,
and whether the event meet s  criteria of an S AE and therefore require s  immediate notification
to M edImmune ( s ee S ection 5.6). S ee S ection 5.2 for the definition of S AE s  and Appendix A
for guideline s  for a ss e ss ment of s everity and relation s hip.
If an AE evolve s  into a condition that meet s  the regulatory definition of “ s eriou s ,” it will be
reported on the S AE Report F orm.
5.5.1 T i me  Per i od  for  Co ll ect i on  of  Adverse  Events
AEs and S AE s  will be recorded from the time of s ignature of informed con s ent through t h e
follow-up period (Day 361).
CONFIDENTIAL AND PROPRIETARY 64 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
All AE S I s  and NOCD s  will be rec o rded from the time of do s ing with s tudy drug through the
follow-up period (Day 361).
5.5.2 Fo ll ow-up  of  Unreso l ved  Adverse  Events
Any AE s  that are unre s olved at the s ubject’ s  la s t vi s it in the s tudy are followed up by the
inves tigator for a s  long a s  medically indicated, but without further recording in the eCR F .
MedImmune retain s  the right to reque s t additional information for any s ubject with ongoing
AE(s )/ S AE( s ) at the end of the s tudy, if judged nece ss ary.
5.5.3 Deaths
All death s  that occur during the s tudy, including the protocol-defined follow-up period must
be reported. Death s  with an unkno w n cau s e s hould alway s  be reported a s  an S AE. A
post-mo r tem (autop s y) may be helpful in the a ss e ss ment of the cau s e of death, and if
performed a copy of the po s t-mortem re s ult s  s hould be forwarded to M edImmune
repre s entative( s ) within the u s ual timeframe s  (refer to S ection 5.6 for additional information ) .
5.5.4 Adverse  Events  Based  on  S i gns  and  Symptoms
All AE s  spontaneou s ly reported by the care provider or reported in re s pon s e to the open
question from the s tudy s ite s taff: ‘Ha s  the child had any health p r oblem s  s ince the p r evious
visit?’, or revealed by ob s ervation w ill be collected and recorded in the eCR F . When
collecting AE s , the recording of diagno s e s  i s  preferred (when po ss ible) to recording a li s t o f
signs  an d  s ymptom s . However, if a diagno s i s  i s  known and there are other s ign s  or s ymptoms
that are not generally part of the diagno s i s , the diagno s i s  and each s ign or s ymptom will b e
recorded s eparately.
5.5.5 Adverse  Events  Based  on  Exam i nat i on  and  Tests
An abnormal laboratory finding that require s  medical intervention by the inve s tigator, or a
finding j u dged by the inve s tigator a s  medically s ignificant s hould be reported a s  an AE. I f
clinical s equelae are a ss ociated with a laboratory abnormality, the diagno s i s  or medical
condition s hould be reported (eg, renal failure, hematuria) not the laboratory abnormality ( eg,
elevated creatinine, urine red blood cell increa s ed)
If deterioration in a laboratory value/vital s ign i s  a ss ociated with clinical s ign s  and s ymptoms,
the s ign or s ymptom will be reported a s  an AE and the a ss ociated laboratory re s ult/vital sign
will be con s idered a s  additional information. Wherever po ss ible the reporting inve s tigato r
uses the clinical, rather than the lab o ratory term (eg, anemia ver s u s  low hemoglobin value ) . I n
the ab s ence of clinical s ign s  or s ymptom s , clinically relevant deterioration s  in non-mandated
parameter s  s hould be reported a s  AE( s ).
Any new or aggravated clinically relevant abnormal medical finding at a phy s ical examination
as compared with the ba s eline a ss e ss ment will be reported a s  an AE.
CONFIDENTIAL AND PROPRIETARY 65 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
5.6 Reporting  of  Serious  Adverse  Events
All S AE s  have to be reported, whether or not con s idered cau s ally related to the inve s tigational
product, or to the s tudy procedure( s) . All S AE s  will be recorded in the eCR F .
If any S AE occur s  in the cour s e of the s tudy, then inve s tigator s  or other s ite per s onnel must
inform the appropriate s pon s or repre s entative( s ) within 1 day, ie, immediately but n o later
than  24 h o u r s  after becoming awa r e of the event.
The de s ignated s tudy repre s entative work s  with the inve s tigator to en s ure that all the
necess ary information i s  provided to the s pon s or’ s  patient s afety data entry s ite within
1 calendar day of initial receipt for f atal and life-threatening event s  and within 5 calenda r  days
of initial receipt for all other S AE s .
For fatal or life-threatening AE s  w h ere important or relevant information i s  mi ss ing, active
follow-u p  i s  undertaken immediately. Inve s tigator s  or other s ite per s onnel inform s pon sor
repre s entative s  of any follow-up in f ormation on a previou s ly reported S AE within 1 calenda r
day, ie, immediately but n o later tha n  24 h o u r s  after becoming aware of the event.
Once the inve s tigator s  or other s ite per s onnel indicate an AE i s  s eriou s  in the electronic data
capture (EDC) s y s tem, an automated email alert i s  s ent to inform the de s ignated s pon s or
repre s entative( s ).
If the EDC s y s tem i s  not available, then the inve s tigator or other s tudy s ite per s onnel repo r ts
an SAE to the appropriate s pon s or r epre s entative by telephone. The s pon s or repre s entative
will advi s e the inve s tigator/ s tudy s ite per s onnel how to proceed.
5.7 Other  Events  Requiring  Immediate  Reporting
5.7.1 Overdose
An overdo s e i s  defined a s  a s ubject receiving a do s e of inve s tigational product in exce ss  o f
that s pecified in the IB, unle ss  otherwi s e s pecified in thi s  protocol.
An overdo s e with a ss ociated AE s  i s  recorded a s  the AE diagno s i s / s ymptom s  on the
relev ant AE module s  in the eCR F  and on the Overdo s e eCR F  module.
 An overdo s e without a ss ociate d  s ymptom s  i s  only reported on the Overdo s e eCR F
modu le.
If an ove r do s e on a M edImmune in v e s tigational product occur s  during the cour s e of the study,
then the inve s tigator or other s ite per s onnel s hould inform appropriate s pon s or repre s entatives
immediately, but n o later t h a n  24 ho u r s  after becoming aware of the event.
CONFIDENTIAL AND PROPRIETARY 66 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
The de s ignated s pon s or repre s entative work s  with the inve s tigator to en s ure that all relevant
information i s  provided to the s ponsor’ s  P atient S afety data entry s ite.
For overdo s e s  a ss ociated with an S AE, the s tandard reporting timeline s  apply; s ee S ectio n  5.6.
For othe r  overdo s e s  (ie, tho s e not a ss ociated with an AE or S AE), reporting mu s t occur w ithin
30 day s .
5.7.2 Med i cat i on  Error
For the purpo s e s  of thi s  clinical s tu d y, a medication error i s  an unintended failure or mi s take
in the treatment proce ss  for a M edImmune s tudy drug that either cau s e s  harm to the s ubject o r
has the potential to cau s e harm to the s ubject.
A medication error i s  not lack of efficacy of the drug, but rather a human- or proce ss -related
failure while the drug i s  in control of the s tudy s ite s taff or s ubject.
Medication error include s  s ituation s  where an error:
Occurred
Wa s  identified and intercepted before the s ubject received the drug
Did n ot occur, but circum s tance s  were recognized that could have led to an error
Examples of event s  to be reported in clinical s tudie s  a s  medication error s :
Di sp en s ing error, eg, medicati o n prepared incorrectly, even if it wa s  not actually given to
the subject
Drug not admini s tered a s  indicated, eg, wrong route or wrong s ite of admini s tration
Dru g  not s tored a s  in s tructed, eg, kept at room temperature when it s hould be in the
refrigerator
Wrong s ubject received the medication (excluding IWR S  error s )
Wrong drug admini s tered to s ubject (excluding IWR S  error s )
Example s  of event s  that d o n ot  require reporting a s  medication error s  in clinical s tudie s :
Erro rs  related to or re s ulting from IWR S  - including tho s e which lead to one of the above
listed event s  that would other w i s e have been a medication error
Accidental overdo s e (will be captured a s  an overdo s e)
Medication error s  are not regarded a s  AE s  but AE s  may occur a s  a con s equence of the
medicati o n error.
CONFIDENTIAL AND PROPRIETARY 67 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
If a medication error occur s  in the cour s e of the s tudy, then the inve s tigator or other s ite
personnel inform s  the appropriate MedImmune repre s entative s  within 1 day, ie, immediately
but n o later t h a n  24 h o u r s  of whe n  he or s he become s  aware of it.
The de s ignated M edImmune repre s entative work s  with the inve s tigator to en s ure that all
relevant information i s  completed w ithin 1 or 5 calendar day s  if there i s  an S AE a ss ociated
with the medication error ( s ee S ection 5.6) and within 30 day s  for all other medication e rr o r s.
Medication error s  s hould be reported u s ing a M edication Error Report F orm.
5.7.3
5.7.3.1Adverse  Events  of  Spec i a l Interest
Hyper s e ns itivity, In clu d i n g A n a ph ylaxi s
Event s  of immediate (type I) hyper s en s itivity, including anaphylaxi s  (a s  defined in
Appendix B ), require that the inve s tigator or other s ite per s onnel inform appropriate s ponso r
study re p re s entative s  immediately, or n o later t h a n  24 h o u r s  of when he or s he become s
aware of the event. The de s ignated spon s or s tudy repre s entative work s  with the inve s tigato r  to
ensure that all relevant information i s  provided and entered in EDC. If the event i s  con s ide r ed
seriou s  it mu s t be reported a s  an SA E ( s ee S ection 5.6).
Signs  of immediate hyper s en s itivity include urticaria, pruritu s , angioedema, s kin ra s h,
difficulty breathing, and wheezing. P arent( s )/legal repre s entative s  will be provided a car d  with
this info r mation to aid in prompt identification and reporting of the s e s ign s . P arent( s )/legal
repre s entative s  will be in s tructed to immediately report the occurrence of any of the s e findings
to the s ite inve s tigator who s hould then report the event s  to appropriate s pon s or s tudy
repre s entative s  immediately, or n o later t h a n  24 h o u r s  of when he or s he become s  aware o f
the event.
5.7.3.2 I mm un e Com p lex Di s ea s e
Event s  of immune complex di s ea s e (a s  defined in S ection 5.3.2 ) require that the inve s tigato r
or other site per s onnel inform appropriate s pon s or s tudy repre s entative s  immediately, or no
later t h a n  24 h o u r s  of when he or s he become s  aware of the event. The de s ignated s ponso r
study repre s entative work s  with the inve s tigator to en s ure that all relevant information i s
provided and entered into EDC. If the event i s  con s idered s eriou s  it mu s t be reported a s  an
SAE ( s ee S ection 5.6).
5.7.3.3 T h rom b ocyto p e n ia
Event s  of thrombocytopenia (platelet count < 120,000 per µ L) require that the inve s tigato r  o r
other s ite per s onnel inform appropriate s pon s or s tudy repre s entative s  immediately, or n o la t er
than  24 h o u r s  of when he or s he become s  aware of the event. The de s ignated s pon s or s tudy
repre s entative work s  with the inve s tigator to en s ure that all relevant information i s  provided
and entered into EDC. If the event i s  con s idered s eriou s  it mu s t be reported a s  an S AE ( s ee
Section 5.6).
CONFIDENTIAL AND PROPRIETARY 68 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
5.7.4 New  Onset  Chron i c  D i sease
If a ca s e of NOCD occur s  in the cour s e of thi s  s tudy, the inve s tigator or other s ite per s onnel
must inform appropriate s pon s or repre s entative s  immediately, or n o later t h a n  24 h o u r s  o f
when he or s he become s  aware of it. The de s ignated s pon s or s tudy repre s entative work s  with
the inve s tigator to en s ure that all relevant information i s  provided and entered into EDC. If  the
event i s  con s idered s eriou s  it mu s t be reported a s  an S AE ( s ee S ection 5.6).
6 STUDY  AND  DATA  MANAGEMENT
6.1 Training  of  Study  Site  Personnel
Before the fir s t s ubject i s  entered into the s tudy, a M edImmune repre s entative will review and
discu ss  the requirement s  of the protocol and related document s  with the inve s tigational s ta ff
and al s o train them in any s tudy- s pecific procedure s  and s y s tem( s ) utilized.
The P rincipal Inve s tigator will en s ure that appropriate training relevant to the s tudy i s  given to
all of these s taff, and that any new information relevant to the performance of thi s  s tudy is
forwarded to the s taff involved.
The P rincipal Inve s tigator will maintain a record of all individual s  involved in the s tudy
(medical ,  nur s ing, and other s taff).
6.2 Monitoring  of  the  Study
During the s tudy, a M edImmune repre s entative will have regular contact s  with the s tudy site,
including vi s it s  to:
P ro v ide information and s uppo r t to the inve s tigator( s )
Confirm that facilitie s  remain acceptable
 Con f irm that the inve s tigational team i s  adhering to the protocol, that data are being
accurately and timely recorded in the eCR Fs , that biological s ample s  are handled in
accordance with the Laboratory M anual and that s tudy drug accountability check s  a r e
being performed
P erform s ource data verification (a compari s on of the data in the eCR Fs  with the s ubject ’ s
medical record s  at the ho s pital or practice, and other record s  relevant to the s tudy)
including verification of informed con s ent of participating s ubject s . Thi s  will require
direct acce ss  to all original record s  for each s ubject (eg, clinic chart s )
En su re withdrawal of informed con s ent to the u s e of the s ubject’ s  biological s ample s  is
reported and biological s ample s  are identified and di s po s ed of/de s troyed accordingly, and
the action i s  documented, and r eported to the s ubject.
The M edImmune repre s entative will be available between vi s it s  if the inve s tigator( s ) or othe r
staff at the center need s  informatio n  and advice about the s tudy conduct.
CONFIDENTIAL AND PROPRIETARY 69 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
6.2.1 Source  Data
Refer to the Clinical S tudy Agreement for location of s ource data.
6.2.2 Study  Agreements
The P rincipal Inve s tigator at each s tudy s ite s hould comply with all the term s , condition s,  and
obligation s  of the Clinical S tudy Agreement, or equivalent, for thi s  s tudy. In the event of any
incon s i s tency between thi s  protocol and the Clinical S tudy Agreement, the term s  of prot o col
shall prevail with re s pect to the conduct of the s tudy and the treatment of s ubject s  and in all
other re s pect s , not relating to s tudy conduct or treatment of s ubject s , the term s  of the Clinical
Study Agreement s hall prevail.
Agreement s  between M edImmune and the P rincipal Inve s tigator mu s t be in place before any
study-related procedure s  can take place, or s ubject s  are enrolled.
6.2.3 Arch i v i ng  of  Study  Documents
The investigator follow s  the principle s  outlined in the Clinical S tudy Agreement.
6.3 Study  Timetable  and  End  of  Study
An individual s ubject will be con s idered to have completed the s tudy if the s ubject wa s
followed through their la s t protocol- s pecified vi s it/a ss e ss ment (including telephone contact ) .
Subject s  will be con s idered not to have completed the s tudy if con s ent wa s  withdrawn or the
subject wa s  lo s t to follow-up ( s ee S ection s  4.1.5 and 4.1.6 ).
The end of the s tudy (“ s tudy completion ”) i s  defined a s  the date of the la s t protocol- s peci f ied
visit/a ss e ss ment (including telephone contact) for the la s t s ubject in the s tudy.
6.4 Data  Management
Data management will be performed by M edImmune Data M anagement s taff or other pa r ty
according to the Data M anagement P lan.
An electronic data capture s y s tem w ill be u s ed for data collection and query handling. The
inves tigator will en s ure that data are recorded in the eCR Fs  a s  s pecified in the s tudy protocol
and in accordance with the eCR F  in s truction s  provided.
The investigator en s ure s  the accuracy, completene ss , and timeline ss  of the data recorded and
of the pr o vi s ion of an s wer s  to data querie s  according to the Clinical S tudy Agreement. The
inves tigator will s ign the completed eCR Fs . A copy of the completed eCR Fs  will be archived
at the s t u dy s ite.
CONFIDENTIAL AND PROPRIETARY 70 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
6.5 Medical  Monitor  Coverage
Each s ubject will be provided with contact information for the P rincipal Inve s tigator. In
addition, each s ubject will receive a toll-free number intended to provide the s ubject’ s
phys ician acce ss  to a medical monitor 24 hour s  a day, 7 day s  a week in the event of an
emergent s ituation where the s ubject’ s  health i s  deemed to be at ri s k. In thi s  s ituation, when a
subject pre s ent s  to a medical facility where the treating phy s ician or health care provider
require s  acce ss  to a phy s ician who ha s  knowledge of the inve s tigational product and the
clinical s tudy protocol and the P rincipal Inve s tigator i s  not available, the treating phy s ician o r
health care provider can contact a medical monitor through thi s  s y s tem, which i s  managed by
a third party vendor.
7 ETHICAL  AND  REGULATORY  REQUIREMENTS
7.1 Subject  Data  Protection
Each s ubject will be a ss igned a S ID to en s ure that per s onally identifiable information i s  kept
separate f rom the s tudy data. S ubject data that are relevant to the trial, eg, demographic
information, phy s ical or mental health condition, diagno s i s , comorbiditie s , laboratory te s t
result s , etc. will only be collected with the s ubject’ s  informed con s ent. The informed con s ent
form will incorporate (or, in s ome ca s e s , be accompanied by a s eparate document
incorporating) wording that de s cribe s  how s ubject data will be collected, u s ed, and di s tributed
in compliance with relevant data protection and privacy legi s lation.
7.2 Ethics  and  Regulatory  Review
The IRB/IEC re s pon s ible for each site mu s t review and approve the final s tudy protocol,
including the final ver s ion of the In f ormed Con s ent F orm and any other written information
and/or material s  to be provided to the s ubject s . The IRB/IEC mu s t al s o approve all advertising
used to recruit s ubject s  for the s tud y . The inve s tigator i s  re s pon s ible for s ubmitting the s e
document s  to the applicable IRB/IEC, and di s tributing them to the s tudy s ite s taff.
The opinion of the IRB/IEC mu s t be given in writing. The inve s tigator mu s t provide a copy o f
the written approval to M edImmune before enrolment of any s ubject into the s tudy.
MedImmune s hould approve any s ub s tantive modification s  to the Informed Con s ent F orm that
are needed to meet local requirement s .
If required by local regulation s , the protocol mu s t be re-approved by the IRB/IEC annually.
Before the s tudy i s  initiated, M edImmune will en s ure that the national regulatory authority in
each country ha s  been notified and their approval ha s  been obtained, a s  required. M edImmune
will provide s afety update s /report s  according to local requirement s , including s u s pected
CONFIDENTIAL AND PROPRIETARY 71 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
unexpected s eriou s  adver s e reactio ns  where relevant, to regulatory authoritie s , IRB/IEC, and
principal inve s tigator s .
Each P rincipal Inve s tigator i s  re s pon s ible for providing report s  of any s eriou s  and unexpected
adver s e drug reaction s  from any other s tudy conducted with the inve s tigational product to the
IRB/IEC .  M edImmune will provide thi s  information to the P rincipal Inve s tigator s o that
he/she can meet the s e reporting requirement s .
7.3 Informed  Consent
Informe d  con s ent of each s ubject will be obtained through a written and verbal explanati o n
proce ss  that addre ss e s  all element s  required by ICH/GC P . M edImmune will develop a c or e
informe d  con s ent form for u s e by all inve s tigator s  in the clinical s tudy. M edImmune mu s t
approve any modification s  to the informed con s ent form that are needed to meet local
requirement s .
The P rincipal Inve s tigator( s ) at eac h  center will:
En s ure each s ubject’ s  legal guardian i s  notified that they are free to di s continue from the
study at any time
 En s ure that each s ubject’ s  legal guardian i s  given the opportunity to a s k que s tion s  and
allowed time to con s ider the in f ormation provided
En s ure each s ubject’ s  legal guardian provide s  s igned and dated informed con s ent be f o r e
conducting any procedure s pecifically for the s tudy
En s ure the original, s igned inf o rmed con s ent form( s ) i s /are s tored in the Inve s tigator ’ s
Study F ile
En s ure a copy of the s igned inf o rmed con s ent form i s  given to the s ubject’ s  legal gua r dian
 En s ure that any incentive s  for subject s  and/or their legal guardian s  who participate in the
study a s  well a s  any provi s ion s  for s ubject s  harmed a s  a con s equence of s tudy
participation are de s cribed in t h e informed con s ent form that i s  approved by an IRB/ I EC
7.4 Changes  to  the  Protocol  and  Informed  Consent  Form
Study procedure s  will not be changed without the mutual agreement of the inve s tigator s  and
MedImmune. Any change s  mu s t be documented in a s tudy protocol amendment.
For a s ub s tantial change to the protocol, M edImmune will di s tribute amended ver s ion s  o f  the
protocol to the P rincipal Inve s tigator( s ). Before implementation, amended protocol s  mu s t be
approve d  by relevant IRB/IEC ( s ee S ection 7.2) and reviewed a s  per local regulatory autho r ity
requirement s . The IRB/IEC mu s t al s o approve revi s ion s  to the informed con s ent form,
adverti s ing, and any other written information and/or material s  re s ulting from the change to
the protocol.
CONFIDENTIAL AND PROPRIETARY 72 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Any non- s ub s tantial change s  will be communicated to or approved by each IRB/IEC.
7.5 Audits  and  Inspections
Authorized repre s entative s  of M edImmune, a regulatory authority, or an IRB/IEC may
perform audit s  or in s pection s  at the center, including s ource data verification. The purpo s e o f
an audit or in s pection i s  to s y s tematically and independently examine all s tudy-related
activities and document s , to determine whether the s e activitie s  were conducted, and data we r e
recorded, analyzed, and accurately reported according to the protocol, GC P , guideline s  o f  the
ICH, and any applicable regulatory requirement s . The inve s tigator will contact M edImm u ne
immediately if contacted by a regulatory agency about an in s pection at the s ite.
CONFIDENTIAL AND PROPRIETARY 73 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
8 REFERENCES
American Academy of P ediatric s . Updated guidance for palivizumab prophylaxi s  among
infant s  and young children at increa s ed ri s k of ho s pitalization for re s piratory s yncytial virus
infection. P ediatric s . 2014;134(2):415-20.
Blanken M O, Rover s  MM , M olenaar JM , Winkler- S ein s tra P L, M eijer A, Kimpen J L et al.
Dutch, R S V Neonatal Network. Re s piratory s yncytial viru s  and recurrent wheeze in healthy
preterm infant s . N Engl J  M ed. 2013;368(19):1791-9.
Carbonell-E s trany X, S imoe s  EA, Dagan R, Hall CB, Harri s  B, Hultqui s t M  et al.
Motavizumab for prophylaxi s  of re s piratory s yncytial viru s  in high-ri s k children: a
noninferiority trial. P ediatric s . 2010;125(1):e35-51.
Carroll KN, Gebret s adik T, Griffin MR, Wu P , Dupont WD, M itchel E F  et al. Increa s ing
burden and ri s k factor s  for bronchioliti s -related medical vi s it s  in infant s  enrolled in a s tate
health care in s urance plan. P ediatric s . 2008;122(1):58-64.
Frogel MP , S tewart DL, Hoope s  M , F ernande s  AW, M ahadevia PJ . A s y s tematic review o f
complia n ce with palivizumab admi n i s tration for R S V immunoprophylaxi s . J  M anag Care
Pharm. 2010;16(1):46-58.
Greenou g h A, Cox S , Alexander J , Lenney W, Turnbull F , Burge ss  S  et al. Health care
utilis atio n  of infant s  with chronic lung di s ea s e, related to ho s pitali s ation for R S V infection.
Arch Dis Child. 2001;85(6):463-8.
Hall CB. Re s piratory s yncytial virus and parainfluenza viru s . N Engl J  M ed.
2001;34 4 (25):1917-28.
Hall CB, Weinberg GA, Iwane M K, Blumkin AK, Edward s  K M , S taat M A et al. The bu r den
of res piratory s yncytial viru s  infection in young children. N Engl J  M ed. 2009;360(6):588 - 98.
Hall CB. The burgeoning burden o f  re s piratory s yncytial viru s  among children. Infect Diso r d
Drug Target s . 2012;12(2):92-7.
JCVI. J oint Committee on Vaccination and Immuni s ation. S tatement on immuni s ation fo r
respirato r y s yncytial viru s . Department of Health, United Kingdom. 2010a.
JCVI. J oint Committee on Vaccination and Immuni s ation: S tatement on immuni s ation f or
respirato r y s yncytial viru s  - page 4 update. Department of Health, United Kingdom. 2010b.
Leader S , Kohlha s e K. Re s piratory syncytial viru s -coded pediatric ho s pitalization s , 1997 to
1999. P ediatr Infect Di s  J . 2002;21 ( 7):629-32.
CONFIDENTIAL AND PROPRIETARY 74 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Madhi SA , Kuwanda L, Cutland C, Klugman K P . F ive-year cohort s tudy of ho s pitalization f o r
respirato r y s yncytial viru s  a ss ociated lower re s piratory tract infection in African childre n . J
Clin Vir o l. 2006;36(3):215-21.
Maifeld S V, Ro B, M ok H, Chu M , Yu L, Yamagata R et al. Development of
electroc h emilumine s cent s erology a ss ay s  to mea s ure the humoral re s pon s e to antigen s  of
respirato r y s yncytial viru s . P Lo S  One. 2016;11(4):e0153019.
Meiss ne r  HC. S elected population s  at increa s ed ri s k from re s piratory s yncytial viru s  infection.
Pediatr Infect Di s  J . 2003;22(2 S uppl): S 40-5.
Paramore LC, M ahadevia PJ , P iedra P A. Outpatient R S V lower re s piratory infection s  among
high-ri sk  infant s  and other pediatric population s . P ediatr P ulmonol. 2010;45(6):578-84.
Parrott RH, Kim HW, Arrobio J O, Hode s  D S , M urphy BR, Brandt CD et al. Epidemiology o f
respirato r y s yncytial viru s  infection in Wa s hington, D.C. II. Infection and di s ea s e with respect
to age, immunologic s tatu s , race an d  s ex. Am J  Epidemiol. 1973;98(4):289-300.
Samp s on HA, M unoz- F urlong A, Campbell RL, Adkin s on N F , J r., Bock S A, Branum A et al.
Second s ympo s ium on the definition and management of anaphylaxi s : s ummary report--
Second N ational In s titute of Allergy and Infectiou s  Di s ea s e/ F ood Allergy and Anaphylaxis
Network s ympo s ium. J  Allergy Clin Immunol. 2006;117(2):391-7.
Shambaugh C, Az s hirvani S , Yu L, P ache J , Lambert S L, Zuo F  et al. Development of a high -
throughput re s piratory s yncytial viru s  fluore s cent focu s -ba s ed microneutralization a ss ay. Clin
Vaccine Immunol. 2017;24(12).
Shay DK, Holman RC, Newman R D , Liu LL, S tout J W, Ander s on L J . Bronchioliti s -
associated ho s pitalization s  among U S  children, 1980-1996. J A M A. 1999;282(15):1440-6.
Shi T, M cAlli s ter DA, O'Brien KL, S imoe s  EA F , M adhi S A, Ge ss ner BD et al. Global,
regional, and national di s ea s e burden e s timate s  of acute lower re s piratory infection s  due to
respirato r y s yncytial viru s  in young children in 2015: a s y s tematic review and modelling
study. Lancet. 2017;390(10098):946-58.
Stewart DL, Ryan K J , S eare J G, P in s ky B, Becker L, F rogel M . A ss ociation of R S V-related
hospitalization and non-compliance with palivizumab among commercially in s ured infa n ts: a
retro s pective claim s  analy s i s . B M C Infect Di s . 2013;13334.
Stockman L J , Curn s  AT, Ander s on L J , F i s cher-Langley G. Re s piratory s yncytial viru s -
associated ho s pitalization s  among infant s  and young children in the United S tate s , 1997-2006.
Pediatr Infect Di s  J . 2012;31(1):5-9.
CONFIDENTIAL AND PROPRIETARY 75 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Zhu Q, McLellan JS , Kallewaard NL, Ulbrandt ND, P ala s zyn s ki S , Zhang J  et al. A highly
potent extended half-life antibody a s  a potential R S V vaccine s urrogate for all infant s . S ci
Tran s l M ed. 2017;9(388).
CONFIDENTIAL AND PROPRIETARY 76 of 80 T e mp late  18.0
MedImmun e
MEDI8897
Appendix  AProt o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Additional  Safety  Guidance
Furt h er G u i d a n ce o n  t h e Defi n itio n  of a S erio us  A d ver s e Eve n t ( S AE)
Life threatening
‘Life-threatening ’ mean s  that the s ubject wa s  at immediate ri s k of death from AE a s  it
occurred or it i s  s u s pected that u s e or continued u s e of the product would re s ult in the
subject’ s  death. ‘Life-threatening ’ doe s  not mean that had an AE occurred in a more s eve r e
form it might have cau s ed death (eg, hepatiti s  that re s olved without hepatic failure).
Hospitalization
Outpatie n t treatment in an ER i s  not in it s elf a s eriou s  AE, although the rea s on s  for it may be
(eg, broncho s pa s m, laryngeal edema). Ho s pital admi ss ion s  and/or s urgical operation s  planned
before or during a s tudy are not con s idered AE s  if the illne ss  or di s ea s e exi s ted before the
subject wa s  enrolled in the s tudy, p r ovided that it did not deteriorate in an unexpected way
during the s tudy.
Importa n t M edical Event or M edical Intervention
Medical and s cientific judgment s hould be exerci s ed in deciding whether a ca s e i s  s erious in
situations where important medical event s  may not be immediately life threatening or result in
death, ho s pitalization, di s ability or incapacity but may jeopardize the s ubject or may req u i r e
medical intervention to prevent one or more outcome s  li s ted in the definition of s eriou s . These
should usually be con s idered a s  s eriou s .
Simply s topping the s u s pect drug doe s  not mean that it i s  an important medical event; medical
judgment mu s t be u s ed.
Example s  of s uch event s  are:
Angioedema not s evere enough to require intubation but requiring intravenou s
hydrocorti s one treatment
Hepatotoxicity cau s ed by paracetamol (acetaminophen) overdo s e requiring treatment with
N-acetylcy s teine
Inten s ive treatment in an ER or at home for allergic broncho s pa s m
Blood dy s cra s ia s  (eg, neutrope n ia or anemia requiring blood tran s fu s ion) or convul s ions
that do not re s ult in ho s pitalization
Asse ss me n t of S everity
Asse ss ment of s everity i s  one of the re s pon s ibilitie s  of the inve s tigator in the evaluation of
AEs and S AE s . The determination of s everity s hould be made by the inve s tigator ba s ed u pon
medical judgment and the s everity categorie s  of Grade 1 to 5 a s  defined below.
CONFIDENTIAL AND PROPRIETARY 77 of 80 T e mp late  18.0
MedImmun e
MEDI8897
Grade 1
Grade 2
Grade 3
Grade 4
Grade 5Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
An event of mild inten s ity that i s  u s ually tran s ient and may
requi r e only minimal treatment or therapeutic intervention. The
event doe s  not generally interfere with u s ual activitie s  of daily
living.
An event of moderate inten s ity that i s  u s ually alleviated with
additional s pecific therapeutic intervention. The event inte rf e r es
with u s ual activitie s  of daily living, cau s ing di s comfort but
poses  no s ignificant or permanent ri s k of harm to the s ubject.
A sev ere event that require s  inten s ive therapeutic intervention.
The event interrupt s  u s ual activitie s  of daily living, or
signi f icantly affect s  the clinical s tatu s  of the s ubject.
An event, and/or it s  immediate s equelae, that i s  a ss ociated with
an imminent ri s k of death.
Death a s  a re s ult of an event.
It is important to di s tingui s h between s eriou s  criteria and s everity of an AE. S everity i s  a
meas ure of inten s ity wherea s  s erio us ne ss  i s  defined by the criteria in S ection 5.2. A Grade 3
AE need not nece ss arily be con s idered an S AE. F or example, a Grade 3 headache that pe r sists
for several hour s  may not meet the r egulatory definition of an S AE and would be con s ide r ed a
nons eriou s  event, wherea s  a Grade 2 s eizure re s ulting in a ho s pital admi ss ion would be
considered an S AE.
Asse ss me n t of Relatio nsh i p
A Guide to Interpreting the Cau s ality Que s tion
The inve s tigator i s  required to provide an a ss e ss ment of relation s hip of AE s  and S AE s  to the
inves tigational product. The following factor s  s hould be con s idered when deciding if there is a
“reas ona b le po ss ibility” that an AE may have been cau s ed by the inve s tigational product.
Time Cour s e. Expo s ure to s u s pect inve s tigational product. Ha s  the s ubject actually
received the s u s pect inve s tigational product? Did the AE occur in a rea s onable tempo r al
relation s hip to the admini s tration of the s u s pect inve s tigational product?
Consi s tency with known inve s tigational product profile. Wa s  the AE con s i s tent with the
previou s  knowledge of the s u s pect inve s tigational product (pharmacology and toxicology )
or product s  of the s ame pharmacological cla ss ? OR could the AE be anticipated from its
pharmacological propertie s ?
De-challenge experience. Did the AE re s olve or improve on s topping or reducing the dose
of the s u s pect inve s tigational product?
CONFIDENTIAL AND PROPRIETARY 78 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
 No alternative cau s e. The AE cannot be rea s onably explained by another etiology s uch as
the underlying di s ea s e, other drug s , or other ho s t or environmental factor s .
 Re-challenge experience. Did the AE reoccur if the s u s pected inve s tigational product was
reintroduced after having been s topped? M edImmune would not normally recommend o r
support a re-challenge.
Lab o ratory te s t s . A s pecific laboratory inve s tigation (if performed) ha s  confirmed the
relation s hip?
In diffic u lt ca s e s , other factor s  could be con s idered s uch a s :
I s  thi s  a recognized feature of overdo s e of the inve s tigational product?
I s  there a known mechani s m?
Caus ality of ‘related’ i s  made if following a review of the relevant data, there i s  evidence f o r  a
‘reas onable po ss ibility’ of a cau s al r elation s hip for the individual ca s e. The expre ss ion
‘reas onable po ss ibility’ of a cau s al relation s hip i s  meant to convey, in general, that there a r e
facts  (evidence) or argument s  to s ugge s t a cau s al relation s hip.
The cau s ality a ss e ss ment i s  performed ba s ed on the available data including enough
information to make an informed j u dgment. With limited or in s ufficient information in the
case, it is likely that the event( s ) will be a ss e ss ed a s  ‘not related ’.
Caus al relation s hip in ca s e s  where the di s ea s e under s tudy ha s  deteriorated due to lack o f
effect s hould be cla ss ified a s  no rea s onable po ss ibility.
Relation s hip to P rotocol P rocedure s
The inve s tigator i s  al s o required to provide an a ss e ss ment of relation s hip of S AE s  to protocol
procedure s  on the S AE Report F orm. Thi s  include s  non-TE S AE s  (ie, S AE s  that occur prio r  to
the admini s tration of inve s tigational product) a s  well a s  TE S AE s . A protocol-related S AE
may occur a s  a re s ult of a procedure or intervention required during the s tudy (eg, blood
collectio n , wa s hout of an exi s ting medication). The following guideline s  s hould be u s ed b y
inves tigator s  to a ss e ss  the relation s hip of S AE s  to the protocol:
Protocol related:
Not protocol related:The event occurred due to a procedure/intervention that wa s  de s cribed
in the protocol for which there i s  no alternative etiology pre s ent in the
subject’ s  medical record.
The event i s  r elated to an etiology other than the procedure/
intervention that wa s  de s cribed in the protocol (the alternative etiology
must be documented in the s tudy s ubject’ s  medical record).
CONFIDENTIAL AND PROPRIETARY 79 of 80 T e mp late  18.0
MedImmun e
MEDI8897
Appendix  BProt o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
National  Institute  of  Allergy  and  Infectious  Diseases  and
Food  Allergy  and  Anaphylaxis  Network  Guidance  for
Anaphylaxis  Diagnosis
Samp s on HA, M uñoz- F urlong A, Campbell RL, Adkin s on F N J r, Bock S A, Branum A, et al.
Second s ympo s ium on the definition and management of anaphylaxi s : S ummary report --
Second N ational In s titute of Allergy and Infectiou s  Di s ea s e/ F ood Allergy and Anaphylaxis
Network s ympo s ium. J  Allergy Clin Immunol. 2006;117:391-7.
National In s titute of Allergy and In f ectiou s  Di s ea s e and F ood Allergy and Anaphylaxi s
Network define anaphylaxi s  a s  a s eriou s  allergic reaction that i s  rapid in on s et and may cause
death. They recognize 3 categorie s  of anaphylaxi s , with criteria de s ignated to capture from
80% of ca s e s  (category 1) to > 95 %  of all ca s e s  of anaphylaxi s  (for all 3 categorie s ).
1Acute on s et of an illne ss  (minute s  to s everal hour s ) with involvement of the s kin, mucosal
tissue, or both (eg, generalized hive s , pruritu s  or flu s hing, s wollen lip s -tongue-uvula )
AND AT LEA S T ONE O F  T H E F OLLOWING
(a) Re s piratory compromi s e (eg, dy s pnea, wheeze-broncho s pa s m, s tridor, reduced peak
expiratory flow [ P E F ], hypoxemia)
(b) Reduced blood pre ss ure (B P ) or a ss ociated s ymptom s  of end-organ dy s function ( eg,
hypotonia [collap s e], s ync o pe, incontinence)
2Two or more of the following t h at occur rapidly after expo s ure to a likely allergen f or  that
patient (minute s  to s everal hour s ):
(a) I nvolvement of the s kin-muco s al ti ss ue (eg, generalized hive s , itch-flu s h, s wollen
lips-tongue-uvula)
(b) Re s piratory compromi s e (eg, dy s pnea, wheeze-broncho s pa s m, s tridor, reduced PE F ,
hypoxemia)
(c) Reduced B P  or a ss ociated s ymptom s  (eg, hypotonia [collap s e], s yncope,
incontinence)
(d) Per s i s tent ga s trointe s tinal symptom s  (eg, crampy abdominal pain, vomiting)
3Reduced B P  after expo s ure to k nown allergen for that patient (minute s  to s everal hou r s ) :
(a) I nfant s  and children: low s y s tolic B P  (age s pecific) or greater than 30% decrea s e in
systolic B P
CONFIDENTIAL AND PROPRIETARY 80 of 80 T e mp late  18.0
SIGNA T UR E P A GE
This is a representation of an elect r onic r eco r d that wa s  s igned
electronically and this page i s  the m anife s tation of the elect r onic s ignatu r e
Docu me n t Name: d5290c00005-c s p-ver s ion-2
Docu me n t Title:
Docu me n t I D:
Vers io n  La b el:D5290C00005 Clinical S tudy P rotocol Ver s ion 2
Doc ID-003966319
2.0 CURRENT LATE S T A PP ROVED
Server D a te S ig n ed b y
(dd-MMM-yyyy HH :mm  ‘ UTC ’ Z )
31-M ar-2 0 21 17:16 UTC
31-M ar-2 0 21 19:25 UTC
31-M ar-2 0 21 18:21 UTC
31-M ar-2 0 21 19:25 UTC
31-M ar-2 0 21 19:49 UTCMea n i n g of S ig n at u re
Author Approval
Content Approval
Content Approval
Content Approval
Content Approval
Note s : (1) Document details as sto r ed in ANG EL, an As t r aZeneca document management s y s tem.